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It’s not that what is past casts its light on what is present, 
or what is present its light on what is past; rather, 
image is that wherein what has been 
comes together in a flash with the now to form 
a constellation.
Walter Benjamin
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The rationale of this thesis is to use targeted molecular imaging and photodynamic 
therapy to overcome the challenges in diagnosis and therapy of hyperinsulinemic 
hypoglycemia. For this purpose, we use exendin-based tracers targeting the glucagon- 
 like peptide 1 receptor.
Molecular imaging
molecular imaging can provide information about biological processes associated 
with malignancies at the cellular or molecular level. Combined with the anatomical 
reference provided by conventional imaging modalities such as computed 
tomography (CT) and magnetic resonance imaging (MRI), this allows for highly 
sensitive localization of tumors. Molecular imaging can be applied for preoperative 
diagnostics and postoperative monitoring as well as during surgery to aid tumor 
detection and resection.
 Localization of tumors with molecular imaging can be achieved by targeting 
specific tumor-associated antigens using various molecules. Monoclonal antibodies 
(mAbs) and peptides are widely used targeting molecules. mAbs are often very 
specific and have high target affinity. They also have relatively slow pharmacoki-
netics, which leads to slow clearance from the circulation and high uptake in target 
organs. Furthermore, mAbs contain an abundance of reactive amino-acid residues 
which can be used for conjugation of dyes (radionuclides, fluorescent tags etc.) 
The use of peptides as targeting molecules benefits from their small size, which 
leads to faster pharmacokinetics and target accumulation as well as rapid clearance 
from non-target tissue. The small size of peptides also poses a disadvantage, since 
conjugation of imaging agents could result in dramatic changes in their pharmaco-
kinetic properties. In general, tumor uptake values of peptide-based agents are 
lower than uptake values of antibody-based agents. However, because of the fast 
pharmacokinetics of peptides, higher tumor-to-background values can be reached.
Radionuclide imaging
Radionuclide imaging is based on the detection of γ-photons. Because of the highly 
penetrating nature of these γ-photons, radionuclide imaging is not hindered by 
limitations in penetration depth in biological tissue. It is therefore a very suitable 
technique for non-invasive preoperative whole-body tumor detection. The nuclear 
imaging technique single photon emission computed tomography (SPECT) visualizes 
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gamma rays using a collimator and a detection crystal. Positron emission tomography 
(PET) detects gamma rays produced by positron-emitting radionuclides. These 
positrons will annihilate upon contact with an electron, resulting in the production 
of two 511 keV gamma rays traveling in opposite directions. With both SPECT and 
PET, 3-dimensional reconstructions of the images show the distribution of the 
tracer in the body. PET has certain advantages over SPECT including a superior 
sensitivity (approximately two to three times higher) and resolution, making it 
more suitable for detection of small lesions. Also, PET enables precise quantitative 
image analysis.
 The most widely used type of radionuclide imaging is imaging of glucose 
metabolism with fluorine-18-fluorodeoxyglucose ([18F]FDG) PET. However, PET 
and SPECT have also been successfully applied to image specific tumor associated 
targets such as the somatostatin-receptor (SSR) for neuroendocrine tumors (1, 2) 
or the prostate specific membrane antigen (PSMA) for prostate cancer (3, 4). When 
developing a targeted radiotracer, the choice of SPECT or PET radionuclide is 
important. The physical half-life of the radionuclide should correspond well with 
the biological half-life of the targeting molecule (5). For long-circulating targeting 
molecules like antibodies, radionuclides with a long physical half-life like 111In (67 
hours) for SPECT (6) and 89Zr (78 hours) for PET (7) are convenient. For small 
molecules, like peptides, with faster pharmacokinetics, PET radionuclides with 
short half-lives like 68Ga (68 minutes) (8) and 18F (110 minutes) (9) would be suitable.
SPECT and PET are used for pre-operative scanning, used to localize lesions and 
for planning of surgical treatment. However, the translation of these preoperative 
images into the operating room often proves challenging. During the operation, 
the position of structures can differ from the appearance on the preoperative scan, 
or the malignant tissue can be obscured by surrounding tissue. SPECT and PET do 
not offer real-time information for detailed tumor-delineation in the operating 
room (10). Radio-guidance, which makes use of a gamma probe to detect radiation 
intra-operatively, can provide such real-time information for tumor localization. 
However, this technique relies solely on an acoustic signal, without a real-time in 
situ image. Achieving accurate tumor delineation is therefore still challenging (11).
Fluorescence imaging
A molecular imaging technique that could provide real-time intra-operative information 
is fluorescence imaging. This technique uses fluorophores, which are molecules 
that can be excited by light of a specific wavelength. This subsequently leads to the 
emission of a photon of a slightly longer wavelength, which can be detected with a 




depth, because of tissue absorption and scattering of the photons. However, the 
high sensitivity and spatial resolution of fluorescence imaging allows for precise 
delineation of tumors during surgery. The most widely used fluorescence imaging 
technique is a non-targeted approach using the fluorophore indocyanine green 
(ICG), which has many applications, such as lymph node detection (12), and 
visualization of liver metastases (13). Currently there is much attention for the 
development of fluorescent tracers targeting specific tumor antigens, like folate 
receptor-alpha (FRa) in ovarian cancer (14) or vascular endothelial growth factor-A 
(VEGF-A) in breast cancer (15).
 In the choice of fluorophores, near infrared (NIR) dyes are preferable since 
photons in the NIR region (650-900 nm) have a higher tissue penetration depth 
than photons in the visible light region (400-600 nm) (16). Another important 
property in the choice of a fluorophore is a large Stokes shift (the difference in 
wavelength between the positions of the band maxima of the absorption and 
emission spectra), which results in minimal interference between the excitation 
and emission wavelengths. Furthermore, to acquire an adequate fluorescent signal, 
a sufficiently high molar absorption coefficient and quantum yield are crucial (17, 
18). Dyes should also be water-soluble to avoid aggregation of the dye in aqueous 
solutions (18). A frequently used dye for fluorescence guided surgery is IRDye800CW, 
which has been conjugated to multiple targeting moieties and is increasingly used 
for clinical fluorescence guided surgery in various solid tumor types (19-21).
Photodynamic therapy
While precise detection of tumors using radionuclide imaging and fluorescence 
imaging can lead to major improvements in the surgical treatment of cancer, 
resection of tumors is in some cases hampered by the proximity of vital structures. 
In such cases, treatment could be further improved by photodynamic therapy 
(PDT). Photodynamic therapy (PDT) is a technique using photosensitizers (PSs), 
which are molecules that can be activated using light of a specific wavelength. The 
activated PS will be converted from the ground singlet state into the excited singlet 
state. Upon decay back to the ground state the PS can emit fluorescence or undergo 
intersystem crossing and switch into an excited triplet state (Figure 1). It can then 
react with a substrate, which reacts with oxygen to produce oxygenated products, 
or it can directly react with oxygen to form 1O2. These reactive oxygen species 
cause cell killing by direct cellular damage, vascular shutdown or activation of an 
immune response against targeted cells (22, 23).
 The use of PDT has a long history, with the first anti-tumor effects in mice 
already reported in 1972 (25) and the first clinical trial in patients with skin cancer 
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in 1978 (26). However, PDT is still not extensively used in the clinic. For a long time 
only non-targeted PDT approaches have been evaluated. The minimal efficiency in 
tumor targeting in these approaches resulted in inadequate tumor eradication. 
Also, high off-target accumulation, like in the skin, resulted in unwarranted side 
effects - especially since the first-generation PSs were activated by visible light (27). 
Currently, several targeted tracers for PDT are under development, for example 
targeting the epidermal growth factor receptor (EGFR) for tumor angiogenesis (28) 
and the human epidermal growth factor receptor 2 (HER2) for breast cancer (28, 
29). PSs which are currently mostly used are chlorine-based PSs and phthalocya-
nines. Phthalocyanines absorb light at a higher wavelength than chlorine-based 
PSs, leading to a higher penetration depth. IRDye700DX is phthalocyanine which 
is frequently used and is already applied in a clinical trial for targeted PDT of 
head and neck cancer (30). In addition to the favorable excitation characteristics of 
IRDye700DX, this PS has a high quantum yield and hydrophilicity.
Figure 1  Schematic illustration of the principle of PDT. Figure from Dai et al. (24) under the 





In healthy people, blood glucose levels are maintained within a narrow range with 
normal values between 4 and 6 mmol per liter. One of the hormones responsible for 
blood glucose homeostasis is insulin, which is produced by the beta cells in the 
pancreatic islets of Langerhans. Insulin acts to lower blood glucose levels by 
stimulating uptake of glucose into the liver, skeletal muscles and fat. Insulin 
production by pancreatic beta cells is usually a well-regulated process (Figure 2). 
Its production is stimulated by high blood glucose levels as well as other substances 
like the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP), which are produced in the intestines upon food 
consumption. When blood glucose levels decrease, insulin production is slowed or 
stopped. If glucose levels drop below physiological values, the hormone glucagon 
is released from alpha cells in the islets of Langerhans. Glucagon promotes the 




release of glucose into the blood from glycogen stores in the liver, thereby preventing 
hypoglycemia. 
 While insulin production is normally well-regulated, uncontrolled overproduction 
can arise, which can lead to hyperinsulinemic hypoglycemia. This is a dangerous 
disorder, since glucose is the most important energy substrate for the brain (31). 
Prolonged hypoglycemia can therefore lead to brain damage.
Adult endogenous hyperinsulinemic hypoglycemia
Potential causes of adult endogenous hyperinsulinemic hypoglycemia
Insulinomas
Adult endogenous hyperinsulinemic hypoglycemia (AHH) is most commonly 
caused by an insulinoma. An insulinoma is a subtype of pancreatic neuroendo-
crine tumor, which arises from the pancreatic beta cells. The insulinoma is the 
most common sporadic islet cell tumor of the pancreas and occurs with an 
incidence of 1-4 people per million per year. Insulinomas can occur at any age, 
but are most often found in people between 40 and 50 years of age, with a slightly 
higher incidence in women than men (60 : 40%). About 5 – 10% of insulinomas are 
part of hereditary disorders like multiple endocrine neoplasms type 1 (MEN-1). 
Insulinomas are benign in about 90% of cases and are mostly solitary and small 
(82% < 2 cm, 47% < 1 cm) (33, 34). 
Nesidioblastosis
In about 0.5 to 5% of cases, AHH is caused by nesidioblastosis. Nesidioblastosis is 
characterized by a proliferation of abnormal beta cells throughout the pancreas. 
Histologic features of nesidioblastosis include enlarged islet size and number, 
increased periductular islets, enlarged beta cell nuclei and abundant clear 
cytoplasm. The cause of nesidioblastosis in adults is unknown. Genetic effects as 
well as reactive processes in response to metabolic and hormonal changes are 
suggested (35, 36).  
Symptoms and diagnosis
Clinical symptoms of AHH are episodic, heterogeneous and not specific. Episodes 
of hypoglycemia occur in most cases after fasting or exercise, but can also occur 
postprandially (37). Hypoglycemia leads to neuroglycopenic symptoms such as 
diplopia, blurred vision, recurrent headaches, behavioral changes, confusion, 
agitation, dizziness, weakness and amnesia. Also autonomic symptoms such as 
palpitations, tremor, diaphoresis, hunger and paresthesia can occur. Because of 
recurrent and prolonged hypoglycemia, impaired awareness of hypoglycemia is 
often seen in patients with AHH (38). This is especially dangerous, since prolonged 




or brain death. Since many patients use continuous eating to prevent or remedy 
hypoglycemia, weight gain often occurs (31, 34).
 Because of the heterogeneity of the symptoms of AHH, a diagnosis is not always 
readily achieved. Symptoms can be misattributed to psychiatric, neurological or 
cardiac disorders, which can lead to a delay in diagnosis (39). Upon recognition of 
the symptoms, a definite diagnosis is achieved biochemically by the presence of 
low blood glucose levels with inappropriately high insulin levels during a 12- to 
71-hour period of fasting (40).
Treatment
The only curative treatment for insulinomas is surgical resection. The type of 
surgery depends on the size and the location of the tumor and its relation to the 
pancreatic duct, major vessels and adjacent organs. In the case of sporadic 
insulinomas with a size smaller than 3 mm and a distance of more than 2-3 mm 
from the pancreatic duct, enucleation is possible. In other cases, depending on the 
location of the tumor, pancreaticoduodenectomy, partial pancreatectomy or distal 
pancreatectomy is performed (34). 
 Nesidioblastosis is primarily treated with medication. Diazoxide, which inhibits 
insulin secretion by opening ATP-sensitive potassium channels of beta cells, is 
used most often. Other medications include somatostatin analogs, glucocorticoids 
and calcium-channel blockers (35).
Diagnostic challenges
Since, in contrast to nesidioblastosis, insulinomas can be cured by surgical 
resection of the tumor, differentiating between these conditions is essential for 
treatment planning. Additionally, precise localization of insulinomas is important 
for planning of the surgical procedure. However, diagnosis and localization of 
insulinomas is hampered by the nature of the tumors. Detection of insulinomas 
with conventional imaging techniques such as CT and MRI is hindered by the 
small size of the tumors, resulting in a sensitivity of these techniques of only 44% 
and 53%, respectively (41). Besides conventional imaging, PET imaging of the 
somatostatin receptor (SSTR) subtypes 2 and 5, using [68Ga]-DOTATOC and [68Ga]-
DOTATATE is also applied. This is the standard nuclear imaging technique for 
neuroendocrine tumors, which often express these SSTR subtypes. However, 
most insulinomas have a low density of the SSTR subtypes 2 and 5, leading to 
reported detection rates between 33% and 85% (42, 43). Since these currently 
available non-invasive methods for diagnosis and localization of insulinomas do 
not always provide a conclusive diagnosis, more invasive techniques like intra- 
arterial calcium stimulation and venous sampling (ASVS) and endoscopic ultrasound 
(EUS) are used. These techniques have sensitivities for detection of insulinomas 
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of 85% and 75%, respectively (41, 44-47). Because non-invasive detection of 
insulinomas is such a challenge, development of a more sensitive non-invasive 
imaging technique for the detection of insulinomas would be of great interest.
Treatment challenges
Even after detection of insulinomas, treatment is still challenging. The surgical 
procedures carry risks of complications such as pancreatic fistulas, abscesses, wound 
infections, pseudocyst formation and bleeding. Also certain medical complications 
can occur after insulinoma surgery, such as pancreatitis, pulmonary embolism and 
diabetes mellitus (48). Treatment of nesidioblastosis is a challenge as well, since 
diazoxide often leads to significant side effects like fluid retention, hypotension, 
hypertrichosis and bone marrow suppression. Other forms of medication have 
varying success. In nesidioblastosis patients with severe side effects or unresponsive-
ness to medicinal treatment, partial pancreatectomy is the only treatment option (31). 
Congenital hyperinsulinism
The most common cause of persistent hypoglycemia in neonates is congenital 
 hyperinsulinism (CHI). CHI is a very rare disorder which occurs in 1:35000 – 
1:40000 live births (49). Mutations in 12 genes (ABCC8, KCNJ11, GLUD1, GCK, 
HADH, SLC16A1, HNF1A, HK1, PGM1 and PMM2) have been found to be 
associated with CHI and novel genetic mechanisms are still being discovered. 
Histologically, there are three subforms of CHI; focal, diffuse and atypical. In focal 
CHI, accounting for 30-40% of cases, there are abnormal beta cells localized in a 
specific region (usually 2-10 mm in size) in the pancreas. Focal CHI is caused by 
paternal mutations in genes encoding beta cell ATP sensitive potassium channels 
(ABCC8 or KCNJ11) and concurrent somatic loss of the maternal chromosome 
11p15 region within the focal area. Diffuse CHI accounts for 60-70% of cases and 
affects all pancreatic beta cells. This subform is most commonly caused by 
homozygous recessive or compound heterozygous mutations in the beta cell ATP 
sensitive potassium channels. Atypical CHI involves rare cases in which the 
pancreatic histology does not fit the focal or diffuse disease pattern (50).
Symptoms and diagnosis
CHI most often presents in neonates, but can also present in infants, children and 
in rare cases  in adulthood (51). Like AHH, CHI presents with a variety of 
symptoms, ranging from non-specific adrenergic symptoms like poor feeding, 
hunger, palpitations and sweating, to life-threatening neuroglycopenic symptoms 
like seizures, unconsciousness, lethargy, coma and even death (52). Early diagnosis 
of CHI is very important to minimize the risk of permanent brain damage as a 




with recurrent and persistent hypoglycemia, upon which blood samples are 
collected during hypoglycemic episodes to confirm the diagnosis biochemically. 
This confirmation relies on inappropriate levels of insulin and c-peptide for the 
level of plasma glucose. In some cases serum insulin levels are low or undetectable 
and diagnosis has to be confirmed by other biochemical features like low β-hydroxy-
butyrate and fatty acid concentration combined with clinical features (53).
Treatment
In addition to early diagnosis of the disease, starting treatment to prevent hypo - 
glycemic episodes is crucial in CHI. Early treatment and emergency management 
include oral and/or intravenous glucose infusion, glucagon administration and 
frequent feeding. Focal CHI can be cured by surgical removal of the lesion. 
Depending on the location of the lesion, this can be achieved with enucleation or 
partial pancreatectomy. Diffuse CHI is primarily treated with medication. Like in 
adult nesidioblastosis, diazoxide is the primary medication used for treatment of 
CHI. In addition, somatostatin analogs and calcium channel blockers are used. In 
patients with diffuse CHI who are unresponsive to medicinal treatment, near-total 
pancreatectomy can be performed (49, 53).
Diagnostic challenges
After initial diagnosis of CHI, it is important for treatment planning to determine 
the subform of the disease. If mutational analysis is not conclusive, imaging is 
performed. Focal lesions cannot be detected by conventional imaging or SSTR PET 
imaging (54). Also, the invasive techniques ASVS and transhepatic portal venous 
insulin sampling (THPVS) are not always reliable for detection of focal CHI (55). 
The current imaging technique used to detect focal lesions in patients with CHI is 
18fluoro-L-dioxyphenylalanine ([18F]F-DOPA) PET. This technique was reported to 
have a sensitivity of 85% for the diagnosis of focal CHI and was also successful for 
precise localization of the lesions, which is crucial for planning of the surgery. 
Despite the high sensitivity of [18F]F-DOPA PET, focal lesions are still missed in 
some cases.
Treatment challenges
While focal CHI, if correctly diagnosed, can be cured by surgical treatment, 
treatment of diffuse CHI is much more challenging. Medicinal treatment, like 
mentioned above, is often associated with severe side effects and is not always 
effective. In patients unresponsive to medication, extensive surgery is required, 
which carries a high risk of developing pancreatic exocrine insufficiency and 
diabetes. Also, despite the extensiveness of the surgery, some patients continue to 
have hypoglycemic episodes (56). 
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Targeting the GLP-1 receptor
The glucagon-like peptide 1 receptor (GLP-1R) is a G-protein-coupled receptor 
expressed in several tissues, including the pancreatic beta cells. Benign insulinomas 
express high levels of the GLP-1R in nearly 100% of cases. Activation of the GLP-1R 
stimulates the adenylyl cyclase pathway, resulting in increased insulin synthesis 
and secretion. The GLP-1R is activated by binding of the hormone GLP-1. This 
peptide hormone is produced and secreted by intestinal enteroendocrine L-cells. 
Endogenous GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 
(DPP-4), neutral endopeptidase 24.11 and cleared by the kidneys. As a result, the 
physiological half-life of GLP-1 is only about 2 minutes, rendering it unsuitable as 
a targeting peptide for imaging purposes. 
 In this thesis we therefore target the GLP-1R with the GLP-1 analogue 
exendin-4. This peptide is derived from the saliva of the Gila Monster (Heloderma 
Suspectum), a lizard native to the southwestern United States and northwestern 
Mexican state of Sorona (57) (Figure 3). Exendin-4 shares 53% sequence homology 
with GLP-1 and binds the GLP-1R with high affinity. Since it is more resistant to 
degradation by DPP-4, it has a longer physiological half-life (58). Several exendin- 
based tracers for imaging of insulinomas have already been developed. The first 
exendin-based tracers that were developed were tracers for SPECT/CT. 111In-labeled 
exendin ([Lys40(Ahx-DTPA-[111In]In)NH2]-exendin-4 and [Lys40(Ahx-DOTA-[111In]
In)NH2]-exendin-4) showed high tumor uptake in the insulinoma Rip1Tag2 mouse 
model and also provided the first successful clinical results by detection of 
insulinomas with a higher sensitivity than conventional imaging (59-62). Also 
SPECT/CT with 99mTc-labeled-exendin ([Lys40(Ahx-HYNIC-[99mTc]Tc/EDDA)NH2]- 
exendin-4) was used for insulinoma detection. With this tracer, insulinomas could 
be localized in several patients in which conventional imaging was negative (63). 




Because of the better sensitivity and spatial resolution of PET compared to SPECT, 
there is recently a focus on the development of exendin-based tracers for PET 
imaging. 68Ga-labeled exendin ([68Ga]Ga-DOTA-exendin-4 and [68Ga]Ga-NO-
TA-exendin-4) was shown to be more sensitive for insulinoma detection than 
111In-labeled exendin as well as conventional imaging techniques (64-66).
Thesis outline
In this thesis, the aim was to develop and investigate exendin-4 based tracers 
for targeted molecular imaging and photodynamic therapy of hyperinsulinemic 
hypoglycemia. 
The first part of this thesis focusses on the use of radiolabeled exendin for 
diagnostic imaging in hyperinsulinemic hypoglycemia.
In chapter 2, we investigate the effectiveness of the radiotracer [68Ga]Ga-NODA-
GA-exendin-4 for the localization of insulinomas by PET/CT. In a prospective 
multicenter trial in 42 patients, a direct comparison between this novel imaging 
method and the current standard non-invasive imaging procedures CT, MRI and 
somatostatin receptor PET is performed.
In chapter 3, we examine the effectiveness of [68Ga]Ga-NODAGA-exendin-4 PET 
for the detection and localization of focal CHI. Based on prospective as well as 
retrospective data of CHI patients, the performance of [68Ga]Ga-NODAGA-exen-
din-4 PET is compared to [18F]F-DOPA PET.
The safety of the use of [68Ga]Ga-NODAGA-exendin-4 for diagnostic and research 
purposes is investigated in chapter 4, in which human PET-based dosimetry is 
performed to estimate radiation doses from this radiotracer to adults as well as 
children.
The second part of this thesis focusses on the treatment of hyperinsulinemic 
hypoglycemia and the potential benefit of fluorescent exendin-based tracers.
In chapter 5, the potential of the near infrared fluorescent tracer exendin-4-IRDye-
800CW for targeting of GLP-1R positive cells is assessed in vitro and in vivo as well 
as the feasibility and translatability of performing fluorescence imaging with this 
tracer.
The potential of the alternative treatment option photodynamic therapy is assessed 
in chapter 6, in which the efficacy and specificity of targeted photodynamic 
therapy of GLP-1R positive lesions using the tracer exendin-4-IRDye700DX is 
examined in vitro and in vivo.
A general discussion of the results and the implications for the future of diagnosis 
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Insulinomas are usually small, benign pancreatic neuroendocrine tumors. Precise 
anatomical localization is crucial for surgical treatment. The current standard 
imaging techniques CT, MRI and somatostatin receptor (SSTR) PET have limited 
sensitivity. The glucagon-like peptide 1 (GLP-1) analog exendin specifically binds 
to the GLP-1 receptor, which is overexpressed in most insulinomas. We have 
performed a prospective multicenter imaging study to compare the effectiveness 
of [68Ga]Ga-NODAGA-exendin-4 PET/CT (GLP-1R PET) with all current standard 
non-invasive imaging procedures for the localization of insulinomas.
Methods
42 adults aged 24-62 with biochemically proven hyperinsulinemic hypoglycemia 
were included. PET/CT images were obtained one and two hours after injection of 
95-105 MBq [68Ga]Ga-NODAGA-exendin-4 (5-7 µg). Current standard imaging, 
consisting of CT or MRI and SSTR PET, was performed within 8 weeks of GLP-1R 
PET in all patients. A patient-based analysis was performed with histopathology 
as a reference standard. Tumor-to-background ratios and contrast-to-noise ratios 
were determined by quantitative analysis of GLP-1R and SSTR PET images by a 
blinded observer.
Results
Lesions were identified in 33 patients. 31 patients underwent surgery and presence 
of an insulinoma was confirmed histopathologically. Analysis showed that GLP-1R 
PET localized insulinomas with a higher accuracy and sensitivity (90.6% and 93.5% 
respectively) than conventional imaging (78.1% and 80.6% respectively) and SSTR 
PET (59.4% and 61.3% respectively). In 12.5% of patients, a correct diagnosis and 
decision to perform surgery was only reached after GLP-1R PET. Mean tumor- 
to-background ratios were 12.2 ± 3.4 for GLP-1R PET compared to 4.0 ± 3.0 for 
SSTR PET (p=0.0017) and mean contrast-to-noise ratios were 24.1 ± 20.8 for GLP-1R 
PET compared to 5.3 ± 4.4 for SSTR PET (p=0.022). The lower peptide dose used in 
this study compared to previous studies with [68Ga]Ga-DOTA-exendin-4 (4-7 µg 
vs. 12-24 µg respectively) resulted in fewer occurrences of nausea (5% vs. 27% of 
patients). 
Conclusion
This study demonstrates the superior performance of GLP-1R PET/CT compared to 
current standard non-invasive imaging modalities for pre-operative localization of 
benign insulinomas. GLP-1R PET significantly influenced the clinical management 
of the patients in this population. Because of its high sensitivity and excellent 
imaging quality, GLP-1R PET/CT could have the potential to be used as the primary 





In this prospective trial, we have examined the effectiveness of a novel radiotracer 
for the non-invasive localization of insulinomas. Insulinomas are neuroendocrine 
tumors arising from the pancreatic beta cells. Insulinomas occur with an incidence of 
1-4 people per million per year and are the most common cause of adult endogenous 
hyperinsulinemic hypoglycemia (AHH). In patients with an insulinoma, episodic 
hypoglycemia results in symptoms such as confusion, diplopia, dizziness and, in 
cases of prolonged hypoglycemia, even seizures, loss of consciousness or death (1, 2).
 Insulinomas are benign in about 90% of cases and can only be completely 
cured by surgical removal. Preferred surgical procedures are pancreas-preserving, 
such as limited resection or enucleation (3). In order to plan such a surgical 
procedure and improve the clinical outcome of the patients, precise pre-operative 
localization of the tumor is essential. However, this is challenging because of the 
usually small size of insulinomas (82% < 2 cm, 47% < 1 cm). The non-invasive 
imaging methods triple phase CT, MRI and ultrasound are currently used, but 
these techniques have sensitivities of only about 44%, 53% and 33% respectively (4). 
Next to these non-invasive imaging techniques, angiography with intra-arterial 
calcium stimulation and venous sampling (ASVS) and endoscopic ultrasound 
(EUS) are used in cases of occult insulinomas, with a sensitivity of about 85% and 
74.8% respectively (4, 5). These techniques have the disadvantage of being invasive 
and carrying risks of complications. 
 Imaging of the somatostatin receptor (SSTR) is the current standard nuclear 
imaging technique for the localization of neuroendocrine tumors. Sensitivities of 
this technique between 33% and 85% for the detection of insulinomas have been 
reported, probably dependent on the number and nature of the cases assessed 
(6, 7). While the SSTR subtypes 2 an 5 are expressed in high levels in the majority 
of neuroendocrine tumors, a mostly low receptor density is found in benign 
insulinomas (8). In contrast to the low expression of the SSTR, benign insulinomas 
express high levels of the glucagon-like peptide 1 receptor (GLP-1R) in 92% of cases 
(8). The GLP-1R is therefore an attractive alternative target for insulinoma detection 
with nuclear imaging.
 In this study, we target the GLP-1R using the peptide exendin-4, a stable 
analogue of the hormone GLP-1, which specifically binds the GLP-1R with high 
affinity. Previous clinical studies have shown the potential of 111In-labelled exendin 
for detection of insulinomas with single photon computed tomography (SPECT) 
(9-11). Subsequently, position emission tomography (PET) using 68Ga-labelled 
exendin ([68Ga]Ga-DOTA-exendin-4), which has the combined benefit of the higher 
sensitivity of PET as compared to SPECT and the lower radiation burden to the 
patient, was shown to perform better then 111In-labelled exendin in a small 
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cross-over trial (12). Recently, the benefit of [68Ga]Ga-DOTA-exendin-4 PET for 
detection of insulinomas over SPECT and magnetic resonance imaging (MRI) was 
shown in a large prospective trial (6). 
 Here, we report data from a clinical trial with an exendin-based radiotracer in 
which we used the chelator NODAGA, instead of DOTA, for radiolabelling with 
Gallium-68. This enables labeling with a higher specific activity (13), allowing the 
use of lower, sub-pharmacological, peptide doses for PET imaging, potentially 
leading to improved image quality, by more efficient targeting with lower 
background signals, and a prevention of adverse effects like hypoglycemia and 
nausea in patients. We performed a multicenter prospective trial in which we 
compared the effectiveness of [68Ga]Ga-NODAGA-exendin-4 with current standard 
non-invasive imaging procedures (CT and/or MRI and SSTR PET/CT ([68Ga]
Ga-Dotatoc or [68Ga]Ga-Dotatate)) for the localization of insulinomas.
Materials and methods
Study design and patients
In this prospective, multicenter imaging study (NCT03189953), patients were 
included at the Radboud University Medical Center Nijmegen and the University 
Medical Center Groningen in The Netherlands, the University of Turku in Finland 
and Uppsala University in Sweden. Recruitment of patients was performed both 
directly in these participating centers as well as by referral from several tertiary 
centers across Europe. Patients with biochemically proven AHH with neuroglyco-
penic symptoms in the fasting state with low plasma glucose levels and inappro-
priately high serum insulin and C-peptide levels were enrolled. Exclusion criteria 
were evidence of other malignancies than insulin-producing tumors in conventional 
imaging, renal insufficiency (creatinine clearance < 40 ml/min), pregnancy and 
breast feeding. The study was approved by the local institutional review board of 
each of the participating institutes. All included patients provided written 
informed consent in accordance with provisions of the Declaration of Helsinki.
Radiopharmaceutical preparation
Hydrochloric acid (HCl) was purchased from Rotem Industries. All other 
components were purchased as one disposable kit (reagent and hardware kit for 
synthesis of 68Ga peptides using cationic purification, ABX, Germany). [68Ga]
Ga-NODAGA-exendin-4 was manufactured using a synthesizer module (GRP 
synthesizer, Scintomics, Germany). Gallium-68-chloride was obtained from a 
68Ge/68Ga generator (Galliapharm, Eckert and Ziegler, Germany). The generator 




cartridge. The cartridge was eluted with 1.5 ml 5M NaCl in 0.1 M HCl into the 
reaction vial, containing 200 µl exendin-NODAGA (10 µg of peptide in water for 
injection), 475 µl 2.5 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer and 50 µl ascorbic acid 100 mg/ml in water for injection. After 15 minutes 
incubation at 100°C, the vessel is cooled and 2 ml ethylenediaminetetraacetic acid 
(EDTA ) 50 mM/ polysorbate 80 0.15% is added. [68Ga]Ga-NODAGA-exendin-4 was 
purified on a HLB cartridge and sterilized by passing through a 0.2 µm filter 
(millex GV).
Imaging procedures
Standard imaging was performed according to local guidelines for insulinoma 
detection following standardized imaging protocols according to the study protocol 
of this trial. In each patient this at least included SSTR PET/CT (68Ga-Dotatoc or 
68Ga-Dotatate), performed according to the EANM guidelines (14) and triple phase 
CT and/or MRI. For triple phase CT nonionic contrast agent was administered at a 
flow rate of 3,5 mL/s followed by a saline flush. Triple phase CT (automatic tube 
current modulation with maximum tube current, 230 mAs; tube voltage 120 kV; 
gantry rotation 0.5s) was performed using bolus tracking. The early arterial phase 
(scan initiation 5s after reaching the 100-Hounsfield-unit threshold in the 
abdominal aorta, resulting in a delay of 25s) and the portal-venous inflow phase 
(20s delay from the beginning of the arterial phase) covering the upper abdomen. 
The venous phase (50s delay from the arterial phase) was performed as a 
whole-body CT. Detector collimation was 16 x 0.75mm for arterial CT and 16 x 
1.5mm for venous CT. Primary image reconstruction was performed at a 0.75- and 
4mm slice thickness for arterial CT and a 2- and 5 mm thickness for venous CT 
(increment 0.5mm) (15). MRI was performed with a 1.5 or 3 Tesla system using 
multichannel body surface coils. Sequences incorporated contained the standard 
for abdominal imaging including precontrast T1 weighted, fat saturated T2 weighted, 
diffusion weighted and post contrast fat saturated T1 weighted sequences.
 For GLP-1R imaging, patients were injected intravenously with [68Ga]Ga- 
NODAGA-exendin-4 (105.6 ± 2.3 MBq) as a slow bolus over one minute. Patients 
fasted for 4 hours before injection of the tracer to prevent competition for binding 
to GLP-1Rs between endogenous GLP-1 and [68Ga]Ga-NODAGA-exendin-4. Blood 
glucose levels were monitored before, and 15, 30, 60 and 120 minutes after injection 
of the tracer. Infusion with 5% glucose for 2 hours was started 15 minutes before or 
just after tracer injection, depending on blood glucose levels of the patients. Two 
consecutive PET scans were obtained at 60 and 120 minutes after injection of [68Ga]
Ga-NODAGA-exendin-4. Images of the abdomen were acquired with 2 bed 
positions at 10 minutes per bed position. A low-dose CT scan without contrast (40 
mAs and 130 kV) was acquired for anatomical localization and attenuation 
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correction. The size of the CT transaxial matrix was 512 x 512 (0.98 × 0.98 mm), and 
the CT slice width was 3 mm. High definition reconstruction of the images was 
performed with 3 iterations, 21 subsets and a post reconstruction Gaussian filter of 
3 mm in full width at half maximum. The transaxial PET matrix size was 200 x 200 
and pixel size was 4 x 4 x 3 mm.
Evaluation
The reference standard was histologic evaluation and clinical outcome (normalization 
of blood glucose levels after surgery). Clinical reports of all standard imaging 
procedures were provided by radiologists or nuclear medicine physicians at the 
referring centers. Clinical reporting of GLP-1R PET/CT scans was performed by 
nuclear medicine physicians at the site of inclusion of the patient.
 Quantitative analysis of SSTR and GLP-1R PET/CT scans of patients in which 
these were both positive, was performed by a non-blinded observer. Volumes of 
interest were drawn to determine uptake in the tumors (SUVmean(tum)) using a 
fixed threshold set to 70 % of the maximum standardized uptake value (SUVmax) 
in the lesions in PET/CT images obtained 1 hour post injection. Volumes to measure 
uptake in the direct background of the lesions (SUVmean(BG)) were drawn within 
the pancreas on all sides 16 mm around the tumor-volumes (with a gap of 8 mm 
(2 voxels) to account for spill-over of signal from the tumor). Also, volumes of 
interest were drawn manually around the whole pancreas excluding the tumor 
(SUVmean(panc)). Tumor-to-background ratios were determined by: (SUVmean(tum)) 
/ (SUVmean(BG)). Contrast-to-noise ratios, as a measure of image quality, were 
determined by: (SUVmean(tum)) - (SUVmean(panc)) / SD(panc).
Statistical analysis
Positive imaging tests supported by histopathology and normalization of blood 
glucose levels in the patient after surgery were regarded as true positives. A patient- 
based analysis was performed, meaning that in patients with multiple lesions, 
an imaging result was regarded as a true positive if at least one lesion was localized 
correctly in relation to histopathology. Numbers of correct assessments (conclusion of 
scan in correspondence with histopathology) and incorrect assessments (conclusion 
of scan not corresponding with histopathology) of the different imaging modalities 
were represented in 2 x 2 contingency tables and compared using a McNemar test 
for comparison of paired nominal data. Tumor-to-background ratios and contrast-
to-noise ratios of GLP-1R PET and SSTR PET were compared using paired sample 







We included 42 patients with biochemically confirmed AHH. Baseline characteris-
tics of the patients are given in Table 1. All patients underwent imaging with SSTR 
PET/CT and 3-phase contrast enhanced CT and/or MRI. Twelve patients had 
undergone only triple phase CT, 17 patients only MRI and 13 patients had 
undergone both, CT and MRI. EUS was only performed in 17 patients. GLP-1R 
PET/CT and SSTR PET/CT was performed in all patients. Median time between 
SSTR PET/CT and GLP-1R PET/CT was 1.9 (0.1 – 4.1) weeks. Median time between 
CT/MRI and GLP-1R PET/CT was 4.7 (0.3 – 11.1) weeks. Disease was expected to 
remain stable within these timeframes ensuring reliable comparison of the scans.
CT/MRI, SSTR PET/CT and GLP-1R PET/CT revealed suspicious lesions in 64%, 
50% and 74% of patients respectively (Table 1). The highest radiotracer uptake was 
present in the tumors and kidneys (Fig 3). 
Table 1   Characteristics of study participants. 
Participants (n=42)
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Data are given as number/total or median and interquartile range.
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 Two patients (5%) experienced nausea and 1 patient (2%) experienced vomiting 
following injection of [68Ga]Ga-NODAGA-exendin-4. No other adverse effects 
were observed. In all patients, exogenous glucose infusion (5%, 250ml/h) for 
2 hours was started 15 minutes before or just after injection of the tracer. As a 
result, no severe hypoglycemic episodes occurred in any of the patients.
Surgery and histopathology
Results of all imaging modalities were used for surgical planning. Median time 
between GLP-1R PET/CT and surgery was 49 (18 – 69) days. Combined results of all 
imaging modalities revealed the presence of a suspicious lesion in 33 patients. 
Of these patients, 2 patients declined surgery because symptoms could be sufficiently 
managed with diet (patient 16) or medication (patient 27). In the other 31 patients, 
successful surgery was performed and histological evaluation showed the presence 
of 1 or multiple insulinomas with a size of 7 – 35 mm. Plasma glucose values 
normalized after the procedure in all these patients with no further episodes of 
hypoglycemia.
 Of the 11 patients in which none of the imaging procedures revealed a suspicious 
focal lesion, only 1 patient (patient 24) underwent surgery (body/tail resection). 
Surgery confirmed diffuse beta cell hyperplasia and blood glucose values normalized 
after the procedure.
 Since histopathology and clinical follow-up were the reference standard, 
patients who did not undergo surgery were excluded from analysis. An overview 
of the performed procedures is shown in Figure 1 and results of imaging as well 
as surgical outcomes of all patients are summarized in Table 2.
Outcomes
Results of SSTR PET/CT, 3-fase CT, MRI, conventional imaging (combined results 
of 3-fase CT and MRI) and GLP-1R PET/CT, for all 32 patients with histopathologi-
cal confirmation, are summarized in Table 3. GLP-1R PET/CT has higher accuracy 
and sensitivity (90.6% and 93.5% resp.) than the other imaging modalities (78.1% 
and 80.6% for anatomical imaging resp. and 59.4% and 61.3% for SSTR PET/CT 
resp.). Since in this patient population, there were no false positive results with any 
of the imaging modalities, positive predictive values are 100% for all modalities. 
 Crosstabs directly comparing GLP-1R PET/CT with the standard imaging 
modalities, based on the number of correct (corresponding with histopathology) 
and incorrect outcomes (not corresponding with histopathology) of the scans, are 
depicted in Figure 2. Results of the GLP-1R PET/CT were correct in 30 of 32 cases, 
compared to 20 correct results of SSTR PET/CT. In only one of the two cases in 
which the result of GLP-1R PET/CT showed no lesion, while an insulinoma proved 




EUS correctly identified the presence of a lesion. Importantly, GLP-1R PET/CT 
provided correct results for 11 out of 12 cases in which SSTR PET/CT was incorrect, 
showing that GLP-1R PET/CT outperformed SSTR PET/CT (p<0.05).
 Conventional imaging provided correct result in 26 cases, compared to 30 with 
GLP-1R PET/CT. Also, conventional imaging was able to provide a correct result in 
one of the 2 cases in which GLP-1R PET/CT was incorrect. GLP-1R PET/CT was 
correct in 5 out of 6 cases in which conventional imaging was incorrect. While this 
result does not reach statistical significance (p = 0.22), GLP-1R imaging did have an 
added value over conventional imaging in this patient population. Especially since 
in 4 of the 32 patients (12.5%), a lesion was only correctly identified using GLP-1R 
PET/CT while all standard imaging modalities were negative. The decision to 
perform surgery in these patients was therefore based solely on the results of the 
GLP-1R PET/CT.
Image quality
GLP-1R PET/CT and SSTR PET/CT images of 2 patients are shown in Figure 3. 
Results of image quantification are shown in Figure 4. Mean tumor-to-background 
ratios were (12.2 ± 3.4) for GLP-1R PET compared to (4.0 ± 3.0) for SSTR PET 
(p=0.0017) and mean contrast-to-noise ratios were (24.1 ± 20.8) for GLP-1R PET 
compared to (5.3 ± 4.4) for SSTR PET (p=0.022), indicating the superior image 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1  Flow chart of patient inclusion and analysis
42 Patients with biochemically confirmed 
hyperinsulinemic hypoglycaemia
10 Did not undergo surgery
- 8 No lesion detection
- 2 Declined surgery:
- 1 stable with diet
- 1 stable with diazoxide 
32 Included for analysis of imaging data
- 32 in [68Ga]Ga-exendin-4 PET/CT analysis
- 32 in SSTR PET/CT analysis
- 25 in triple phase CT analysis
- 30 in MRI analysis
- 14 in EUS analysis
32 underwent surgery 
42 underwent [68Ga]Ga-exendin-4 PET/CT 
42 eligible for inclusion
Table 3   Overview of imaging results in participants who have undergone 

















GLP-1R PET/CT (n=32) 90.6% 93.5%
Accuracy and sensitivity are given in percentages. Tumor-to-background ratios and contrast-to-noise 




Figure 3  GLP-1R PET/CT and SSTR PET/CT images of patient 4 (A) and patient 9 (B). Location 
of tumors is indicated with green arrows.
Figure 2  Crosstabs comparing the number of correct (correctly corresponding to histopathology) 
and incorrect (not corresponding with histopathology) assessments of GLP-1R PET/CT and 
SSTR PET/CT (A), Conventional imaging (B) and the combination of all standard imaging 
modalities (C).
A GLP-1R PET/CT SSTR PET/CT
B GLP-1R PET/CT SSTR PET/CT
A GLP-1R PET/CT
 SSTR PET/CT Correct Incorrect
 Correct 19 1
 Incorrect 11 1
B GLP-1R PET
 Conventional Correct Incorrect
 Correct 25 1
 Incorrect 5 2
C GLP-1R PET
 Standard Correct Incorrect
 Correct 26 1




The results of this prospective multicenter imaging trial show a superior accuracy 
(90.6%) and sensitivity (93.5%) of GLP-1R PET/CT for the localization of insulinomas 
compared to current standard imaging modalities. With GLP-1R PET/CT alone, 
30 out of 32 patients (94%) were correctly diagnosed. In 4 out of 32 patients (12.5%), 
correct diagnosis and decision to perform surgery was only reached with GLP-1R 
PET/CT. GLP-1R PET/CT therefore significantly influenced the clinical management 
of the patients in this population.
 SSTR PET/CT had an accuracy and sensitivity of only 59.4% and 61.3% respectively. 
While a detection rate of 85% was reported for SSTR PET/CT in a previous study 
(7), the levels of accuracy and sensitivity of SSTR PET/CT found in this study 
correspond well with expression levels of SSTR subtype 2 (69%) reported previously 
in insulinoma samples, using in vitro autoradiography (8). In addition to the 
superior detection rate of GLP-1R PET/CT, the image quality, quantified as tumor- 
to-background ratios and contrast-to-noise ratios, was clearly superior to SSTR 
PET.
 A previous prospective imaging study by Antwi et al., comparing GLP-1R 
PET/CT using [68Ga]Ga-DOTA-exendin-4 with conventional imaging, reported 
levels of accuracy (93.9%) and sensitivity (94.6%) of GLP-1R PET/CT for detection of 
insulinomas, which are comparable to this study. In this previous study, an 
accuracy of 67.6% and sensitivity of 69.4% was reported for the study MRI (6), 
which is also comparable to the accuracy and sensitivity (69.6% and 72.7% resp.) 
Figure 4  Tumor-to-background and contrast-to-noise ratios of GLP-1R PET and SSTR-PET 




found for MRI in the current trial. In the current trial however, GLP-1R PET was 
compared to the combination of conventional imaging modalities performed by 
the referring centers in the included patients, thereby better reflecting the current 
standard of care of patients with confirmed AHH in these centers and thus 
reflecting current best clinical practice. This combination of conventional imaging 
modalities resulted in an accuracy of 78.1% and sensitivity of 80.6%. While 
insulinomas can be difficult to discriminate from surrounding pancreatic tissue 
using conventional imaging, GLP-1R imaging provides more straightforward 
detection, because of the high tumor-to-background ratios. An interesting case 
which demonstrates this is patient 8. Both MRI as well as SSTR PET/CT were 
assessed as showing no suspicious lesions. However, after GLP-1R PET/CT 
revealed a very clear hotspot in the pancreatic body, the MRI was re-assessed and 
correlated with the GLP-1R PET after which a hypo-intense lesion was found at the 
same site (Figure 5).
In our patient population, the median size of the lesions identified by GLP-1R PET/
CT was 12 (10 – 18) mm, including 5 lesions smaller than 10 mm, showing the 
excellent sensitivity of the technique. The nature of the cases included in our trial 
thereby matches with the cases included in the trial by Antwi et al., in which a 
median tumor size of 12 mm was reported as well. The 2 false negative GLP-1R 
PET/CT findings in the current trial were identified in patients with tumors of 20 
mm (patient 25) and 35 mm (patient 30). These are therefore probably unrelated to 
the size of the tumors, but related to the lack of GLP-1R expression, which is in 
agreement with to the GLP-1R expression rate of 92% found by Reubi et al.
 Without invasive procedures such as EUS and AVSV, GLP-1R PET correctly 
diagnosed 30 out of 32 patients in our study population. Performance of EUS 
identified a lesion in only 1 additional patient. In addition to the multiple non- 
invasive imaging procedures which were performed in all patients, 13 patients 
Figure 5  Images of GLP-1R PET/CT, SSTR PET/CT and MRI (T1) of patient 8. Location of the 
tumor is indicated with green arrows.
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underwent an EUS before being referred for GLP-1R PET/CT. Performing GLP-1R 
PET as the primary diagnostic imaging procedure, potentially combined with 
contrast enhanced CT for optimal anatomical correlation and surgical planning, 
could thus grossly reduce the burden for AHH patients, eliminating the need for 
additional diagnostic procedures in most patients. 
 The first studies on GLP-1R imaging for detection of insulinoma have focused 
on SPECT/CT using 111In-labeled exendin (9, 16). The use of an exendin-based PET 
tracer has the advantage of the higher sensitivity and spatial resolution of the 
scanner and has therefore been shown to perform better than GLP-1R SPECT/CT 
(6, 12). In contrast to previous studies on GLP-1R PET/CT in patients with AHH (6, 
12, 17), we used the chelator NODAGA instead of DOTA. Because of the higher 
specific activity achieved through the use of this chelator and optimized labeling 
protocols, we injected a peptide dose of 4-7 µg in contrast to 12-24 µg used with 
[68Ga]Ga-DOTA-exendin. This lower peptide dose reduces the pharmacological 
effects of the peptide, resulting in the occurrence of nausea in only 5% of patients 
in this study compared to 27% of patients injected with [68Ga]Ga-DOTA-exendin. 
The ability to perform GLP-1R PET/CT imaging using such a low peptide dose 
with [68Ga]Ga-NODAGA-exendin is also favorable for the use of this tracer in 
children, in whom this technique could benefit diagnostic imaging of congenital 
hyperinsulinism, as is currently being assessed in a prospective trial (NCT03768518).
 A limitation of this study is the comparison of GLP-1R PET/CT to standard 
procedures performed according to the protocols of the referring centers. This 
could entail certain variation in the execution of these imaging procedures. Also, 
GLP-1R PET/CT was compared to all current standard imaging modalities except 
18F-DOPA PET/CT. While 18F-DOPA PET/CT is performed for diagnostic imaging 
of patients with AHH in certain centers, we did not include it in this trial, since it 
was not used as a standard diagnostic procedure in the majority of the referring 
centers. Previous studies assessing 18F-DOPA PET/CT included no more than 11 
patients and showed detection rates of 90% (18), 73% (19) and 50% (20). Antwi et al. 
Could not detect any insulinoma using 18F-DOPA in 5 patients in which GLP-1R 
PET/CT had a detection rate of 93% (6). These inconsistent results for 18F-DOPA 
compared to the consistently high reported sensitivity of GLP-1R PET/CT probably 
point towards a better performance of GLP-1R PET/CT.
 The study is furthermore limited by the fact that biochemically proven AHH 
is no confirmation of the presence of an insulinoma. Histopathological confirmation 
and clinical outcome was chosen as a reference standard and only patients 
undergoing surgery could therefore be included in the analysis. A considerable 
number of patients in this study (19%) did not undergo surgery because no lesion 
was detected with any of the imaging techniques, including GLP-1R PET. Therefore, 




While insulinomas are the most common cause of AHH and in the general 
population only 0.5% to 5% of cases are instead caused by diffuse beta cell 
hyperplasia, the percentage of patients with diffuse beta cell hyperplasia in this 
study is probably higher because of an inclusion bias because of referral of difficult 
cases with negative imaging results. 
Conclusion
This study demonstrates the superior performance of [68Ga]Ga-NODAGA-exen-
din-4 PET/CT compared to current standard non-invasive imaging modalities for 
pre-operative localization of benign insulinomas. Because of its high sensitivity 
and excellent imaging quality, [68Ga]Ga-NODAGA-exendin-4 PET/CT has the 
potential to be the primary diagnostic imaging modality in patients with AHH. 
[68Ga]Ga-NODAGA-exendin-4 PET combined with contrast enhanced CT could 
provide a one stop shop procedure for insulinoma diagnostics, which would 
eliminate the need for any further diagnostics in most patients. Since currently 
multiple different imaging procedures are performed, sometimes repeatedly, in most 
patients to reach a definite diagnosis, such a one stop shop procedure would benefit 
the patients considerably and could additionally improve cost-effectiveness of the 




1. Kinova MK. Diagnostics and treatment of insulinoma. Neoplasma. 2015;62(5):692-704.
2. Senniappan S, Shanti B, James C, Hussain K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, 
diagnosis and management. Journal of inherited metabolic disease. 2012;35(4):589-601.
3. Richards ML, Gauger PG, Thompson NW, Kloos RG, Giordano TJ. Pitfalls in the surgical treatment of 
insulinoma. Surgery. 2002;132(6):1040-9; discussion 9.
4. Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review 
of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675-86.
5. Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, et al. Localization of 
insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. The 
Journal of clinical endocrinology and metabolism. 2009;94(4):1074-80.
6. Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, et al. Comparison of glucagon-like 
peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: 
evaluation of diagnostic accuracy in a prospective crossover imaging study. European journal of 
nuclear medicine and molecular imaging. 2018;45(13):2318-27.
7. Prasad V, Sainz-Esteban A, Arsenic R, Plockinger U, Denecke T, Pape UF, et al. Role of (68)Ga 
somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative 
study. European journal of nuclear medicine and molecular imaging. 2016;43(9):1593-600.
8. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: 
molecular basis for in vivo multireceptor tumour targeting. European journal of nuclear medicine 
and molecular imaging. 2003;30(5):781-93.
9. Christ E, Wild D, Ederer S, Behe M, Nicolas G, Caplin ME, et al. Glucagon-like peptide-1 receptor 
imaging for the localisation of insulinomas: a prospective multicentre imaging study. The lancet 
Diabetes & endocrinology. 2013;1(2):115-22.
10. Wild D, Macke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult 
insulinomas. The New England journal of medicine. 2008;359(7):766-8.
11. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor 
imaging for localization of insulinomas. The Journal of clinical endocrinology and metabolism. 
2009;94(11):4398-405.
12. Antwi K, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, et al. Localization of Hidden 
Insulinomas with (6)(8)Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. Journal of nuclear medicine : 
official publication, Society of Nuclear Medicine. 2015;56(7):1075-8.
13. Fani M, Del Pozzo L, Abiraj K, Mansi R, Tamma ML, Cescato R, et al. PET of somatostatin recep-
tor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. 
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011;52(7):1110-8.
14. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/
CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 
68Ga-DOTA-TATE. European journal of nuclear medicine and molecular imaging. 2010;37(10):2004-10.
15. Denecke T, Grieser C, Froling V, Steffen IG, Rudolph B, Stelter L, et al. Multislice computed tomography 
using a triple-phase contrast protocol for preoperative assessment of hepatic tumor load in patients 
with hepatocellular carcinoma before liver transplantation. Transplant international : official journal 
of the European Society for Organ Transplantation. 2009;22(4):395-402.
16. Christ E, Wild D, Antwi K, Waser B, Fani M, Schwanda S, et al. Preoperative localization of adult ne-
sidioblastosis using (6)(8)Ga-DOTA-exendin-4-PET/CT. Endocrine. 2015;50(3):821-3.
17. Cuthbertson DJ, Banks M, Khoo B, Antwi K, Christ E, Campbell F, et al. Application of Ga(68) -DOTA-
exendin-4 PET/CT to localize an occult insulinoma. Clinical endocrinology. 2016;84(5):789-91.
18. Kauhanen S, Seppanen M, Minn H, Gullichsen R, Salonen A, Alanen K, et al. Fluorine-18-L-dihy-
droxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or 





19. Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F, et al. 18F-FDOPA PET/CT imaging of 
insulinoma revisited. European journal of nuclear medicine and molecular imaging. 2015;42(3):409-18.
20. Nakuz TS, Berger E, El-Rabadi K, Wadsak W, Haug A, Hacker M, et al. Clinical Value of (18)F-FDOPA 
PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with 




improves the diagnostic accuracy of 
focal congenital hyperinsulinism
Marti Boss1, Christof Rottenburger2,3, Winfried Brenner4, Oliver Blankenstein5, 
Vikas Prasad4,6, Sonal Prasad4,7, Paolo de Coppi8, Mijke Buitinga1,
Pirjo Nuutila9,10, Timo Otonkoski11,12, Khalid Hussain13, Maarten Brom1, 
Annemarie Eek1, Jamshed Bomanji3, Pratik Shah14,15, Martin Gotthardt1
Submitted
 1 Department of Medical Imaging, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands
 2 Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
 3 Institute of Nuclear Medicine, University College London, London, United Kingdom
 4 Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
 5 Department of Pediatric endocrinology, Charité University Hospital of Berlin, Berlin, Germany
 6 Department of Nuclear Medicine, University Hospital of Ulm, Ulm, Germany
 7 Berlin Experimental Radionuclide Imaging Center (BERIC), Charité-Universitätsmedizin Berlin, Berlin, Germany
 8 Department of Pediatric Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
 9 Department of Endocrinology, Turku University Hospital, Turku, Finland
 10 Turku PET Center, University of Turku, Turku, Finland
 11 Stem cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
 12 Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
 13 Department of Pediatric Medicine, Division of Endocrinology, Sidra Medical and Research Centre, Doha, Qatar
 14 Pediatric Endocrinology Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom





Surgery with curative intent can be offered to congenital hyperinsulinism (CHI) 
patients, provided that the lesion is focal. Radiolabeled exendin-4 specifically 
binds the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) on pancreatic beta 
cells. In this study we compared the performance of [18F]F-DOPA PET (DOPA PET) 
and PET with the new tracer [68Ga]Ga-NODAGA-exendin-4 (Exendin PET) in the 
preoperative diagnostics of focal CHI
Methods
Nineteen CHI patients underwent both DOPA PET and Exendin PET prior to 
surgery. The images were evaluated in three settings a) standard clinical reading 
b) blinded expert reading and c) joined reading. Target (lesion) / non target (normal 
pancreas) ratio were determined using maximum standard uptake value (SUVmax). 
Image quality was rated by pediatric surgeons in a questionnaire.
Findings
Fourteen/nineteen patients having focal lesions underwent surgery. Based on 
clinical readings, the sensitivity of Exendin PET (100% (CI 77-100%)) was higher 
than DOPA PET (71% (CI 42-92%)). Interobserver agreement between readings was 
higher for Exendin than DOPA PET (Fleiss’ kappa 0.91 vs. 0.56). Exendin PET 
provided significantly (p=0.021) higher target / non target ratios (2.02 ± 0.65 ) than 
DOPA PET (1.40 ± 0.40). On a five point scale, Pediatric surgeons rated Exendin PET 
superior to DOPA PET.
Interpretation
Exendin PET has higher clinical sensitivity and better interobserver correlation 
than DOPA PET for the detection of focal CHI. Better contrast and image quality 
makes Exendin PET superior to DOPA in surgeons’ intra-operative quest for lesion 
localization.
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Introduction
CHI is the most common cause of persistent and recurrent hypoglycemia in 
neonates. It occurs with an incidence of one in 35000-40000 births (1). CHI often 
presents in neonates with poor feeding, seizures, jitteriness, hypotonia, apnea, 
cyanosis, hypothermia or a hypoglycemia-induced life-threatening event (2). CHI 
can also present in infancy or childhood and in rare cases even in adolescents or 
young adults (3). To avoid brain injury by hypoglycemia, an early diagnosis and 
proper treatment of CHI are of crucial importance. The diagnosis of CHI is based 
on clinical findings as well as hypoglycemic events combined with inappropriately 
high insulin levels (4). In diffuse CHI, which accounts for 60-70% of all cases, there 
is diffuse involvement of the pancreatic beta cells with enlarged hyperfunctioning 
cells with abnormally large nuclei and abundant cytoplasm (5,6). This subform is 
caused by recessive or dominant mutations in the ABCC8 or KCNJ11 genes, 
encoding for the beta cell ATP-sensitive potassium channels. Diffuse CHI is 
primarily treated with medication for the suppression of insulin secretion, such as 
diazoxide. However, many patients with recessive mutations in the ABCC8 and 
KCNJ11 genes are unresponsive to this therapy and near-total pancreatectomy 
may then be the only option to avoid devastating hypoglycemia. Even after such an 
invasive procedure, which carries a risk of developing insulin-dependent diabetes 
and exocrine pancreatic insufficiency, some children present with recurring 
hypoglycemia requiring further treatment with medication or even re-operation (7). 
 Focal CHI accounts for 30-40% of all CHI cases associated with the KATP channel 
genes. This form is characterized by focal adenomatous islet cell hyperplasia 
caused by the concurrence of a paternal mutation in the ABCC8 or KCNJ11 gene 
and somatic loss of heterozygocity of the maternal chromosome 11p15 region 
within a limited region in the pancreas (8,9). Because there is only involvement of 
a specific area in the pancreas in focal CHI, this subform can be treated successfully 
by partial pancreatectomy or limited lesionectomy, which can cure the disease in 
case of complete removal of the lesion (6). Since focal CHI can be treated with much 
less invasive surgery than diffuse CHI, correct differentiation between these 
subforms is of great importance. Also, precise pre-surgical localization of the focal 
lesion is important for correct surgical planning and optimization of surgical 
outcome. If the lesion resides in the body or tail of the pancreas, even a minimally 
invasive, laparoscopic procedure may be performed (10).
 The current standard imaging technique used for non-invasive detection of 
focal CHI is 18fluoro-L-dioxyphenylalanine ([18F]F-DOPA) PET (DOPA PET) (11). 
This technique was shown to have a sensitivity of 85%-89% for the diagnosis of 
focal CHI (12), so in some cases focal lesions are still missed. In this study, we use 
a new radiotracer based on the peptide exendin-4, which specifically binds to the 
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GLP-1R expressed on pancreatic beta cells with high affinity (13). 68Ga-labeled 
exendin has already been shown to detect insulinomas with high sensitivity 
(14,15), and the specific tracer used in the current study, [68Ga]Ga-NODAGA-exen-
din-4, is currently being assessed in a large prospective trial for insulinoma 
imaging (NCT03189953). We have now analyzed data of patients with CHI who 
underwent both DOPA PET and [68Ga]Ga-NODAGA-exendin-4 PET (Exendin PET) 
to compare the effectiveness of these two imaging techniques for the diagnosis and 
localization of focal CHI.
Materials and methods
Study design and patients
In this multicenter imaging study (NCT03768518), patients were included at the 
Great Ormond Street Hospital London in the United Kingdom and the Radboud 
University Medical Center Nijmegen in The Netherlands. Recruitment of patients 
was performed directly in these centers as well as by referral from several tertiary 
centers across Europe. 
 Patients were enrolled with biochemically proven endogenous CHI who were 
unresponsive to medical treatment and qualified for DOPA PET based on mutation 
analysis (no genetically proven diffuse CHI based on a homozygous or compound 
heterozygous ABCC8/KCNJ11 mutation). Exclusion criteria were renal insufficiency 
(creatinine clearance < 40 ml/min) and evidence of other malignancies than insulin 
producing lesions in imaging studies. The study was approved by the local 
institutional review board of each of the participating institutes. Parents of all 
included patients provided written informed consent in accordance with provisions 
of the Declaration of Helsinki.
 In addition, data from subsequent CHI patients diagnosed and treated at the 
Charité University Hospital Berlin in Germany were analyzed in accordance with 
national drug regulations. Parents of these patients provided written informed 
consent for the use of the new radiotracer as well.
Radiopharmaceutical preparation of [68Ga]Ga-NODAGA-exendin-4
GRP synthesizer module was purchased from Scintomics GmbH, Germany and 
Modular Lab PharmTracer synthesis module from Eckert & Ziegler GmbH, 
Germany. Hydrochloric acid (HCl) was supplied by Rotem Industries Ltd. 68GaCl3 
was obtained from 1850 MBq 68Ge/68Ga generator (Galliapharm®, Eckert & Ziegler 
GmbH, Germany), SEPPAK C8 Plus Light Cartridges (C8) were purchased from 
Waters, UK and Chromafix® PS-H+ (small) from Macherey NagelTM, Germany. 
All other components were acquired as one disposable kit (Reagent and hardware 
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kit for synthesis of 68Ga peptides using cationic purification) from ABX GmbH, 
Germany. 
GRP Synthesizer Module (RadboudUMC Nijmegen)
The generator was eluted with 10 ml of 0.1 N HCl and 68Ga was trapped on a 
polystyrene-H+ (PS-H+) cartridge. The cartridge was then eluted with 1.5 ml of 5M 
NaCl in 0.1 M HCl (eluent) into the reaction vial, containing 200 µl of 
exendin-NODAGA (10 µg of peptide in water for injection (WFI)), 475 µl of 2.5 M 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer and 50 µl 
ascorbic acid (100 mg/ml in WFI). After 15 minutes incubation at 100°C, the vessel 
is cooled and 2 ml ethylenediaminetetraacetic acid (EDTA ), 50 mM/polysorbate 80 
0.15% is added. [68Ga]Ga-NODAGA-exendin-4 was purified on a HLB cartridge, 
sterilized by passing through a 0.2 µm filter (millex GV) and diluted with saline.
Modular Lab PharmTracer Module (Charité Berlin and UCLH London)
The C18 cartridge of the cassette (C4-GA68-AFPP) was replaced by a C8 cartridge 
and the STRATA X cartridge was replaced by a PS-H+ cartridge (s) after pre- 
conditioning with 2ml of eluent followed by 5 ml of WFI. The generator was 
then eluted with 10 ml of 0.1 N HCl and 68Ga was trapped on the PS-H+(s) cartridge. 
The cartridge was eluted with 1.7 ml of eluent into the reaction vial, containing 
200 µl exendin-NODAGA (10 µg of peptide in WFI), 475 µl of 2.5 M HEPES buffer 
and 50 µl ascorbic acid (100 mg/ml in WFI). After 10 minutes incubation at 85 °C, 
the reactor was allowed to cool down to 70° C before adding 2 ml of EDTA, 50 mM/
polysorbate 80 0.15%. [68Ga]Ga-NODAGA-exendin-4 was purified on a C8 cartridge, 
sterilized by passing through a 0.2 µm filter (millex GV) and diluted with saline. 
 Quality controls were performed on Radio-HPLC and Radio-TLC systems 
with a radiochemical purity of ≥ 95%. The pH of the tracer was around 6, the 
radiochemical yield and the molar specific activity were determined to be 50-60% 
and 175-200 MBq/nmol, respectively.
Procedures
In all patients, [18F]F-DOPA (3 MBq/kg with a lower limit of 40 MBq) was injected 
as a slow bolus over one minute. Patients were not fasted and no pre-treatment 
with carbidopa was performed. A PET acquisition of one bed position and ten 
minutes per bed position was started 20 minutes after injection of the tracer. 
Depending on assessment of the first scan, additional PET acquisitions were 
performed at 40 and/or 60 minutes after injection of the tracer.
 For Exendin PET, [68Ga]Ga-NODAGA-exendin-4 (1.6 MBq/kg with a lower 
limit of 20 MBq, corresponding to a peptide dose of maximally 0.12 µg/kg and a 
lower limit of 1.4 µg) was injected intravenously as a slow bolus over five minutes 
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in all patients. Patients were fasted for one hour prior to injection of the tracer 
aiming to reduce endogenous GLP-1 production. Blood glucose levels were 
monitored before, and at least at 5, 10, 15, 30, 60, 90 and 120 minutes after injection of 
the tracer. Since blood glucose levels may decrease as a result of exendin injection, 
close monitoring was performed. Intravenous glucose injection was given to all 
patients as required to manage glucose levels during the procedure.
 PET acquisition methods varied because of differences in institutional standard 
of care for CHI patients. Details on Exendin PET/CT and PET/MRI acquisition 
procedures for all centers as well as reconstruction parameters are given in Table 1. 
At the Great Ormond Street Hospital London, a protocol has been developed over 
the last eight years for DOPA PET/CT to be carried out under oral sedation with 
chloral hydrate in children with CHI to avoid general anesthesia (manuscript 
in submission). The same protocol was adopted to undertake the Exendin PET 
in London.
 At the Radboudumc in Nijmegen, one patient was included. Scans in Nijmegen 
were performed without anesthesia with the use of a vacuum mattress. 
 Real world evidence from an institutional database of 11 CHI patients who 
underwent an Exendin PET for diagnostic purposes at the Charité University 
Hospital Berlin were included. In Berlin, patients are imaged under inhalation 
anesthesia with isoflurane under the supervision of an anesthesiologist unless 
older children are able to undergo the procedure without sedation.
Evaluation
Histological evaluation and clinical outcome (normalization of blood glucose 
levels after surgery) were used as a reference standard. Clinical reading of DOPA 
PET and Exendin PET scans was performed at the site of patient inclusion. The 
clinical reading was performed by a pediatric endocrinologist (hyperinsulinism 
expert) together with a nuclear medicine physician and a pediatric surgeon at the 
site of the PET scan. In addition, all DOPA and Exendin PET images were 
re-evaluated by one (MG) blinded Exendin-experienced nuclear medicine 
physician (expert reading). Additionally, a joint re-evaluation of all images was 
performed by this Exendin-experienced nuclear medicine physician together with 
a pediatric endocrinologist highly experienced in DOPA PET reading. For the 
expert and joint readings all images were evaluated in terms of the subform of the 
disease (focal vs. diffuse) and, if detected, the size and location of the focal lesion. 
For exact localization of the focal lesion, the pancreas was divided into six areas 
based on anatomical relation to the pancreatic duct and portal vein (Figure 1). In all 
image evaluations, images from all timepoints were used for interpretation.
 Quantitative analysis of all DOPA PET and Exendin PET/CT or PET/MR scans 
was performed by a non-blinded expert. Volumes of interest were drawn to 
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determine tracer uptake expressed as maximum standardized uptake value 
(SUVmax) in different parts of the pancreas as well as in visible focal lesions. SUVmax 
ratios of the areas with the highest tracer uptake and of the area with the next 
highest tracer uptake were determined. VOIs were drawn over the head, body and 
tail of the pancreas. Within these VOIs, isocontour VOIs were created consisting of 
the voxels with the 30% highest intensity (example of resulting VOIs are depicted 
in Figure 2). For quantification of the dynamic PET scans, reconstructed images of 
Table 1  Imaging and reconstruction parameters.
GOSH London
Scanner PET/CT: Discovery PET/CT 710 slice scanner (GE Healthcare)
PET acquisition List mode, start with tracer injection, 50 min duration
PET reconstruction 2 iterations, 24 subsets, standard Z filter 5 mm, 256x256 matrix
CT parameters Low-dose CT scan without contrast, 100 kV, modulated between 10 
and 210 mA, slice thickness 5 mm, 50 cm field of view
RadboudUMC Nijmegen
Scanner PET/CT: Biograph mCT-40 time-of-flight (Siemens)
PET acquisition Static, started 45 minutes after tracer injection, 10 min duration
PET reconstruction 3 iterations, 21 subsets, post-reconstruction Gaussian filter of 3 mm in 
full width at half maximum, 200x200 matrix
CT parameters Low-dose CT scan without contrast, 120 kV, 50mA, slice thickness 5 
mm, 780 mm field of view
Charité Berlin
Scanner PET/CT: Philips Gemini TF16 ASTONISH
PET/MRI: Siemens Biograph mMR
PET acquisition PET/CT: dynamic, started with tracer injection, 40 min duration
PET/MRI: List mode, started with tracer injection, 1 hour duration
PET reconstruction PET/CT + PET/MRI: 8 frames à 5 min; 20 min p.i. 1 frame à 10 min; 
30 min p.i. 1 frame à 10 min 
PET/CT: BLOB-OS-TF, reconstruction filter “smooth”, 144x144, 
4.0x4.0x4.0 mm
PET/MR: 3 iterations, 21 subsets, post-reconstruction Gaussian filter 
of 4 mm, 172x172 matrix, pixel spacing 4.2x4.2x2.0 mm
CT parameters Low-dose CT without contrast, 100 kV, modulated between 10 and 
210 mA, slice thickness 5 mm, 50 cm field of view
MRI parameters Attenuation: STARVIBE, TR 3.9 ms, TE 1.2 ms, Alpha 10.6°




the timeframe 30 to 40 minutes (Berlin) or 40 to 45 minutes (London) after injection 
were used.
 To estimate the optimal imaging time point for Exendin PET, SUVmax ratios in 
reconstructed images of five-minute intervals over the imaging period from 0 to 45 
minutes after tracer injection were determined in four patients with focal disease 
at the Great Ormond Street Hospital in London. 
 To evaluate image quality and correlation of imaging results with the intra-
operative findings, DOPA PET and Exendin PET images of 13 patients with a 
detected focal lesion were rated by the involved pediatric surgeon using a 
questionnaire based on the Leiden-surgical rating scale (Figure 3).







A = Head 
B = Body
C = Tail 
1 = Above the pancreatic duct
2 = Below the pancreatic duct
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Figure 2  VOIs created of the voxels with the 30% highest intensity in the head (A), body (B) 
and tail (C) of the pancreas, used to calculate SUVmax ratios.
Figure 3  Surgeon questionnaire.
A B C
Surgeon questionnaire
The questionnaire for the pediatric surgeons, used to assess image quality and 
correlation of imaging results with intra-operative findings, contained the following 
questions:
1) How many CHI surgeries have you performed during your career?
1. > 10
2. < 10
2) How many CHI surgeries have you performed during the last 3 years
1. > 5
2. < 5
3) How do you rate the preoperative image quality for your decision on 
performing surgery? lesion? Please rate according to the following scale:
1. Image quality extremely poor for decision making
2. Image quality poor for decision making
3. Image quality acceptable for decision making
4. Image quality good for decision making
5. Image quality optimal for decision making
1) How well did the imaging results correlate with the intraoperative findings? 
Please rate according to the following scale:
1. Extremely poor correlation with intra-operative findings
2. Poor correlation with intra-operative findings
3. Acceptable correlation with intra-operative findings
4. Good correlation with intra-operative findings
5. Optimal correlation with intra-operative findings




Positive imaging results confirmed by histopathology and the clinical outcome in 
terms of normalization of blood glucose levels in the patient after surgery were 
regarded as true positives. 59% confidence intervals for sensitivity were calculated 
using the Clopper-Pearson method. Interobserver variation was calculated using 
Fleiss’ kappa. SUVmax ratios in DOPA PET and Exendin PET scans were compared 
using paired sample T-tests. Surgeon scores of image quality were compared using 
Wilcoxon signed rank tests. Statistical analyses were performed using SPSS 
(version 22; SPSS, Chicago, IL).
Results
Patients
We included data of 19 CHI patients. Baseline characteristics of the patients are 
given in Table 2 and clinical details of the patients are given in Table 3. All patients 
underwent DOPA PET and Exendin PET, with a median time of 13 (4 – 72) days 
between the procedures. Upon clinical reading of the scans, DOPA PET revealed 
focal areas of high tracer uptake suspicious for focal lesions in ten patients (53%) 
and Exendin PET revealed suspicious focal lesions in 14 patients (74%) (Table 4). 
The study profile is depicted in Figure 4.
Table 2   Patient characteristics. 
Participants (n=19)
Age (months) 8.3 (4.0 – 22.0)
















Data are given as median and interquartile range or number/total and percentage
59
 LOCALIZATION OF FOCAL CHI
3
















1 18 Paternal ABCC8 mutation Lanreotide  
+ gastrostomy feeds
Partial
2 22 Paternal ABCC8 mutation Octreotide + Diazoxide  
+ gastrostomy feeds
Partial
3 125 Paternal ABCC8 mutation Octreotide, switched to 
Lanreotide
Full response to 
Lanreotide
4 50 Paternal ABCC8 mutation Octreotide  
+ gastrostomy feeds
Partial
5 61 Paternal ABCC8 mutation Octreotide + Sirolimus  
+ gastrostomy feeds
Partial
6 12 Paternal ABCC8 mutation Octreotide Full 
7 8 Paternal ABCC8 mutation Octreotide  
+ gastrostomy feeds
Partial
8 8 Paternal ABCC8 mutation Octreotide Partial
9 4 Paternal ABCC8 mutation Octreotide Full
10 5 Paternal ABCC8 mutation Octreotide + Diazoxide Partial (limited)
11 2 Paternal ABCC8 mutation Octreotide Partial
12 2 Paternal ABCC8 mutation Octreotide (continuous) Partial
13 9 Paternal ABCC8 mutation Octreotide Partial
14 10 Unknown (no mutation  
in ATP-sensitive potassium 
channel)
Octreotide + Diazoxide  
+ gastrostomy feeds
Partial
15 68 No mutation in known 
CHI-genes
Diazoxide Partial/full 
16 4 No mutation in known 
CHI-genes
Octreotide Full
17 4 Paternal ABCC8 mutation Octreotide Partial
18 6 Paternal ABCC8 mutation Octreotide Full




One patient (5%) experienced vomiting following injection of [68Ga]Ga-exendin. 
In two patients (11%), episodes of mild hypoglycemia occurred following injection 
of [68Ga]Ga-exendin, requiring intervention. In the other patients, glucose levels 
were stable (> 3.5 mmol/L) under regular monitoring and intravenous glucose 
infusion. No other adverse events occurred in any of the patients.
Table 4   Sensitivity of DOPA PET and Exendin PET based on clinical  
and study readings.
DOPA PET Exendin PET
Focal lesions detected 
(clinical reading) 10/19 (53%) 14/19 (74%)
Sensitivity
Based on clinical reading
Based on expert reading
Based on joint reading
71% (42 – 92%)
86% (57 – 98%)
100% (77 – 100%)
100% (77 – 100%)
93% (66 – 100%)
100% (77 – 100%)
Data given as value and 95% confidence interval, and percentages of agreement between readings. 
Sensitivity is calculated for cases with focal lesions only.
Figure 4  Study profile.
19 Patients with biochemically confirmed 
congenital hyperinsulinism
16 patients underwent surgery
- 14 patients: lesion detected
- 2 patients: no lesion detected, but 
insufficient response to medication




- Impact on surgical ease
16 patients underwent surgery
19 patients underwent DOPA PET
& Exendin PET
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Surgery
Results of both imaging procedures were used for surgical planning. Suspicious 
lesions were detected by clinical reading of the PET images in 14 patients. These 
patients underwent surgery and presence of a focal lesion was confirmed by histo-
pathological evaluation in all of these. All surgically treated patients with focal 
lesions were cured after surgery (normalization of blood glucose levels in long-term 
follow-up).
 Of the remaining five patients, in which no focal lesion was detected by clinical 
reading (diffuse tracer uptake on both DOPA and Exendin PET), two underwent 
near-total pancreatectomy because of insufficient response to medication. In line 
with the imaging results, histopathology indicated focal disease in these patients. 
Diagnostic performance
Results of the DOPA PET and Exendin PET are summarized in Table 4. In this 
patient population, Exendin PET has a sensitivity of 100% (CI 77-100%) for detection 
of focal lesions compared to a sensitivity of 71% (CI 42-92%) for DOPA PET, based 
on clinical readings of the images. In four out of 19 patients (21%), focal lesions 
were only identified using Exendin PET in the clinical reading. In these patients, 
the surgery planning was based solely on the results of the Exendin PET. DOPA 
PET and Exendin PET images of these four cases are shown in figure 5. Based on 
the clinical readings, Exendin PET performed better for detection of focal lesions 
in CHI. 
Interobserver correlation
Upon re-evaluation of the DOPA PET images by an expert nuclear medicine 
physician, two additional focal lesions were identified, increasing the sensitivity to 
86% (57-98%). In the expert readings of the Exendin PET images, one focal lesion 
was missed, decreasing the sensitivity to 93% (66-100%). By joint reading of the 
images by an expert nuclear medicine physician and pediatric endocrinologist, 
all focal lesions were detected on both Exendin PET and DOPA PET. While the 
sensitivity of both techniques reached 100%, the interobserver agreement between 
the readings is higher for Exendin PET than DOPA PET (Fleiss’ kappa 0.91 vs. 0.56). 
For Exendin PET there is almost perfect agreement while for DOPA PET, the level 
of agreement between the readings is only moderate. The increased sensitivity of 
DOPA PET only upon re-evaluation of the images, together with the higher 
interobserver agreement in evaluation of the Exendin PET images, clearly indicates 
a facilitated and more reliable interpretation of the Exendin PET images compared 
to the DOPA PET images leading to more unequivocal results.
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Figure 5  Exendin PET and DOPA PET images of patient 2 (A), patient 4 (B), patient 6 (C) and 
patient 9 (D), in which Exendin PET scans were reported as focal while DOPA PET scans 
were reported as diffuse in clinical readings. Locations of the focal lesions (for F-DOPA PET 
detected during joined readings) are indicated with green arrows. In D, the focal lesion in 
the head is indicated with green arrows and for comparison tracer uptake in the tail is 
indicated with red arrows. Presence of focal lesions was confirmed by histopathology in all 
four patients.
Exendin PET DOPA PETA
Exendin PET DOPA PETB
Exendin PET DOPA PETC
Exendin PET DOPA PETD
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Semiquantitative analysis
In patients with histopathologically proven focal CHI, SUVmax ratios between the 
focal lesion and the area of the pancreas with the next highest tracer uptake are 
significantly higher in Exendin PET than DOPA PET (2.02 ± 0.65 and 1.40 ± 0.40, 
respectively, p=0.021), while SUVmax ratios in patients with diffuse disease 
(between the two pancreatic regions with the highest tracer uptake) were 
comparably low (1.08 ± 0.06 for Exendin PET and 1.15 ± 0.13 for DOPA PET) (Figure 
6). These quantitative data show that Exendin PET provides better contrast to 
discriminate between focal and diffuse disease, and thus explains the different 
findings for interobserver agreement levels of the two tracers. 
Quantification of reconstructed images of five-minute intervals over the imaging 
period shows some variability between patients in the timepoint which shows the 
highest SUVmax ratio. SUVmax ratios over time of these patients are depicted in 
Figure 7. For all four patients, the highest SUVmax ratio is between 30 and 45 
minutes after tracer injection. This therefore seems to be the best timeframe for 
Exendin PET imaging.
Figure 6  SUVmax ratios between the area with the highest tracer uptake and the area with 
the next highest tracer uptake. Scans with identified focal lesions during clinical reading are 




The influence of the PET image quality on the surgical ease was measured by 
rating of the DOPA and Exendin PET images by the involved pediatric surgeons. 
These surgeons were all experienced surgeons who have performed more than ten 
CHI surgeries during their career and more than five CHI operations during the 
last three years. Rating of the PET image quality by the surgeons showed 
significantly higher scores for Exendin PET than for DOPA PET for the decision to 
perform surgery (4.5 vs. 3.8 resp., p=0.025, figure 8A) as well as correlation of the 
imaging results with intra-operative findings (4.4 vs. 3.7 resp., p=0.0083, figure 8B). 
Out of 13 cases, surgeons reported to prefer Exendin PET imaging for future CHI 
patients in nine cases, versus DOPA PET in only one case and no preference in 
three cases, indicating a better image quality of Exendin PET compared to DOPA 
PET and the possible benefit for the surgical treatment of CHI patients.
Figure 7  SUVmax ratios in Exendin PET images at different imaging timepoints of 4 patients 
with detected focal lesions.
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Discussion
The results of the present study indicate that Exendin PET is a promising tool for 
detection and localization of focal CHI. Standard clinical reading of the images 
provided a correct diagnosis of focal CHI in all 14 histologically proven cases 
based on Exendin PET (sensitivity: 100%, CI: 77-100%), while in four of the 14 cases 
diffuse disease was incorrectly diagnosed based on DOPA PET (sensitivity 71%, CI: 
42-92%). While sensitivity of both techniques reached 100% upon joint reading by 
an expert nuclear medicine physician and a pediatric endocrinologist, the higher 
sensitivity of Exendin PET in clinical readings indicates easier reading and superior 
performance providing more unequivocal results. The more reliable performance 
of Exendin PET is also indicated by the higher interrater agreement between 
clinicians and experienced readers. Previously, a large prospective study with 50 
cases and retrospective reviews of 105 and 195 cases reported sensitivities of 88%, 
85%, and 89% respectively, for diagnosis of focal CHI using DOPA PET (12,16,17). 
The fact that in our small population of 19 patients, four cases of focal CHI were 
clinically not identified using DOPA PET, is suggestive of a high complexity of the 
cases. An overrepresentation of such difficult cases in our study population could 
result from an increased incentive to refer patients with complex and equivocal 
imaging results for a new investigative diagnostic procedure. In this population, 
Exendin PET outperformed DOPA PET in the clinical non-expert setting, 
Figure 8  Rating scores of Exendin PET and DOPA PET images by pediatric surgeons. Scores on 
preoperative image quality for the decision to perform surgery (A) and correlation of imaging 




facilitating curative surgery without the need for further medicinal treatment or 
near-total pancreatectomy in four additional patients. Exendin PET therefore had 
a major positive impact on the clinical management of these patients. 
 All focal lesions identified by Exendin PET were confirmed by histopathology. 
Four patients in which both, DOPA PET and Exendin PET indicated diffuse disease 
did not undergo surgery, but received continued medical treatment. Therefore, we 
cannot exclude the possibility that a focal lesion was missed in these patients by 
both imaging procedures. 
 Quantitative analysis of scans of patients with histopathologically confirmed 
focal CHI showed significantly higher SUVmax ratios in Exendin PET compared to 
DOPA PET (2.04 ± 0.56 vs. 1.23 ± 0.19 resp., p=0.02). The higher contrast between 
uptake in the focal lesion and the remainder of the pancreas in the Exendin PET 
scans enables easier detection of focal lesions, explaining the higher sensitivity of 
Exendin PET based on the initial clinical reading, and the higher rate of agreement 
in readings of Exendin PET images between clinical and expert readers, compared 
to DOPA PET images. This is of importance, especially in cases with a heterogeneous 
pattern of tracer uptake in the pancreas, which are usually difficult to diagnose (12).
 The superior image quality of Exendin PET is important for both the scan 
reading and the surgical procedure, since successful surgery depends on precise 
pre-surgical diagnosis of focal CHI and subsequently finding and completely 
removing the focal lesion intraoperatively. This is reflected in the rating of the 
images by pediatric surgeons. Exendin PET could benefit the surgical treatment of 
CHI patients by facilitating the decision to perform surgery as well as the intra- 
operative localization of the focal lesion.  
 Image quantification of dynamic Exendin PET scans of four patients showed 
the highest SUVmax ratios, indicating that the best timeframe for imaging is 
between 30 and 45 minutes after tracer injection. Focal lesions in the tail of the 
pancreas, which overlap with the contour of the left kidney pose a diagnostic 
challenge with DOPA PET, which has been described previously (12). Because of 
the high renal accumulation of Exendin, this issue also occurs with Exendin PET. 
In such cases, performing additional scans at later time points could be beneficial, 
since uptake of Exendin in the kidneys was shown to decrease over time in adult 
patients (18).
 The introduction of DOPA PET to discriminate between focal and diffuse CHI 
has had a major impact on the clinical approach for CHI patients by eliminating 
the need for more invasive diagnostic procedures like selective arterial calcium 
stimulation and simultaneous venous sampling (ASVS) or transhepatic portal 
venous insulin sampling (THPVS), and by optimizing surgical treatment because 
of increased diagnostic accuracy. In addition to the better image quality of Exendin 
PET compared to DOPA PET, another important advantage of Exendin PET is the 
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production of 68Ga with a generator system, enabling on site production of the 
radiotracer even at PET centers without a cyclotron facility. Since [18F]F-DOPA is 
often difficult to obtain, this could transform the care for focal CHI patients in such 
centers. An additional important advantage of [68Ga]Ga-exendin-4 is the very low 
radiation dose to the patients, which we previously calculated to be about four-fold 
lower for newborn patients than the radiation dose from [18F]F-DOPA (18).
Conclusion
In this study we provide the first clinical evidence for detection and localization of 
focal CHI using Exendin PET. These first results demonstrate a better image quality 
of Exendin PET compared to the standard DOPA PET, resulting in a higher 
sensitivity in clinical reading which changed the surgical management in four out 
of 19 patients. Exendin PET therefore has the potential to improve treatment of 
patients with focal CHI by improving the diagnostic accuracy and certainty. This 
could enable the performance of curative surgery in more patients and benefit 
surgical planning by providing more precise and reliable pre-operative images. 
While the performance of Exendin PET needs to be further assessed in a larger 
patient population, we believe that Exendin PET has the potential to replace DOPA 
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[68Ga]Ga-NODAGA-exendin-4 is a promising tracer for beta cell imaging using 
PET/CT. Possible applications include pre-operative visualization of insulinomas 
as well as discrimination between focal and diffuse forms of congenital hyperin-
sulinism. There is also a significant role for this tracer in extending our knowledge 
on the role of beta cell mass in the pathophysiology of type 1 and type 2 diabetes 
by enabling non-invasive quantification of tracer uptake as a measure for beta cell 
mass. Calculating radiation doses from this tracer is important to assess its safety 
for use in patients (including young children) with benign diseases and healthy 
individuals.
Methods
Six patients with hyperinsulinemic hypoglycemia were included. After intravenous 
injection of 100 MBq of the tracer, 4 successive PET/CT scans were obtained at 30, 
60, 120 and 240 minutes post injection. Tracer activity in the pancreas, kidneys, 
duodenum and remainder of the body were determined and time-integrated activity 
coefficients for the measured organs were calculated. OLINDA/EXM version 1.1 
software was used to calculate radiation doses using the reference adult male and 
female models and to estimate radiation doses to children.
Results
The mean total effective dose for adults is very low (0.71 ± 0.07 mSv) for a standard 
injected dose of 100 MBq. The organs with the highest absorbed dose are the 
kidneys (47.3 ± 10.2 mGy/ 100 MBq). The estimated total effective dose is 2.32 ± 
0.32 mSv for an injected dose of 20 MBq in newborns. This dose decreases to 0.77 ± 
0.11 / 20 MBq for children of 1 year old and 0.59 ± 0.05 mSv for an injected dose 
of 30 MBq in 5 year old children.
Conclusion
Our human PET/CT based dosimetric calculations show that the effective radiation 
doses from the novel tracer [68Ga]Ga-NODAGA-exendin-4 for adults as well as 
children are very low. The doses are lower than reported for other polypeptide 
tracers such as somatostatin analogs (2.1-2.6 mSv/ 100 MBq) and are beneficial for 





For new radiopharmaceuticals, estimating effective radiation doses is important to 
determine their safety for patients. The radiopharmaceutical [68Ga]Ga-NODA-
GA-exendin-4 binds specifically to the glucagon-like peptide 1 (GLP-1) receptor 
(GLP-1R), which is expressed on pancreatic beta cells (1). It is a promising tracer for 
in vivo targeting of beta cells using positron emission tomography/ computed 
tomography (PET/CT) with several possible applications in clinical diagnostics of 
insulin-producing lesions as well as diabetes research. Since these applications 
entail the use of this radiopharmaceutical in patients with a generally normal life 
expectancy (i.e. patients with benign tumors or diabetes mellitus) and even in 
completely healthy individuals in control groups for research, performing 
dosimetric calculations is of substantial importance.
 A promising application of this new tracer is pre-operative visualization of 
insulin-producing neuroendocrine tumors (insulinomas), for which current standard 
imaging methods have limited sensitivity (2-4). Clinical studies have shown the 
potential of 111In-labelled exendin for detection of such tumors with single-photon 
emission computed tomography (SPECT)/CT (5-7). [68Ga]Ga-exendin PET/CT has 
been demonstrated to be superior to 111In-exendin SPECT/CT in a small cross-over 
clinical trial (8) and its superiority over conventional imaging was shown in a large 
prospective trial (9). Currently, a multicenter prospective trial is ongoing comparing 
the sensitivity of [68Ga]Ga-NODAGA-exendin-4 PET/CT for detection of insulinomas 
with all current standard non-invasive imaging modalities (Somatostatin receptor 
PET/CT, triple phase CT and magnetic resonance imaging (MRI)) (NCT03189953). 
Next to this, [68Ga]Ga-NODAGA-exendin-4 PET/CT is being investigated as a 
potential new imaging method to distinguish between diffuse and focal forms of 
congenital hyperinsulinism (NCT03768518) (10, 11).
 In addition to these clinical applications, [68Ga]Ga-NODAGA-exendin-4 has 
great potential as a research tool to determine beta cell mass in vivo. Changes in 
beta cell mass over time in type 1 diabetes as well as type 2 diabetes are not well 
characterized, since previous studies had to rely on data obtained after autopsy or 
pancreatectomy, which only provided data at a single point in time and did not 
always provide information from the complete pancreas (12, 13). By using [68Ga]
Ga-NODAGA-exendin-4 PET/CT, it would be possible to investigate the dynamics 
of beta cell mass during onset and progression of the disease. Hereby, this 
technique can contribute to the knowledge regarding the role of beta cell mass in 
the pathophysiology of diabetes.
 For these applications of [68Ga]Ga-NODAGA-exendin-4, a low effective 
radiation dose is important, especially for the possibility of performing repeated 
imaging. Moreover, low effective doses are essential since an important application 
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involves the use in often very young children with congenital hyperinsulinism. 
In this study we therefore performed human PET-based dosimetry in adult patients 
with a suspicion of insulinoma to determine effective radiation doses as well as 




Hydrochloric acid was purchased from Rotem Industries (Mishor Yamin: Israel). 
All other components were purchased as one disposable kit (reagent and hardware 
kit for synthesis of 68Ga peptides using cationic purification, ABX, Germany). 
[68Ga]Ga-NODAGA-exendin-4 was manufactured using a synthesizer module 
(GRP synthesizer, Scintomics, Germany). Gallium-68-chloride was obtained from 
a 68Ge/68Ga generator (Galliapharm, Eckert and Ziegler, Germany). The generator 
was eluted with 10 ml of 0.1 M hydrochloric acid and gallium-68 was trapped on a 
polystyrene-H+ cartridge. The cartridge was eluted with 1.5 ml 5 M NaCl in 0.1 M 
hydrochloric acid into the reaction vial, containing 200 µl exendin-NODAGA (10 µg 
of peptide in water for injection), 475 µl 2.5 M 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (HEPES) buffer and 50 µl ascorbic acid 100 mg/ml in water 
for injection. After 15 minutes incubation at 100ºC, the vessel was cooled and 2 ml 
ethylenediaminetetraacetic acid (EDTA ) 50 mM/ polysorbate 80 0.15% was added. 
[68Ga]Ga-NODAGA-exendin-4 was purified on a HLB cartridge and sterilized by 
passing through a 0.2 µm filter (millex GV).
Human subjects
Six adult patients with a suspicion of insulinoma based on biochemically confirmed 
hyperinsulinemic hypoglycemia were included. Patients were diagnosed by a 
positive fasting test with the occurrence of neuroglycopenic symptoms in the 
fasting state combined with inappropriately low plasma glucose levels and high 
insulin and C-peptide levels. Characteristics of the patients are shown in table 1. 
Subjects were included as part of an ongoing prospective clinical trial for evaluation 
of [68Ga]Ga-NODAGA-exendin-4 for diagnosis of insulinoma (ClinicalTrials.gov 
number: NCT03189953). Lesions were detected in three of the included patients 
(Figure 1). These patients underwent surgery, which confirmed presence of lesions 
at the indicated sites, which were histopathologically confirmed to be insulinomas. 
In the other three patients, nesidioblastosis was suspected, but no definite diagnosis 
could be reached. The study was approved by the Radboud University Medical 





Imaging was performed on a Siemens Biograph mCT-40 time-of-flight PET/CT 
scanner. Patients were injected intravenously with [68Ga]Ga-NODAGA-exendin-4 
(105.6 ± 2.3 MBq, peptide dose 4-7 µg). Four consecutive PET scans were obtained 
at 30, 60, 120 and 240 minutes after injection. Images were acquired with 2 bed 
positions including the liver, pancreas and kidneys at 10 minutes per bed position. 
A low-dose CT scan without contrast (40 mAs and 130 kV) was acquired for 
anatomical localization and attenuation correction. The size of the CT transaxial 
matrix was 512 x 512 (0.98 × 0.98 mm), and the CT slice width was 3 mm. High 
definition reconstruction of the images was performed with 3 iterations, 21 subsets 
and a post-reconstruction Gaussian filter of 3 mm in full width at half maximum. 
The transaxial PET matrix size was 256 x 256 and pixel size was 3.18 x 3.18 x 3 mm.











Time after injection (min)
Scan 1 Scan 2 Scan 3 Scan 4
1 F 24 72.0 106.1 32 66 121 239
2 F 53 58.0 107.5 32 62 120 238
3 F 55 75.6 108.0 30 83 119 235
4 M 65 83.6 105.0 30 61 120 234
5 F 64 88.8 105.1 30 56 115 235
6 M 63 84.5 101.6 30 62 118 236
Figure 1  Transversal fused PET/CT images of the abdomen showing the detected insulinomas 





The PET/CT images were analyzed using Inveon Research Workplace software 
(version 4.1; Siemens Healthcare). Volumes of interest (VOIs) were drawn over the 
kidneys, pancreas and duodenum, which showed visually identifiable tracer 
uptake on the PET/CT images. The total activity in each organ at each timepoint 
was determined by multiplying the mean activity concentration (Bq/ml) by the 
CT-derived VOI. Since the uptake in the kidneys is high compared to the pancreas, 
there is spillover of activity in the left kidney to the pancreatic tail, which could 
lead to an overestimation of tracer uptake in the pancreatic tail. To correct for this, 
the VOI of the left kidney was dilated by 9 mm and subtracted from the VOI of 
the pancreas. The tracer uptake in this part of the pancreas was then assumed to 
be equal to the mean uptake in the rest of the pancreas. Organ time-activity curves 
were plotted and cumulated activity was calculated as the area under the curves 
by the trapezoid rule. Only physical decay was assumed after the last measurement. 
The time-integrated activity coefficient was determined by dividing the cumulated 
activity by the total injected activity. The activity in the remainder of the body was 
determined by multiplying the total activity in the scanned area, minus the source 
organs, by the total body volume, based on length and body weight of the patient. 
With this, a homogenous tracer distribution over the remainder of the body was 
assumed.
Radiation dose estimates
The calculated time-activity coefficients of the source organs and the remainder of 
the body were used as input in OLINDA/EXM version 1.1 software. Organ 
absorbed doses and total effective doses for each patient were obtained using the 
reference adult male and female models. To estimate radiation doses in children, a 
comparable biodistribution of the tracer between adults and children was assumed. 
Organ absorbed doses and effective doses were determined using the newborn, 
1-year old and 5-year old models.
Results
Figure 2 shows typical axial slices of [68Ga]Ga-NODAGA-exendin-4 PET/CT 
images at various time points after injection. The highest tracer uptake is observed 
in the kidneys, which is a result of renal clearance of the tracer. Furthermore, 
highest specific tracer uptake is present in the pancreas and proximal duodenum. 
Retention of the tracer in these organs over time is high (Figure 2B). As a result, 
physical decay is the main cause of reduction in activity concentration in the 




























































































































































































remainder of the body of the patients are depicted in figure 3. Table 2 lists the mean 
organ absorbed doses and the effective dose acquired using the reference adult 
male and female models in OLINDA/EXM. The organs with the highest absorbed 
dose are the kidneys (0.47 ± 0.10 mGy/MBq), followed by the pancreas (0.023 ± 0.008 
mGy/MBq), the adrenals (0.012 ± 0.002 mGy/MBq), the spleen (0.011 ± 0.001 mGy/
MBq) and the small intestine (0.008 ± 0.001 mGy/MBq). Doses to the pancreas and 
small intestine partly consist of the organ self-dose, but will mostly originate from 
the kidneys. The mean total effective dose is very low (0.007 ± 0.0007 mSv/MBq).
Estimated doses for newborn children and children of 1 year and 5 years old are 
depicted in table 3. The kidneys are the dose-limiting organs, receiving a dose of 
5.4 ±1.1 mGy/MBq in newborns. This dose decreases with age to 2.0 ± 0.4 mGy/
MBq in 1 year old children and 1.1 ± 0.2 mGy/MBq in 5-year old children. The 
estimated effective dose for newborns is 0.12 ± 0.02 mSv/MBq. This low dose 
decreases further to 0.019 ± 0.003 mSv/MBq for 5-year old children.
Figure 3  Time-activity curves of kidneys, pancreas, duodenum and remainder of body (n=6). 




Table 2   Organ absorbed doses (mGγ/MBq) and effective doses (mSv/MBq) 
acquired using the reference adult models in Olinda/ EXM 1.1.




Gallbladder wall 0.008 0.0008
Stomach wall 0.007 0.0007
Heart wall 0.006 0.0006
Kidneys 0.472 0.1019
Intestine, lower large: wall 0.006 0.0007
Intestine, upper large: wall 0.007 0.0007






Red marrow 0.006 0.0005






Urinary bladder wall 0.005 0.0007
Uterus 0.004 0.0003
Total body 0.008 0.0009




Up to now, reported dosimetry of 68Ga-labelled exendin has relied on extrapolation 
of human SPECT/CT scans using 111In-labelled exendin or data from small animal 
SPECT with 111In-labelled exendin. In this study, PET/CT based dosimetry of [68Ga]
Ga-NODAGA-exendin-4 was, for the first time, assessed by using human PET/CT 
scans. The mean total body effective dose is very low (0.71 ± 0.07 mSv/100 MBq, 
which is currently the standard injected dose in adults). The highest mean absorbed 
dose of 47.2 ± 10.2 mGγ/100 MBq is received by the kidneys. The calculated effective 
dose received by adults from [68Ga]Ga-NODAGA-exendin-4 is lower than total 
body effective doses reported in dosimetry studies for the different tracers used for 
somatostatin receptor imaging, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTANOC and 
[68Ga]Ga-DOTATATE, which were between 2.1 and 2.6 mSv/100 MBq (14-17). The 
dose is also much lower than the dose from a low-dose CT scan, which is 4.5 mSv 
for a whole body scan and 1.8 mSv for a scan of 1 bed position of the abdomen in 
adults. This low dose will allow repeated examinations using [68Ga]Ga-NODA-
GA-exendin-4 in adults. The low total body effective dose allows 2-4 PET/CT 
examinations per year in adults (depending on the range of the low-dose CT scan) 
and up to 14 PET/MRI examinations without exceeding the maximum dose of 10 
mSv. Even with this number of examinations, the kidney absorbed dose will 
remain well below 7 Gγ, which is the threshold for the human kidney acute dose 
(18) . The absorbed dose to the red marrow is only 0.6 ± 0.05 mGγ/100 MBq. Over 
400 examinations could be performed while still remaining below 0.25 Gγ per 
Table 3   Estimated absorbed doses (mGγ/MBq) and effective doses (mSv/MBq) 
in children acquired using the newborn, 1-year old and 5-year old 
models in Olinda/EXM 1.1. 
Newborn 1-year old 5-year old
Kidneys 5.430 ± 1.086 2.037 ± 0.408 1.125 ± 0.225
Pancreas 0.530 ± 0.217 0.160 ± 0.062 0.082 ± 0.021
Adrenals 0.129 ± 0.015 0.059 ± 0.007 0.033 ± 0.004
Spleen 0.112 ± 0.017 0.050 ± 0.006 0.028 ± 0.003
Small intestine 0.114 ± 0.017 0.047 ± 0.007 0.047 ± 0.007
Whole body 0.117 ± 0.014 0.046 ± 0.006 0.023 ± 0.003
Effective dose (mSv/MBq) 0.116 ± 0.016 0.038 ± 0.005 0.019 ± 0.003




year, which has shown to have no damaging effects (18). The number of annual 
examinations will therefore not be limited by the radiation dose to the kidneys or 
red marrow. 
 The dosimetry data derived from adult patients were extrapolated to children 
of various ages. The estimated total effective dose in newborns is 2.3 ± 0.3 mSv/ 
20 MBq, which is the dose given to children with a body weight under 12.5 kg. 
This effective dose is significantly higher than in adults, but still nearly 4-fold 
lower than the effective dose reported for the standard PET tracer currently used 
to diagnose congenital hyperinsulinism in newborns, [18F]FDOPA, which is 0.4 ± 
0.04 mSv/MBq resulting in a total dose of 8 ± 0.8 mSv/20 MBq (19).
 The pancreas is the organ receiving the second highest radiation dose (2.3 ± 0.8 
mGγ/100 MBq in adults). The absorbed dose to the pancreas was determined by 
assuming a homogenous distribution of the radiotracer across the organ. However, 
since exendin specifically targets the beta cells in the islets of Langerhans in the 
pancreas, the activity concentration in these small clusters of endocrine cells is 
much higher than in exocrine pancreatic tissue (20). Therefore, the radiation dose 
to the islets may be underestimated using organ-based dosimetry, while the dose 
to the exocrine pancreas may be overestimated. This issue was previously 
examined using a macro- and small-scale dosimetry model combining animal and 
human data using 111In-labelled exendin. These data were extrapolated to 
gallium-68 showing that the absorbed dose to the islets of Langerhans (maximum 
66.0 mGγ for 111In and 1.38 mGγ for 68Ga) (21) remains clearly below the dose 
known to cause diabetes, which was estimated as a relative risk of 1:61 (95% CI 
1·21–2·68) with a radiation dose of 1Gγ to the tail of the pancreas (22). The estimated 
time-integrated activity coefficients for the pancreas and the kidneys in this study 
were obtained by converting 111In-exendin SPECT/CT scans of 5 humans to 
gallium-68. When comparing these to the current data, we find approximately 3 
times higher time-integrated activity coefficients for the pancreas (0.0034 ± 0.0014 
vs. 0.0012 ± 0.0001) and about 2 times lower coefficients for the kidneys (0.29 ± 0.05 
vs. 0.5 ± 0.05). Because of the almost equal contribution of both these organs to the 
islet dose with the use of gallium-68 (21), these differences will not greatly increase 
the estimated absorbed dose to the islets. So, even though the data in this study 
show some differences in comparison to 111In-exendin, it remains clear that use of 
[68Ga]Ga-NODAGA-exendin-4 will not result in islet toxicity. Especially since the 
estimated absorbed doses to the pancreas in this study (10.6 ± 4.5 mGγ/20 MBq in 
newborns, 3.2 ± 1.2 mGγ/ 20MBq in 1-year olds, 2.5 ± 0.4 mGγ/30 MBq in 5-year old 
and 2.3 ± 0.8 mGγ/ 100 MBq in adults) are by far lower than 1 Gγ.
 Previous studies on dosimetry for 68Ga-labelled exendin have relied on animal 
data extrapolated to humans. Extrapolation of organ and whole-body dosimetry 
data to other species might be unreliable due to variations in tracer biodistribution 
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between species, resulting for instance from differences in receptor expression, 
like for example the strikingly higher GLP-1R expression found in the lungs and 
thyroid gland of rodents as compared to humans (23). Reported total effective 
doses vary considerably between the different animal models that have previously 
been used. Reported effective doses range from 0.012 to 0.032 mSv/MBq depending 
on the studied species (Spraque-Dawley rats, Lewis rats, pigs, cynomolgus 
monkeys and one human) (24-26). Also estimated organ absorbed doses are not 
consistent. Based on a Rip1Tag2 mouse model of pancreatic beta cell tumors, an 
extrapolated human kidney absorbed dose of 1.85 mGγ/MBq was reported (25). In 
other studies, based on various different species, lower kidney doses were found 
better corresponding to the kidney doses found in this study. In Spraque-Dawley 
rats, a kidney dose of 0.52 mGγ/MBq was described (26) and in a dosimetry study 
comparing several species (Lewis rats, pigs, cynomolgus monkeys and one 
human), similar kidney doses (0.25-0.65 mGγ/MBq) were reported.
Conclusion
Our dosimetric calculations demonstrate low effective radiation doses from [68Ga]
Ga-NODAGA-exendin-4 to adults as well as to children. These doses are several 
fold lower than those reported for current tracers used for imaging of insulinomas/
neuroendocrine tumors and congenital hyperinsulinism and are much lower than 
doses from a low-dose CT scan. This is beneficial for the application of [68Ga]
Ga-NODAGA-exendin-4 as a diagnostic or research tool in children, patients with 
benign diseases and healthy volunteers, allowing repeated examinations in case of 
prospective follow-up studies, for example to examine beta cell mass in different 
phases of progression of diabetes mellitus or to assess transplantation success and 
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The treatment of choice for insulinomas and focal lesions in congenital hyperinsu-
linism (CHI) is surgery. However, intra-operative detection can be challenging. 
This could be overcome with intra-operative fluorescence imaging, which provides 
real-time lesion detection with a high spatial resolution. Here, a novel method for 
targeted near-infrared (NIR) fluorescence imaging of glucagon-like peptide 1 
receptor (GLP-1R) positive lesions, using the GLP-1 agonist exendin-4, labeled with 
IRDye800CW, was examined in vitro and in vivo.  
Methods
A competitive binding assay was performed using Chinese hamster lung (CHL) 
cells transfected with the GLP-1R. Tracer biodistribution was determined in 
BALB/c nude mice bearing subcutaneous CHL-GLP-1R xenografts. In vivo NIR 
fluorescence imaging of CHL-GLP-1R xenografts was performed. Localization of 
the tracer in the pancreatic islets of BALB/c nude mice was examined using 
fluorescence microscopy. Laparoscopic imaging was performed to detect the 
fluorescent signal of the tracer in the pancreas of mini pigs. 
Results
Exendin-4-IRDye800CW binds the GLP-1R with an IC50 value of 3.96 nM. The 
tracer accumulates in CHL-GLP-1R xenografts. Subcutaneous CHL-GLP-1R 
xenografts were visualized using in vivo NIR fluorescence imaging. The tracer 
accumulates specifically in the pancreatic islets of mice and a clear fluorescent 
signal was detected in the pancreas of mini pigs.
Conclusion
These date provide the first in vivo evidence of the feasibility of targeted fluorescence 
imaging of GLP-1R positive lesions. Intra-operative lesion delineation using exen-
din-4-IRDye800CW could benefit open as well as laparoscopic surgical procedures 
for removal of insulinomas and focal lesions in CHI.
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Introduction
While pre-operative imaging is essential for tumor detection before surgical cancer 
treatment, translating this information into the operating room is often challenging. 
Intra-operative optical imaging can provide real-time detection of tumor lesions 
and thereby contribute to optimal surgical procedures (1).
 Insulinomas; insulin-producing neuroendocrine tumors arising from stem 
cells or pancreatic beta cells, are the most common cause of endogenous adult 
hyper insulinemic hypoglycemia (2). Persistent hypoglycemia also occurs in 
neonates and is in most cases caused by CHI. There are two subforms of this 
disease: focal CHI, caused by focal adenomatous islet cell hyperplasia, and diffuse 
CHI, resulting from diffuse involvement of pancreatic beta cells (3). Symptoms of 
insulinomas and CHI, caused by episodic hypoglycemia, are severe and include 
confusion, diplopia and dizziness and, in cases of prolonged hypoglycemia, even 
seizure, loss of consciousness or death (4).
 Insulinomas and focal CHI can be completely cured by surgical removal of the 
lesion. However, these procedures are complicated by the usually small size of the 
lesions and their proximity to the pancreatic duct and major vessels (5). Precise 
localization of the lesion is of great importance and starts with sensitive 
pre-operative detection. For insulinomas, this is performed using various imaging 
modalities; Contrast enhanced CT and MRI with sensitivities around 70% and 90% 
respectively (6), somatostatin receptor PET, for which sensitivities from 33% to 85% 
are reported (7, 8) and the more invasive endoscopic ultrasound, with a sensitivity 
of 75% for detection of insulinomas (9). Currently, there is increasing evidence for 
the superior performance of the novel imaging method GLP-1R SPECT/CT or PET/
CT, using radiolabeled exendin-4, a stable analogue of the hormone GLP-1, which 
specifically binds the GLP-1R on pancreatic beta cells with high affinity (10). With 
this technique, insulinomas are detected with a sensitivity of up to 97.7% (7, 11, 12). 
Focal CHI is pre-operatively localized using 18F-DOPA PET/CT with a sensitivity 
of 85% (13). GLP-1R PET is also being investigated as a potentially more sensitive 
imaging technique for focal CHI (NCT03768518). 
 However, even after pre-operative visualization of the lesion, intra-operative 
detection can be challenging, especially in patients with multiple insulinomas, 
where very small lesions (< 1 cm) are even more common. Intra-operative ultra - 
sound is routinely used for intraoperative localization of insulinomas. In combination 
with palpation, success rates ranging from 91% to 100% have been reported (9, 14, 
15).  However, a laparoscopic procedure, which is preferred when enucleation of 
the lesion is possible, excludes palpation. Radioguided detection of insulinomas 
has been proven successful only in a limited number of patients to date (16). 
Another interesting option for intra-operative detection of GLP-1R positive lesions 
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is fluorescence imaging, which has a better spatial resolution and could be used for 
precise delineation of the lesion and fluorescence-guided surgery (1, 17).
 Currently, there is much attention for the development of tracers for intra- 
operative fluorescence imaging, mostly using NIR fluorophores, which have the 
benefit of a high penetration depth (5-10 mm) through tissue (18). Coupling of the 
fluorophore to a tumor-targeting moiety is crucial to ensure specific and efficient 
delivery of a fluorophore to the lesion of interest.
 For targeting of insulinomas and focal CHI, the peptide exendin-4 is an attractive 
targeting agent for optical imaging. 
 We have developed exendin-4 coupled to the NIR fluorophore IRDye800CW as 
a specific tracer for fluorescence imaging of insulinomas and focal CHI. We assessed 
the potential of targeting GLP-1R positive cells in vitro and in vivo and the feasibility 
of performing in vivo fluorescence imaging with this compound.
Materials and methods
Reagents
Exendin-4-IRDye800CW was supplied by piCHEM (Graz, Austria). IRDye800CW 
NHS ester was obtained from LI-COR Biosciences (Lincoln, Nebraska, U.S.A.). The 
N-epsilon amino group of lysine at position 40 was site specifically modified 
during solid phase peptide synthesis with a mercapto-propionic acid, releasing an 
unprotected exendin-4 with a free thiol function after triisopropylsilane cleavage. 
IRDye800CW was modified with a maleimide and coupling to exendin-4 was 
performed using a thiol reactive crosslinking approach. The purity was >90%. 
Stock solutions of exendin-4-IRDye800CW were prepared in phosphate-buffered 
saline (PBS).
Cell Culture
CHL cells stably transfected with the human GLP-1R (19) were cultured (at 37°C 
and 5% CO2) in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher 
Scientific, Waltham, MA, USA) with 4.5g/L D-glucose and Glutamax, supplemented 
with 10% fetal calf serum (FCS) (Life technologies, Carlsbad, CA, USA), 100 IU/mL 
penicillin G, 10 mg/mL streptomycine, 1 mM sodium pyruvate, 0.1 mM non- 
essential amino acids and 0.5 mg/ml G418 geneticin.
Competitive Binding Assay
The half-maximal inhibitory concentration (IC50) of exendin-4-IRDye800CW, and 
unlabeled exendin, as a reference, was determined using CHL-GLP-1R cells in a 
competitive binding assay as described previously (10, 20). Cells were grown 
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overnight in six well plates (approximately 106 cells/well). Exendin-3-DTPA, 
labeled with 111In as described earlier (21), was used as tracer. The cells were 
washed twice with PBS and incubated for 4 hours on ice with 50,000 cpm 111In-DT-
PA-exendin-3 in the presence of increasing concentrations of exendin-4-IRDye-
800CW or exendin-4 (0.1 – 300 nM). After incubation, cells were washed with PBS, 
solubilized with 2 mL sodium hydroxide (NaOH), collected and the cell-associated 
activity was measured in a gamma-counter (Wizard 2480, PerkinElmer, Groningen, 
The Netherlands).
Binding Assay
Receptor specificity of the binding of the exendin-4-IRDye800CW to CHL-GLP-1R 
cells was determined in a fluorescent binding assay. CHL-GLP-1R cells were grown 
overnight in 24 well plates to approximately 95% confluency. Cells were washed 
twice with binding buffer (DMEM supplemented with 0.5% bovine serum albumin 
(BSA)) and incubated with 300nM exendin-4-IRDye800CW in triplicate with and 
without a 50x excess of unlabeled exendin-4 (four hours at 37ºC). After incubation, 
cells were washed twice with PBS, lysed using 200 µl sodium hydroxide per well, 
collected and transferred to a black flat-bottom 96-well plate. Fluorescence was 
measured using a TECAN infinite M200 Pro plate reader (Infinite Pro 200, Tecan 
Austria GmbH, Groedig, Austria) (excitation: 750 nm, emission 795 nm). Standard 
curves were created and binding percentages to the cells were calculated using 
Microsoft Office Excel 2007.
Animal Tumor Model
Female BALB/c nude mice (Janvier, Le Genest Saint Isle, France) (age: 6-8 weeks) 
were housed in individually ventilated cages (6 mice per cage) under non-sterile 
conditions with ad libitum access to chlorophyll-free animal chow and water. 
CHL-GLP-1R cells were injected subcutaneously on the right shoulder (5*106 cells/
mouse) in 200 µL DMEM with 4.5 g/L D-glucose and Glutamax. All animal 
experiments were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Centre and were conducted in accordance to the 
guidelines of the Revised Dutch Act on Animal Experimentation.
In Vivo Biodistribution
Female BALB/c nude mice bearing subcutaneous CHL-GLP-1R xenografts were 
injected intravenously with various concentrations of exendin-4-IRDye800CW in 
200 µL PBS with 0.5% BSA (N=6 mice per group, 3, 10, 30 and 100 µg exen-
din-4-IRDye800CW). Control mice (N=4) were injected with PBS with 0.5% BSA 
only. After 4 hours, the mice were sacrificed by CO2 asphyxiation and blood and 
organs of the mice were removed and collected in Roche MagNA Lyser tubes 
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(F Hoffmann- La Roche Ltd., Basel, Switzerland), which were weighed before and 
after organ collection. The circulation time of 4 hours was chosen based on our previous 
experience with radiolabeled exendin tracers (10). Radioimmunoprecipitation 
assay (RIPA) lysis buffer (500 µL; 50mM (hydroxymethyl)aminomethane-hydro-
chloride (TRIS-HCl), pH 7.4 with 150 mM sodiumchloride (NaCl), 1 mM ethylene-
diaminetatraacetic acid (EDTA), 1% Triton-X-100 and 1% sodium dodecyl sulphate 
(SDS)) was added to each tube. Organs were then homogenized using a Roche 
MagNA Lyser (F Hoffmann-La Roche Ltd., Basel, Switzerland) with repeated cycles 
of 6000 rpm for 25 seconds with cooling on ice for 1 minute after each cycle. Organ 
homogenates of control mice were used to create standard curves for each organ. 
Organ homogenates (100 µl) and the standards were transferred in triplicate to a 
black flat-bottom 96-well plate. Fluorescence was measured using a TECAN infinite 
M200 Pro plate reader (Infinite Pro 200, Tecan Austria GmbH, Groedig, Austria) 
(excitation 750 nm, emission 795 nm). Standard curves were created and tracer 
uptake in the various organs were calculated using Microsoft Office Excel 2007. 
Tracer uptake in each organ type was corrected for the weight of the dissected 
organ. To determine the specificity of the tumor uptake, an additional biodistribu-
tion experiment was performed with two groups of mice (n=6 per group), which 
were injected with 3 µg exendin-4-IRDye800CW with co-injection of 150 µg 
unlabeled exendin-4 in one of the groups).  
 We validated the biodistribution of the fluorescent tracer using a dual labeled 
version of the exendin-tracer DTPA-exendin-4 (piCHEM, Graz, Austria), labeled 
with both 111In and Cy5.5, as previously described (21). With this tracer, 
we performed biodistribution studies and we compared the tracer uptake in the 
different organs based on the fluorescent signal with that of the radioactive signal 
(Figure 1).
In Vivo Fluorescence Imaging of GLP-1R Positive Tumors
To show the feasibility of visualizing GLP-1R positive tumors using in vivo 
fluorescence imaging, BALB/c nude mice bearing subcutaneous CHL-GLP-1R 
xenografts were injected intravenously with 3 µg exendin-4-IRDye800CW (N=3 
per group). One group of mice was co-injected with an excess (150 µg) of unlabeled 
exendin-4. After 4 hours, fluorescence imaging was performed using the IVIS 
Lumina closed-cabinet fluorescence scanner (Caliper LifeSciences, Hopkinton, 
MA) (excitation 745 nm, autofluorescence correction excitation 640 nm, both 
measured with the ICG filter). After resection of the tumor lesions, mice were 
imaged again. Subsequently, the mice were dissected to remove the pancreas. 
Pancreata were fixed overnight in 4% formalin and embedded in paraffin for 
fluorescence microscopy and immunohistochemistry as described in the following 
paragraph.
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Fluorescence Microscopy and Immunohistochemistry
Sections of 4 µm were cut at 2 levels, 100 µm apart. One section of each level was 
deparaffinated in xylene for 2 minutes, after which fluorescence imaging was 
performed using an Odyssey CLx flatbed fluorescence scanner (800 nm channel, 
recording time 1-5 minutes, focus 1.0 mm) (LI-COR biosciences, Lincoln, NE, USA). 
Subsequently, these sections were stained for insulin as previously described (22). 
Consecutive sections were used for fluorescence microscopy. After deparaffination 
in xylene (2 times five minutes), cell nuclei were stained with Hoechst (33258, 
Invitrogen, Waltham, MA, USA). Sections were mounted under a glass cover in 
modified Kaiser’s glycerine. Fluorescence imaging was performed using an 
inverted microscope (DMI6000B, Leica Biosystems, GmbH, Wetzlar, Germany) 
equipped with a NIR light source ranging up to 900 nm (X-Cite 200DC, Excelas 
Excelitas Technologies, Waltham, MA, USA), an NIR filter set (microscope two 
band- pass filters 850–890 m–2p and a long-pass emission filter HQ800795LP; 
Chroma Technology Corp, Bellows Falls, VT, USA), a monochrome DFC365 FX 
fluorescence camera (1·4M Pixel CCD, Leica Biosystems GmbH), and LAS-X 
software (Leica Biosystems GmbH).
Figure 1  Biodistribution of 111In-DTPA-exendin-4-Cy5.5 (0.3 µg, 1 µg and 3 µg, N=6 mice per 
group) in tumor, pancreas and kidney. Uptake in organs were determined with radiochemical 
and fluorescent analysis. Given are the ratios of uptake values determined by the different 

















Laparoscopic Imaging of Pancreatic Tracer Uptake in Mini Pigs
The possibility of visualizing tracer uptake in the pancreatic beta cells in vivo using 
a laparoscopic laser device was assessed in mini pigs. This was performed in the 
Department of Experimental Research of the Lille 2 University Facilities, Lille, 
France. Surgical interventions were approved by the local ethics committee 
(IACUC). Three healthy adult Göttingen-like mini pigs (Sus scrofa, Denis’s breeding, 
Templeuve, France) were anesthetized using 4% isoflurane (Aerrane, Baxter, 
France) after receiving premedication (intramuscular injection of ketamine 
(Ketamine1000, Virbac, Carros, France, 10 mg/kg of body weight) and xylazine 
(Sédaxylan, CEVA Santé Animale, Libourne, France, 2.5 mg/kg of body weight)). 
The mini pigs were infused with 1.3 µg/kg exendin-4-IRDye800CW in 20 mL PBS 
over 30 minutes through an intravenous catheter in the external jugular vein. Four 
hours after tracer injection, laparoscopic surgery was performed to access the 
pancreas upon which fluorescence imaging of the pancreatic head and tail was 
performed using a laser device emitting light at 800 nm and a fluorescence camera 
(SurgVision BV, The Netherlands). 
Statistical Analyses
Statistical calculations were performed using GraphPad Prism (GraphPad 
Software, La Jolla, CA, USA). IC50 values were calculated by fitting the data with 
non-linear regression using least squares fit with GraphPad Prism. 
Results
Exendin-4-IRDye800CW Specifically Binds the GLP-1R 
with High Affinity 
The IC50 values of unlabeled exendin-4 and exendin-4-IRDye800CW were 2.5 nM 
(95% CI; 1.32 - 4.90) and 4.0 nM (95% CI; 2.9 – 5.5) respectively (Figure 2). While the 
binding affinity of the labeled peptide is significantly lower compared to the 
unlabeled peptide (p < 0.01), the binding affinity is in the same nanomolar range.
Addition of an excess of unlabeled exendin-4 decreased binding of exen-
din-4-IRDye800CW to CHL-GLP-1R cells from 4.1 ± 0.4% to 0.3 ± 0.2% (p < 0.01) 
(Figure 3A).
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Figure 2  Competition binding assay (IC50) of unlabeled exendin-4 and exendin-4-IRDye800CW 
on CHL-GLP-1R cells.
Figure 3  Binding of exendin-4-IRDye800CW (300nM) to CHL-GLP-1R cells with and without 
an excess of unlabeled exendin-4 (N=3) (A). Biodistribution of exendin-IRDye800CW with 
and without an excess of unlabeled exendin-4 in blood and various tissues of female BALB/c 
nude mice carrying subcutaneous CHL-GLP-1R tumors (N=6/group) at 4 hours after tracer 
injection (B).
































Exendin-4-IRDye800CW Accumulates in CHL-GLP-1R Tumors
Absolute tumor uptake of exendin-4-IRDye800CW was 9.6 ± 4.2 µg tracer/g organ 
with an injected dose of 3 µg and increased dose-dependently to 25.5 ± 2.1 µg/g, 
43.2 ± 3.6 µg/g and 62.4 ± 31.8 µg/g with injected doses of 10 , 30 and 100 µg, 
respectively. Highest uptake of exendin-4-IRDye800CW was observed in the 
kidneys, due to renal clearance of the tracer (Figure 4).
 Co-injection of an excess of unlabeled exendin-4 decreased the tumor uptake 
of exendin-4-IRDye800CW from 11.6 ± 1.6% ID/g to 1.3 ± 0.4% ID/g (p < 0.001) 
(Figure 3B).
In Vivo Fluorescent Tumor Detection is Feasible
Tumors were clearly visualized by fluorescence imaging (Figure 5A and Figure 6). 
After resection of the tumors, no residual fluorescent signal was detected (Figure 
5B). Next to the signal in the tumors, a fluorescent signal was observed in the 
kidneys. In the mice receiving an excess of the unlabeled peptide, no fluorescent 
signal was seen in the tumor while the signal in the kidneys persists, demonstrating 
the receptor specificity of the uptake of exendin-4-IRDye800CW (Figure 5C). 
Figure 4  Biodistribution of exendin-IRDye800CW in blood and various tissues of female 
BALB/c nude mice carrying subcutaneous CHL-GLP-1R tumors (N=6/group) at 4 hours after 
tracer injection.
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Figure 5  NIR fluorescence images of BALB/c nude mice bearing subcutaneous CHL GLP1-R 
tumors. Tumors are indicated with red arrows and kidneys with green arrows. (A) Image of 
an intact mouse. (B) Image of a mouse after resection of the tumor. (C) Image of a mouse 
injected with the exendin-4-IRDye800CW and an excess of unlabeled peptide.
Figure 6  NIR fluorescent images of the additional two BALB/c nude mice bearing subcutaneous 




















Exendin-4-IRDye800CW Accumulates Specifically in 
Murine Pancreatic Islets of Langerhans
Representative images of the islets of one of the mice are shown in Figure 7. 
The presence of pancreatic islets is clearly indicated by the positive insulin staining. 
A clear NIR fluorescent signal is observed at the site of the pancreatic islets. 
Figure 7  Immunohistochemistry, flat bed fluorescence (A) and fluorescence microscopy 
(B,C) images of pancreatic tissue of a mouse injected with exendin-4-IRDye800CW. Insulin 
staining shown in brown (left), 800 nm fluorescent signal in red and nuclei in blue (right). 
Microscopy images at 40x (B) and 63x (C) magnification. Scale bars indicate 1000 µm (A) or 10 
µm (B,C).
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The signal appears to be mostly intracellular, which corresponds with the fast 
 internalization of exendin-4 based tracers. A much lower signal is observed in the 
exocrine pancreatic tissue. The higher fluorescent signal in the pancreatic islets 
points to receptor specificity of the uptake of exendin-4-IRDye800CW. 
Pancreatic Uptake of Exendin-4-IRDye800CW is Detected by 
In Vivo Laparoscopic Imaging in Mini Pigs
Laparoscopic NIR fluorescence imaging of the pancreas in healthy mini pigs 
revealed a clear fluorescent signal in the pancreatic head and tail with which it is 
possible to discriminate between pancreatic tissue and surrounding tissues (Figure 8). 
Figure 8  Laparoscopic images of the pancreatic head and tail of a healthy mini pig. On the 
left white light images, in the middle NIR fluorescent imaging and on the right layover 
images where the fluorescent signal is depicted in green.
Pancreas head White-light Fluorescence Overlay




Surgery to remove insulinomas or lesions in focal CHI is challenging and carries 
substantial risks of morbidity (4, 5). Precise detection of the lesion is essential for an 
optimal surgical procedure. Real-time intra-operative detection with a high 
sensitivity and spatial resolution for precise lesion delineation can be provided by 
targeted fluorescence imaging. An agent for targeted NIR fluorescence imaging of 
the GLP-1R was developed and examined in vitro and in vivo in this study.
 Exendin-4-IRDye800CW was shown to have a high affinity for the GLP-1R. 
Because of the high target affinity of the tracer combined with fast clearance from 
non-target tissues, a signal with high target-to-background values can be achieved. 
 Exendin-4-IRDye800CW was shown to accumulate dose-dependently in 
subcutaneous GLP-1R positive tumors in mice. We demonstrate the reliability of 
the method used to assess the biodistribution of the fluorescent tracer by showing 
comparable results of fluorescent and radioactive quantification of the uptake of 
the dual-labeled tracer 111In-DTPA-exendin-4-Cy5.5 in GLP-1R positive tumors, 
pancreas and kidneys of mice. We furthermore show that with exendin-4-IRDye-
800CW, subcutaneous GLP-1R positive tumors could be visualized using NIR 
fluorescence imaging. Co-injection of an excess of unlabeled exendin-4 completely 
abolished the fluorescent signal in the tumors, demonstrating the receptor-speci-
ficity of the tumor uptake. Furthermore, fluorescence microscopy shows uptake of 
the tracer specifically in the pancreatic islets of these mice.
 The first report on intra-operative imaging of insulinomas involved a non- 
targeted approach based on the NIR dye methylene blue, which showed higher 
uptake in insulinomas than normal pancreatic tissue in the proper dilution (23). 
A targeted approach, as described in this study, has the benefit of creating signals 
with higher contrast between the target and surrounding tissue and therefore 
more precise delineation of the lesion. Exendin-4 has already been shown to be 
very effective for targeting of GLP-1R positive tumors in pre-clinical as well as 
clinical studies using radiolabeled exendin (7, 10, 11). Reiner et al. have previously 
developed NIR imaging agents, based on exendin-4, for the purpose of in vivo 
quantification of beta cell mass. These tracers were shown to bind the GLP-1R with 
high affinities (IC50: 0.3 – 3 nM) and a fluorescent signal was observed in the 
pancreatic islets. However, uptake of these tracers in GLP-1R positive tumors 
leading to a possible application for fluorescent-guided surgery was not assessed 
(24, 25). Exendin-4 was used by Brand et al. to develop a dual-labeled tracer 
(64Cu-exendin-4-Cy5) for combined PET and fluorescence imaging of GLP-1R 
positive tumors. While the affinity of this tracer for the GLP-1R (IC50: 50 nM) was 
lower than exendin-4-IRDye800CW, specific accumulation in GLP-1R tumors was 
shown and GLP-1R positive xenografts were visualized using in vivo PET imaging. 
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However, while a fluorescent signal in the xenografts was detected using fluorescence 
microscopy, in vivo fluorescent imaging was not performed (26). We therefore here 
provide the first evidence of the feasibility of targeted in vivo fluorescence imaging 
of GLP-1R positive lesions.
 Using a laparoscopic NIR fluorescence imaging device, a fluorescent signal of 
exendin-4-IRDye800CW in the pancreas of mini pigs could be detected. Since the 
exocrine pancreas in pigs is known to have a relatively high GLP-1R density 
resulting in a low endocrine-exocrine ratio of GLP-1R expression (27), the detected 
signal is most probably not only originating from the pancreatic islets. In mice, 
where fluorescence microscopy showed specific uptake of the tracer in the 
pancreatic islets, the endocrine-exocrine ratio of GLP-1R expression is known to be 
much higher (27). However, even if the NIR fluorescent signal detected with the 
laparoscope originates from both the endocrine and exocrine pancreas of the mini 
pigs, the feasibility of using this laparoscopic procedure to detect the NIR 
fluorescent signal clearly demonstrates the potential for clinical translation of this 
approach. Despite the background fluorescence signal in the pancreas resulting 
from uptake of the tracer in healthy pancreatic beta cells, visualization and 
delineation of insulinomas in humans using this approach is most likely possible, 
since insulinomas have a very high GLP-1R density in almost 100% of cases (higher 
than healthy pancreatic islets) (28) and visualization with high tumor-to-back-
ground ratios has been achieved with radiolabeled exendin (7). 
 Contributing to the potential for clinical translation of this tracer is the use of 
the NIR fluorophore IRDye800CW. This dye is widely used in the development of 
targeted fluorescence imaging approaches and several studies already show the 
first successful clinical applications using this fluorophore. Detection of primary 
breast cancer lesions as well as peritoneal metastases of colorectal cancer was 
shown to be feasible using IRDye800CW coupled to the monoclonal antibody 
(mAb) bevacizumab (29, 30). Also, IRDye800CW coupled to the mAb cetuximab 
was successfully used for detection of glioblastomas (31). While the first successful 
clinical results with targeted NIR intra-operative imaging are obtained with mAb 
based approaches, various peptide-based NIR imaging approaches have been 
developed and demonstrated to be successful in preclinical settings for a wide 




We here show the feasibility of in vivo fluorescence imaging of GLP-1R positive 
lesions using the novel tracer exendin-4-IRDye800CW. While applicable in open as 
well as laparoscopic procedures, this approach could be especially beneficial for 
laparoscopic procedures, in which surgeons currently rely solely on intra-opera-
tive ultrasound. In the future, fluorescence imaging using exendin-4-IRDye800CW 
could benefit surgical removal of insulinomas as well as focal lesions in CHI by 
providing sensitive and specific real-time intra-operative optical lesion delineation.
105
OPTICAL IMAGING OF GLP-1R
5
References
1. de Boer E, Harlaar NJ, Taruttis A, Nagengast WB, Rosenthal EL, Ntziachristos V, et al. Optical 
innovations in surgery. The British journal of surgery. 2015;102(2):e56-72.
2. Kinova MK. Diagnostics and treatment of insulinoma. Neoplasma. 2015;62(5):692-704.
3. Lord K, Dzata E, Snider KE, Gallagher PR, De Leon DD. Clinical presentation and management of 
children with diffuse and focal hyperinsulinism: a review of 223 cases. The Journal of clinical 
endocrinology and metabolism. 2013;98(11):E1786-9.
4. Senniappan S, Shanti B, James C, Hussain K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, 
diagnosis and management. Journal of inherited metabolic disease. 2012;35(4):589-601.
5. Richards ML, Gauger PG, Thompson NW, Kloos RG, Giordano TJ. Pitfalls in the surgical treatment of 
insulinoma. Surgery. 2002;132(6):1040-9; discussion 9.
6. Zhu L, Xue H, Sun Z, Li P, Qian T, Xing X, et al. Prospective comparison of biphasic contrast-enhanced 
CT, volume perfusion CT, and 3 Tesla MRI with diffusion-weighted imaging for insulinoma detection. 
Journal of magnetic resonance imaging : JMRI. 2017;46(6):1648-55.
7. Antwi K, Fani M, Heye T, Nicolas G, Rottenburger C, Kaul F, et al. Comparison of glucagon-like 
peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: 
evaluation of diagnostic accuracy in a prospective crossover imaging study. European journal of 
nuclear medicine and molecular imaging. 2018;45(13):2318-27.
8. Prasad V, Sainz-Esteban A, Arsenic R, Plockinger U, Denecke T, Pape UF, et al. Role of (68)Ga 
somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative 
study. European journal of nuclear medicine and molecular imaging. 2016;43(9):1593-600.
9. Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review 
of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675-86.
10. Brom M, Joosten L, Oyen WJ, Gotthardt M, Boerman OC. Radiolabelled GLP-1 analogues for in vivo 
targeting of insulinomas. Contrast media & molecular imaging. 2012;7(2):160-6.
11. Christ E, Wild D, Ederer S, Behe M, Nicolas G, Caplin ME, et al. Glucagon-like peptide-1 receptor 
imaging for the localisation of insulinomas: a prospective multicentre imaging study. The lancet 
Diabetes & endocrinology. 2013;1(2):115-22.
12. Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, et al. Glucagon-Like Peptide-1 Receptor PET/CT with 
68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. Journal of 
nuclear medicine : official publication, Society of Nuclear Medicine. 2016;57(5):715-20.
13. Laje P, States LJ, Zhuang H, Becker SA, Palladino AA, Stanley CA, et al. Accuracy of PET/CT Scan in 
the diagnosis of the focal form of congenital hyperinsulinism. Journal of pediatric surgery. 
2013;48(2):388-93.
14. Fendrich V, Bartsch DK, Langer P, Zielke A, Rothmund M. [Diagnosis and surgical treatment of insu-
linoma--experiences in 40 cases]. Deutsche medizinische Wochenschrift (1946). 2004;129(17):941-6.
15. Kisker O, Bastian D, Frank M, Rothmund M. [Diagnostic localization of insulinoma. Experiences with 
25 patients with solitary tumors]. Medizinische Klinik (Munich, Germany : 1983). 1996;91(6):349-54.
16. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al. Glucagon-like peptide-1 receptor 
imaging for localization of insulinomas. The Journal of clinical endocrinology and metabolism. 
2009;94(11):4398-405.
17. DeLong JC, Hoffman RM, Bouvet M. Current status and future perspectives of fluorescence-guided 
surgery for cancer. Expert review of anticancer therapy. 2016;16(1):71-81.
18. Ash C, Dubec M, Donne K, Bashford T. Effect of wavelength and beam width on penetration in 
light-tissue interaction using computational methods. Lasers in medical science. 2017;32(8):1909-18.
19. van Eyll B, Lankat-Buttgereit B, Bode HP, Goke R, Goke B. Signal transduction of the GLP-1-receptor 
cloned from a human insulinoma. FEBS letters. 1994;348(1):7-13.
20. Jodal A, Lankat-Buttgereit B, Brom M, Schibli R, Behe M. A comparison of three (67/68)Ga-labelled 
exendin-4 derivatives for beta-cell imaging on the GLP-1 receptor: the influence of the conjugation site 
of NODAGA as chelator. EJNMMI research. 2014;4:31.
106
CHAPTER 5
21. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC. 68Ga-labelled exendin-3, a new agent for the 
detection of insulinomas with PET. European journal of nuclear medicine and molecular imaging. 
2010;37(7):1345-55.
22. Brom M, Woliner-van der Weg W, Joosten L, Frielink C, Bouckenooghe T, Rijken P, et al. Non-invasive 
quantification of the beta cell mass by SPECT with (1)(1)(1)In-labelled exendin. Diabetologia. 2014; 
57(5):950-9.
23. Winer JH, Choi HS, Gibbs-Strauss SL, Ashitate Y, Colson YL, Frangioni JV. Intraoperative localization 
of insulinoma and normal pancreas using invisible near-infrared fluorescent light. Annals of surgical 
oncology. 2010;17(4):1094-100.
24. Reiner T, Kohler RH, Liew CW, Hill JA, Gaglia J, Kulkarni RN, et al. Near-infrared fluorescent probe 
for imaging of pancreatic beta cells. Bioconjugate chemistry. 2010;21(7):1362-8.
25. Reiner T, Thurber G, Gaglia J, Vinegoni C, Liew CW, Upadhyay R, et al. Accurate measurement of 
pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proceedings 
of the National Academy of Sciences of the United States of America. 2011;108(31):12815-20.
26. Brand C, Abdel-Atti D, Zhang Y, Carlin S, Clardy SM, Keliher EJ, et al. In vivo imaging of GLP-1R with 
a targeted bimodal PET/fluorescence imaging agent. Bioconjugate chemistry. 2014;25(7):1323-30.
27. Eriksson O, Rosenstrom U, Selvaraju RK, Eriksson B, Velikyan I. Species differences in pancreatic 
binding of DO3A-VS-Cys(40)-Exendin4. Acta diabetologica. 2017;54(11):1039-45.
28. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: 
molecular basis for in vivo multireceptor tumour targeting. European journal of nuclear medicine 
and molecular imaging. 2003;30(5):781-93.
29. Harlaar NJ, Koller M, de Jongh SJ, van Leeuwen BL, Hemmer PH, Kruijff S, et al. Molecular fluorescence- 
guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. 
The lancet Gastroenterology & hepatology. 2016;1(4):283-90.
30. Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, et al. Tumor-Specific 
Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast 
Cancer: A Phase I Feasibility Study. Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2017;23(11):2730-41.
31. Miller SE, Tummers WS, Teraphongphom N, van den Berg NS, Hasan A, Ertsey RD, et al. First- 
in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab- 
IRDye800. Journal of neuro-oncology. 2018;139(1):135-43.
32. Joshi BP, Wang TD. Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications. 
Contrast media & molecular imaging. 2018;2018:2015237.
107





therapy of glucagon-like peptide 1 
receptor positive lesions 
Marti Boss, Desiree Bos, Cathelijne Frielink, Gerwin Sandker,
Patricia Bronkhorst, Sanne A.M. van Lith, Maarten Brom, Mijke Buitinga, 
Martin Gotthardt
Journal of Nuclear Medicine, 2020 May8. doi: 10.2967/jnumed.119.238998




Treatment of hyperinsulinemic hypoglycemia is challenging. Surgical treatment of 
insulinomas and focal lesions in congenital hyperinsulinism (CHI) is invasive and 
carries major risks of morbidity. Medication to treat nesidioblastosis and diffuse 
CHI has varying efficacy and causes significant side effects. Here, we describe a 
novel method for therapy of hyperinsulinemic hyperglycemia, highly selectively 
killing beta cells by receptor-targeted photodynamic therapy (rtPDT) with exen-
din-4-IRDye700DX, targeting the glucagon-like peptide 1 receptor (GLP-1R). 
Methods
A competitive binding assay was performed using Chinese hamster lung (CHL) 
cells transfected with the GLP-1R. The efficacy and specificity of rtPDT with exen-
din-4-IRDye700DX was examined in vitro in cells with different levels of GLP-1R 
expression. Tracer biodistribution was determined in BALB/c nude mice bearing 
subcutaneous CHL-GLP-1R xenografts. Induction of cellular damage and the effect 
on tumor growth were analyzed to determine treatment efficacy. 
Results
Exendin-4-IRDye700DX has a high affinity for the GLP-1R with an IC50 value of 
6.3 nM. rtPDT caused significant specific phototoxicity in GLP-1R positive cells 
(2.3 ± 0.8 % and 2.7 ± 0.3 % remaining cell viability in CHL-GLP-1R and INS-1 cells 
resp.). The tracer accumulates dose-dependently in GLP-1R positive tumors. In vivo 
rtPDT induces cellular damage in tumors, shown by strong expression of cleaved-
caspase-3 and leads to a prolonged median survival of the mice (36.5 vs. 22.5 days 
resp. p<0.05).
Conclusion
These data show in vitro as well as in vivo evidence for the potency of rtPDT using 
exendin-4-IRDye700DX. This could in the future provide a new, minimally invasive 
and highly specific treatment method for hyperinsulinemic hypoglycemia.
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Introduction
Insulin production by pancreatic beta cells is usually a well-regulated process. 
However, uncontrolled overproduction of insulin can arise, in most cases as a 
result of insulin-producing lesions. Such lesions cause major clinical symptoms 
and treatment can be challenging. In adults, these lesions manifest in endogenous 
adult hyperinsulinemic hypoglycemia, most often caused by an insulinoma; 
an insulin-producing neuroendocrine tumor arising from pancreatic beta cells (1). 
In 0.5% to 5% of cases, adult hyperinsulinemic hypoglycemia is caused by nesidio-
blastosis, characterized by proliferation of abnormal beta cells throughout the 
pancreas (2). In neonates, the most common cause of persistent hyperinsulinism is 
CHI (3). In diffuse CHI, there is diffuse involvement of the pancreatic beta cells, 
while in focal CHI the disease is caused by focal adenomatous islet cell hyperplasia 
(4). Episodic hypoglycemia due to endogenous hyperinsulinism causes neurogly-
copenic and autonomic symptoms. Prolonged hypoglycemia may lead to seizures, 
loss of consciousness, permanent brain damage or brain death (5).
 Insulinomas and focal CHI can be cured by surgical removal of the lesion (3, 
6). Enucleation is possible in case of superficially localized lesions with sufficient 
distance to the pancreatic duct (2-3 mm). Otherwise, a more extensive surgical 
procedure like partial or distal pancreatectomy may be required. While such 
procedures can often be performed laparoscopically (7, 8), they remain challenging 
and may carry major risks of morbidity (9, 10). The only surgical treatment option 
for patients with nesidioblastosis and diffuse CHI not responding to medication is 
partial pancreatectomy. Even after such an invasive procedure, hypoglycemic 
episodes often persist, requiring continued treatment with medication and, in 
certain cases of CHI, total pancreatectomy (2, 4).
 Because of these challenges, a novel, preferably minimally invasive treatment 
option for hyperinsulinemic hypoglycemia in adults as well as in children is 
warranted. In this study, we assess the feasibility of specific ablation of insulin- 
producing cells with PDT. PDT is based on inducing cell death by irradiation of a 
light-sensitive molecule, or photosensitizer (PS). The PS absorbs photons and is 
transferred to a higher energy state. By transfer of energy from the activated PS to 
the oxygen in the surrounding tissue, reactive oxygen species (ROS) are produced, 
which can cause cellular damage (11). To ensure efficient and specific delivery of 
the PS to the target tissue, the PS is coupled to a tumor-specific targeting moiety (12).
 An attractive targeting moiety for rtPDT of insulin-producing cells is exendin-4. 
This peptide is a stable analogue of the hormone GLP-1. It specifically binds to the 
GLP-1R, which is expressed on pancreatic beta cells and in high levels in nearly 
100% of benign insulinomas (13). GLP-1R imaging using 111In- and 68Ga-labelled 
exendin-4 has been shown to be a successful pre-operative imaging technique for 
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insulinomas (14-16) and is also under investigation in CHI (clinicaltrials.gov; 
NCT03768518). 
 We have developed an approach for rtPDT of insulin producing lesions using 
the peptide exendin-4 coupled to the photosensitizer IRDye700DX. We hypothesize 
that this novel method will allow specific cell killing of GLP-1R positive cells. 
Materials and methods
Reagents
Exendin-4-IRDye700DX was supplied by piCHEM (Graz, Austria). IRDye700DX 
NHS ester was obtained from LI-COR Biosciences (Lincoln, Nebraska, U.S.A.). 
IRDye700DX absorbs and emits light in the NIR range and has a higher extinction 
coefficient (2.1x105 M-1cm-1 at 689 nm) than non-NIR PSs (12, 17). The N-epsilon 
amino group of lysine at position 40 was site specifically modified during solid 
phase peptide synthesis with a mercapto-propionic acid, releasing an unprotected 
exendin-4 with a free thiol function after triisopropylsilane cleavage. IRDye700DX 
was modified with a maleimide and coupling to exendin-4 was performed using a 
thiol reactive crosslinking approach. The purity was >90%. Stock solutions of 
exendin- 4-IRDye700DX were prepared in phosphate-buffered saline (PBS). The 
structure and amino acid sequence of the tracer are shown in figure 1. Absorbance 
and emission spectra of exendin-4-IRDye700DX are shown in figure 2.
Cell culture
CHL cells stably transfected with the GLP-1R (18) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) with 4.5g/L D-glucose and Glutamax, 
supplemented with 10% fetal calf serum (FCS), 100 IU/mL penicillin G, 10mg/mL 
streptomycine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids and 0.3 
mg/mL G418 geneticin. The rat insulinoma cell line INS-1 was cultured in RPMI 
1640 medium, supplemented with 10% FCS, 100 IU/mL penicillin G, 10mg/mL 
streptomycine, 2 mmol/L L-glutamine, 1 mmol/L pyruvate, 10 mmol/L 4-(2-hy-
droxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 50 µmol/L 2-mercap-
toethanol. The human pancreatic tumor cell line PANC-1 was cultured in RPMI 
1640 medium supplemented with 10% FCS, 100 IU/mL penicillin G, 10 mg/mL 
streptomycine and 2 mmol/L L-glutamine.
Competitive binding assay
The half-maximal inhibitory concentration (IC50) of exendin-4-IRDye700DX and 
unlabeled exendin, as a reference, was determined using CHL-GLP-1R cells as 
described previously (19, 20). 106 cells/well were grown overnight in six well plates. 
113
RTPDT OF GLP-1R POSITIVE LESIONS
6
Cells were washed twice with PBS and incubated for 4 hours on ice with 50,000 
cpm 111In-labelled exendin in the presence of increasing concentrations of 
 exendin-4-IRDye700DX (0.1–300 nM). Cells were then washed with PBS, solubilized 
with 2 mL sodium hydroxide (NaOH), collected and the cell-associated activity 
was measured in a gamma-counter (Wizard 2480, PerkinElmer, Groningen, 
The Netherlands).
Figure 1  Structure and amino acid sequence of exendin-4-IRDye700DX
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In vitro receptor-targeted photodynamic therapy 
CHL-GLP-1R cells, INS-1 cells and PANC-1 cells were seeded into 24-well plates 
(Thermo Scientific) (150,000 cells/well) and grown overnight. Medium was replaced 
by binding buffer (medium with 0.1% bovine serum albumin (w/v) (BSA)) with 
exendin-4-IRDye700DX (300nM for CHL-GLP-1R cells and 400nM for INS-1 and 
PANC-1 cells (concentrations based on optimization experiments). As a control, 
cells incubated with binding buffer only were used. Separate wells were incubated 
with an excess (15 µM for CHL-GLP-1R cells and 20 µM for INS-1 and PANC-1 cells) 
of unlabeled exendin-4 together with exendin-4-IRDye700DX. After incubation 
at 37ºC (CHL-GLP-1R cells 4 hours, INS-1 and PANC-1 cells 24 hours), cells were 
washed with binding buffer. Subsequently, cells were irradiated with a NIR 
light-emitting diode (LED) (21) (emission wavelength 670-710 nm, forward voltage: 
2.6 V, power output: 490 mW) using 126 individual LED bulbs ensuring homogenous 
illumination (21). CHL-GLP-1R cells were irradiated at 90 J/cm2 (over 6 min). INS-1 
and PANC-1 cells were irradiated at 150 J/cm2 (over 10 min). Cells incubated with 
exendin-4-IRDye700DX that were not irradiated were included as a control. 
All experiments were carried out in triplicate.
 Four hours after irradiation, during which the cells were kept at 37ºC and 5% CO2, 
the ATP content as a measure of cell viability was determined using a CellTiter-Glo® 
luminescent assay (Promega Benelux, Leiden, The Netherlands) according to the 
instructions of the manufacturer. Luminescence was measured using a TECAN 
infinite M200 Pro plate reader (PerkinElmer, Groningen, The Netherlands). 
The ATP content as a measure of cell viability was expressed as a percentage, 
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determined by comparing the luminescent signal with the signal from untreated 
cells, which were considered 100% viable.
 Additionally, a co-culture of INS-1 and PANC-1 cells was plated in 24-well 
plates (70,000 and 40,000 cells/well, respectively). Before seeding, INS-1 cells were 
labeled with the fluorescent dye DiO and PANC-1 cells with DiD dye according to 
the manufacturer’s protocol (Life Technologies, Thermo Fisher Scientific, Waltam, 
MA, USA). Cells were grown overnight and then incubated with 400 nM exen-
din-4-IRDye700DX in binding buffer or binding buffer alone for 24 hours at 37ºC 
and 5% CO2. Subsequently, cells were irradiated with 150 J/cm2 of NIR light. After 
4 hours, cells were incubated with 1 µg/mL propidium iodide (Thermo Fisher 
Scientific, Waltham, MA, USA) in PBS for 15 minutes at room temperature. Cells 
were visualized using an EVOS microscope (Thermo Fisher Scientific, Waltam, 
MA, USA).
Animal tumor model
Female BALB/c nude mice (Janvier, Le Genest Saint Isle, France), 6-8 weeks old, 
were housed in individually ventilated cages (6 mice per cage) under non sterile 
conditions with ad libitum access to chlorophyll-free animal chow and water. 
CHL-GLP-1R cells (5*106 cells/ mouse in 200 µl DMEM with 4.5g/L D-glucose and 
Glutamax) were injected subcutaneously on the right flank of the mice. 
In vivo biodistribution
Female BALB/c nude mice with CHL-GLP-1R xenografts were injected intra -
venously with exendin-4-IRDye700DX in 200 µl PBS with 0.5% BSA (N=5 per 
group, 1, 3 and 10 µg exendin-4-IRDye-700DX). Four mice were injected with only 
PBS with 0.5% BSA. After 4 hours, mice were sacrificed by CO2 asphyxiation and 
the tumor and organs were removed and collected in Roche MagNA Lyser tubes (F 
Hoffmann-La Roche Ltd., Basel, Switzerland). Radioimmunoprecipitation assay 
(RIPA) lysis buffer (500 µL; 50mM (hydroxymethyl)aminomethane-hydrochloride 
(TRIS-HCl), pH7.4 with 150 mM sodiumchloride (NaCl), 1 mM ethylenediamine-
tetraacetic acid (EDTA), 1% Triton-X-100 and 1% sodium dodecyl sulfate (SDS)) 
was added to each tube. Organs were homogenized using a Roche MagNA Lyser 
(F Hoffmann-La Roche Ltd., Basel, Switzerland) with repeated cycles of 6000 rpm 
for 25 sec with cooling on ice for 1 minute between cycles. Organ homogenates of 
the control mice (injected only with PBS with 0.5% BSA) were used to create standard 
curves of exendin-4-IRDye700DX for each organ. 100 µl of homogenates were transferred 
in triplicate to a black flat-bottom 96-well plate and fluorescence intensity was 
measured using a TECAN infinite M200 Pro plate reader (PerkinElmer, Groningen, 
The Netherlands) (excitation wavelength: 620 nm, emission wavelength: 700 nm). 
Standard curves and tracer uptake were calculated using Microsoft Office Excel 2007.
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Receptor-targeted photodynamic therapy in vivo; 
immunohistochemistry
Female BALB/c nude mice with subcutaneous GLP-1R positive xenografts (N=8 
per group) were injected intravenously with 30 µg exendin-4-IRDye700DX in 200 µl 
PBS with 0.5% BSA or 200 µl PBS with 0.5% BSA only, and after 4 hours exposed to 
100 J/cm2 NIR LED light. One group was treated only with exendin-4-IRDye700DX 
without NIR light exposure. Two or 24 hours after NIR light exposure, mice were 
sacrificed by CO2 asphyxiation. Tumors were harvested, fixated in 4% buffered 
formalin, embedded in paraffin and sectioned at 4 µm thickness. Slices were 
deparaffinized with xylene and rehydrated in ethanol. Antigen retrieval was 
performed with 10 mM citrate pH 6.0 in a PT-Module (Thermo Fisher Scientific, 
Waltam, MA, USA) (10 min, 96ºC). Endogenous peroxidase activity was quenched 
with 3% H2O2 for 10 min. Slices were incubated with 20% normal goat serum for 30 
min and subsequently with rabbit-anti-cleaved-caspase-3 (1:4000 in PBS + 1% BSA, 
ASP175, Cell Signaling Technology, Leiden, The Netherlands) in a humidified 
chamber at 4ºC overnight in the dark. Slides were then washed 3 times with 10 mM 
PBS and incubated with goat-anti-rabbit-biotin (1:200 in PBS + 1% BSA, Vector 
Laboratories, Peterborough, UK) for 30 min at room temperature. After washing 
with PBS, slides were incubated with Vectastain Elite ABC kit (Vector Laboratories, 
Peterborough, UK) for 30 min at room temperature. The bound antibodies were 
visualized using diaminobenzine (DAB, Bright DAB, BS04 Immunologic, VWR, 
Dublin, Ireland). Slides were counterstained with 3 times diluted hematoxylin 
(Klinipath, Olen, Belgium) for 5 seconds and mounted with a cover slip (permount, 
Fisher Scientific, Waltam, MA, USA).
 The immunohistochemical staining was independently analyzed by two 
blinded observers. Scores were allocated to each slide following an ordinal 6-point 
scale ranging from 0 (no staining), 1 (very weak staining), 2 (weak staining), 
3 (intermediate staining), 4 (intense staining) to 5 (very intense staining). The scores 
of the two observers were averaged.
Receptor-targeted photodynamic therapy in vivo; survival
Female BALB/c nude mice with CHL-GLP-1R xenografts were randomized into 
2 groups of 8 animals based on tumor size. When tumors were at least 30 mm3, 
mice were injected intravenously with 30 µg exendin-4-IRDye700DX in 200 µl PBS 
with 0.5% BSA or PBS with 0.5% BSA only. After 4 hours, mice were exposed to 
150 J/cm2 of NIR LED light under inhalation anesthesia (2,5% isoflurane mixed 
with 100% O2 (1 L/min)). Kidneys were protected from exposure by covering them 
with gauze and aluminum foil. Tumor diameters were measured by a blinded 
observer three times per week in three dimensions using a caliper. Mice were 
euthanized by CO2 asphyxiation when tumor volume reached more than 1000 mm3 
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(tumor volume was calculated by 1.25*π* (((length + width + height) / 6) ^3). 
Overall survival was defined as the day that tumors reached a size of 1000 mm3.
Statistics
Statistical calculations were performed using GraphPad Prism (GraphPad 
Software, La Jolla, CA, USA). IC50 values were calculated by fitting the data with 
non-linear regression using least squares fit with GraphPad Prism. In vitro cell 
viability after various treatments, assessed by a CellTiter-Glo® assay, were 
compared by two-way ANOVA with post-hoc Bonferroni tests. Tracer uptake in 
various tumors was compared between the different injected doses by one-way 
ANOVA.
 Survival curves were compared with the log-rank (Mantel-Cox) test using 
GraphPad Prism (version 5.03).
Study approval
All animal experiments have been approved by the institutional Animal Welfare 
Committee of the Radboud University Medical Centre and were conducted in 
accordance to the guidelines of the Revised Dutch Act on Animal Experimentation.
Results
Exendin-4-IRDye700DX binds the GLP-1R with high affinity
The IC50 values of exendin-4 and exendin-4-IRDye700DX, were 2.54 nM (95% CI; 
1.32–4.90) and 6.25 nM (95% CI; 3.07–12.74), respectively (Fig. 3). While the binding 
affinity of the labeled peptide is significantly lower compared to the unlabeled 
peptide (p < 0.0001), it binds with a high affinity to the GLP-1R in the nanomolar 
range.
In vitro receptor-targeted PDT with exendin-4-IRDye700DX and 
NIR light causes specific GLP-1R positive cell death.
rtPDT with exendin-4-IRDye700DX caused significant phototoxicity in cells with 
high GLP-1R expression (CHL-GLP-1R cells) and the rat insulinoma cell line INS-1, 
with GLP-1R expression comparable to human insulinomas. Remaining cell 
viabilities were 2.3±0.8 % and 2.7±0.3 % respectively (Fig. 4). In PANC-1 cells no 
cellular phototoxicity was observed under these conditions (96.1±1.2 % viable 
cells). Co-incubation with an excess of unlabeled exendin-4 abolished the 
phototoxic effect in CHL-GLP-1R cells as well as in INS-1 cells (99.3±1.3 and 98.4±2.1 
% cell viability respectively). NIR light irradiation alone did not cause cellular 
phototoxicity in any of the cell types (106.6±1.2 %, 102.5±5.9 % and 102.0±1.8 % 
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Figure 3  Competition binding assay (IC50) using CHL-GLP-1 cells of unlabeled exendin-4 
and exendin-4-IRDye700DX. 111In-DTPA-exendin-4 was used as a tracer.
Figure 4  ATP content as a measure of cell viability of CHL-GLP-1R cells, INS-1 cells and 
PANC-1 cells following incubation with binding buffer (control), exendin-4-IRDye700DX or 
exendin-4-IRDye-700DX combined with an excess of unlabeled exendin-4 and with or 
without NIR light irradiation. Experiments were performed in triplicate. Data are presented 
as mean ± SD. * indicates p<0.001.
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viable cells in CHL-GLP-1R, INS-1 and PANC-1 cells, respectively). No dark toxicity 
of the tracer was observed (103.3±6.7 %, 105.2±4.7 % and 103.6±1.4 % cell viability 
without irradiation in CHL-GLP-1R, INS-1 and PANC-1 cells, respectively). 
Incubation of a co-culture of INS-1 and PANC-1 cells with exendin-4-IRDye700DX 
followed by irradiation specifically caused cell death in INS-1 cells, as shown by 
co-localization of the red and green nuclei (Fig. 5). Absence of p.i. signal upon 
rtPDT indicated that exendin-4-IRDye700DX alone or NIR light alone did not cause 
cell death in either cell type.
Exendin-4-IRDye700DX accumulates in GLP-1R positive tumors.
Relative uptake of exendin-4-IRDye700DX in subcutaneous GLP-1R tumors in 
mice was 3.9±1.9 % injected dose (ID)/g for 1 µg tracer dose and diminishes slightly 
to 3.3±0.6 %ID/g for 3 µg tracer dose and 2.5±0.8 %ID/g for 10 µg tracer dose 
(p = 0.25) (Fig. 6). As a result, the absolute tumor uptake increases with increasing 
injected tracer doses to 25.0 µg/g with 10 µg tracer injection. Highest uptake of 
 exendin-4-IRDye700 was observed in the kidneys, due to renal clearance. 
In vivo receptor-targeted PDT causes cell death in GLP-1R positive 
tumors and improves survival
Analysis of the immunohistochemical staining revealed a low expression of 
cleaved-caspase-3 in the control groups. In both treatment groups the expression 
of cleaved-caspase-3 was higher than in the control groups. While the intensity of 
cleaved-caspase-3 staining was variable at 2 hours after treatment, the intensity of 
Figure 5  Fluorescence microscopy of INS-1 cells labeled with the fluorescent dye DiO (green) 
and PANC-1 cells labeled with the fluorescent dye DiD (cyan), co-cultured and incubated 
with propidium iodide (red), after incubation of exendin-4-IRDye700DX or only binding 
buffer and with and without NIR irradiation with a radiant exposure of 150 J/cm2. The scale 
bar denotes 100 µm.
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the staining was high and uniform in the tumors 24 hours after treatment, showing 
a significant induction of apoptosis in the tumors. The expression of cleaved-
caspase-3 was slightly increased in control group receiving only NIR light 
irradiation, showing that the light itself induces some cell death, most likely due to 
the heat produced by the LED light source (Fig. 7).
Figure 6  Biodistribution of exendin-4-IRDye700DX (1 µg, 3 µg and 10 µg, N=5 mice per 
group) in tumors, spleen, pancreas, kidneys and liver of female BALB/c nude mice 4 hours 
after tracer injection. (A) Relative uptake expressed as % of the injected dose per gram of 
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Figure 7  Representative examples of cleaved-caspase-3 and HE staining of CHL-GLP-1R 
tumors. A) Control tumors after i.v. administration of exendin-4-IRDye700DX. B) Control 
tumors after only illumination. C) Tumors after i.v. administration of exendin-4-IRDye700DX 
and illumination, dissected after 2 hours. D) Tumors after i.v. administration of exendin- 4-
IRDye700DX and illumination dissected after 24 hours. E) Intensity scores of capase-3 







 At the start of the survival experiment, sizes of the subcutaneous GLP-1R were 
very variable, although mean tumor sizes were similar between the groups 
(161±205 mm3 (35-657 mm3) in the exendin-4-IRDye700DX group and 171±144 mm3 
(36-480 mm3) in the control group. Upon light exposure, tumor growth was slower 
in the group which received exendin-4-IRDye700DX leading to a significantly 
longer median survival in this group compared to the control group (36.5 vs. 22.5 
days resp. p<0.05) (Fig. 8).
Figure 7  Continued.
E
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Discussion
Treatment of hyperinsulinemic hypoglycemia is challenging. To address this issue, 
a treatment strategy which specifically destroys GLP-1R positive cells with rtPDT 
was developed as an alternative treatment option for all forms of hyperinsuline-
mic hypoglycemia.
 We show effectivity of rtPDT with exendin-4-IRDye700DX in vitro and in vivo. 
The specific cytotoxic effect demonstrates that rtPDT with exendin-4-IRDye700DX 
could enable destruction of GLP-1R positive lesions without causing damage to the 
surrounding pancreatic tissue.
 This is the first evidence of the effectiveness of a peptide-based agent for rtPDT 
in vivo to date. In the current development of tracers for rtPDT, the most widely 
used carrier molecules are mAbs and nanoparticles, because of their slow clearance 
from the circulation and high uptake in target organs. A single previous study 
examining rtPDT using various targeting peptides was limited to in vitro studies 
and showed no efficient cytotoxic effect (22). 
 We believe that rtPDT with exendin-4-IRDye700DX has the potential to be 
used as a minimally invasive technique to destroy insulin-producing cells with 
minimal morbidity. Upon delivery of the tracer, NIR light can be administered 
interstitially using diffuser fibers which are placed into the target tissue. Using this 
method of so-called interstitial PDT (iPDT), it is feasible to deliver light to deeply 
seeded lesions/tissues. Successful results of iPDT have been obtained in for 
example prostate cancer (23), head and neck cancer (24) and importantly pancreatic 
Figure 8  Kaplan-Meier plot of survival of BALB/c nude mice with GLP-1R positive tumors 
after injection of 30 µg exendin-4-IRDye700DX or PBS (control), followed by illuminaton 
with a radiant exposure of 150 J/cm2.















tumors (25). An optimal treatment result depends on optimization of the number 
of light sources as well as their specific placement and power output (26-28). With 
percutaneous delivery, areas up to 23 cm2 can be treated (29), making it suitable for 
treatment of CHI and nesidioblastosis. Alternatively, the less invasive endoscopic 
delivery of a fiber can be applied for treatment of small lesions, since a single fiber 
can be applied using this technique (30, 31). 
 The data in this paper do not show 100% cell killing. Since these experiments 
were performed in an immunocompromised mouse model, they did not take into 
account the possible added effect on cell killing of the immune response elicited by 
PDT, as has been shown for other tumor types (32). Additionally, because of the 
minimal invasiveness of PDT, treatment can easily be repeated if hypoglycemia 
persist. Of interest, in a clinical situation, killing of enough cells to prevent over-
production of insulin will be sufficient, eliminating the need for 100% cell killing. 
 The receptor-targeted approach of PDT with exendin-4-IRDye700DX enables 
specific killing of GLP-1R expressing cells without damaging the surrounding 
tissue, and the focused irradiation of the tissue of interest avoids a risk of damaging 
the kidneys. Since treatment of nesidioblastosis and diffuse CHI will involve 
irradiation of a larger part of the pancreas, this risks development of impaired 
glucose tolerance. However, rtPDT has advantages over near-total pancreatectomy, 
since it avoids the risk of exocrine pancreatic insufficiency and is much less 
invasive. Also, localization and quantification of the insulin-overproducing cells 
based on pre-operative PET images using radiolabeled exendin-4 could be used for 
planning of the rtPDT to optimize the treatment and minimize side effects. 
 We believe that the data presented here, together with the advances in the 
technology of interstitial PDT, can provide a basis towards clinical translation of 
rtPDT using exendin-4-IRDye700DX. For this, verification of efficient targeting to 
human tissues as well as the potential treatment efficacy by ex-vivo analysis of 
human tissues will be necessary before initiation of a first clinical trial.
Conclusion
Here, we show the feasibility of rtPDT with exendin-4-IRDye700DX, which is also 
the first demonstration of efficient PDT using small molecules in vivo. In the future, 
ablating insulin-producing cells using rtPDT with exendin-4-IRDye700DX could 
provide a new, minimally invasive treatment method for patients with hyperinsu-
linemic hypoglycemia. Since this treatment could be applied to a specific site of 
the pancreas in the case of insulinomas or focal CHI or to a larger pancreatic area in 
the case of nesidioblastosis or diffuse CHI, it clearly has the potential to be effective 
to normalize blood glucose regulation in all forms of hyperinsulinemic hypoglycemia.
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For patients with AHH, a fast and accurate diagnosis is of high importance, as 
AHH has a large impact on the quality of life of the patients. For example, episodic 
hypoglycemia can lead to fear of engaging in certain activities like sports, driving a 
car or even going for walk alone. Patients can also be afraid to go to sleep, because of 
fear of having a hypoglycemic episode during the night. Recurrent hypoglycemic 
episodes prevent some patients from working and many patients gain weight because 
of frequent eating. Untreated AHH can even be dangerous, since hypoglycemia 
unawareness can prevent patients from taking action to raise their blood glucose 
levels. This could result in seizures, loss of consciousness and even brain damage 
or brain death. Since symptoms of hypoglycemia can be misattributed to psychiatric, 
neurological or cardiac disorders, the diagnosis of patients can be delayed if lesions 
are not readily discovered using imaging (1). Currently, multiple different imaging 
procedures, and in some cases more invasive diagnostic procedures, are performed 
in most of the patients before a definite diagnosis is reached, and procedures are 
sometimes repeated over time if an insulinoma is not detected. Accelerating this 
process by introducing a more sensitive non-invasive imaging technique would 
thus be of great interest.
 Because of the improved sensitivity and image quality of [68Ga]Ga-NODA-
GA-exendin-4 PET/CT compared to other imaging techniques, its implementation 
as the primary diagnostic procedure for insulinomas could significantly reduce 
the burden of the diagnostic process for the patients. In many patients, performance 
of GLP-1R PET as a primary diagnostic procedure could eliminate the need for 
additional diagnostics. A combination with triple phase CT would also provide the 
anatomical information for surgical planning. Such a one-stop shop for insulinoma 
detection, besides being beneficial for the patients, could also improve the cost- 
effectiveness of the diagnostic process for AHH. To precisely determine the 
potential cost benefit, cost effectiveness modeling based on the results of our 
prospective clinical trial would be of interest. 
Malignant insulinomas
In less than 10% of cases, malignant insulinomas occur. When presenting with 
liver metastases, these malignant insulinomas have a poor patient prognosis (2). 
While overexpressed in almost all benign insulinomas, the receptor density of the 
GLP-1R in malignant insulinomas has been described to be lower (3). In contrast, 
malignant insulinomas express the SSTR more often than benign insulinomas, 
leading to a higher detection rate of malignant insulinomas by SSTR PET compared 
to GLP-1R PET (4). While GLP-1R PET has the potential of becoming the primary 
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diagnostic modality for benign insulinomas, SSTR PET is more suitable as primary 
diagnostic modality for detection of the rarer malignant insulinomas. Because of 
the difference in receptor expression between benign and malignant insulinomas, 
the combination of GLP-1R and SSTR imaging could impact patient care, since a 
negative GLP-1R imaging result combined with a positive SSTR imaging result in 
a patient with AHH could indicate towards a malignant insulinoma in cases 
without metastases.
CHI
In patients with CHI, replacement of [18F]F-DOPA PET by [68Ga]Ga-NODAGA- 
exendin-4 PET as the primary diagnostic imaging modality could lead to the 
detection focal lesions which would otherwise have been missed. This would have 
a major impact on the lives of these patients. It could provide the possibility for a 
cure and prevent continuing medicinal treatment with its associated side effects 
(5). It could also prevent the execution of unnecessary near-total pancreatectomies 
and thereby the occurrence of associated morbidities like pancreatic exocrine 
insufficiency and diabetes (6). GLP-1R PET could thus significantly improve the 
future quality of life of these patients. 
A challenge: kidney uptake
A challenge in diagnostic imaging of insulinomas and focal CHI with [68Ga]
Ga-NODAGA-exendin-4 PET is the high uptake of the tracer in the kidneys due to 
renal clearance and tubular re-absorption (7). Tracer uptake in the left kidney in 
some cases hinders detection of lesions in the pancreatic tail. There are certain 
methods to reduce kidney uptake of peptide-based tracers. Co-infusion of 
positively charged amino acids, trypsinized albumin or the plasma expander 
gelofusine can be used for competitive inhibition of tubular re-absorption. In 
pre-clinical models, co-infusion of poly-glutamic acid and gelofusine was reported 
to reduce renal uptake of 111In-labeled exendin-4 by 48% (8). Gelofusine alone was 
shown to reduce renal uptake of 111In-labeled exendin-4 by 18% in healthy 
volunteers, without affecting tracer uptake in the pancreas (9). An effect of 
gelofusine on renal uptake of 68Ga-labeled exendin-4 is still to be established. 
There are several other strategies that have been developed to reduce renal uptake 
of radiolabeled exendin, such as introduction of a cleavable linker to allow renal 
excretion of the radionuclides (10) and incorporation of highly lipophilic groups 
(11), but these have not yet been tested in humans. Further research into effective 
methods to reduce the renal uptake of radiolabeled exendin is of interest, since it 
would be beneficial for the diagnostic accuracy of [68Ga]Ga-NODAGA-exendin-4.
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Since it can be difficult to detect insulinomas and focal lesions in CHI intra-opera-
tively, even after pre-operative detection, fluorescence-guided surgery would be 
beneficial. Surgery of the pancreas is challenging and associated with risks of 
complications like pancreatic fistulas and bleeding (12). By giving the surgeon very 
specific real-time information on the location of the lesion by fluorescence imaging, 
surgeons will not have to rely on palpation and intra-operative ultrasound. This 
could lead to more optimal and faster surgical procedures (13-15) and possibly a 
lower risk of morbidity. A great benefit of fluorescence-guided surgery is that it can 
be performed in an open setting as well as laparoscopically (16), so it can benefit 
enucleations as well as partial pancreatectomies, depending on the location of the 
lesion. 
Combining fluorescence-guiding with radio-guiding
A disadvantage of fluorescence imaging is the limited penetration depth, as a 
result of tissue absorption and scattering of the photons. A fluorescent signal will 
therefore only be detected in close proximity to the lesion. This will probably not 
be a problem in most cases of insulinomas and focal CHI, since the surgeon can be 
initially guided to the location of the lesion by the pre-operative scan. However, in 
particular for occult lesions located deep in the pancreatic tissue, combining fluo-
rescence-guiding with radio-guiding could be of interest. Radio-guided detection 
of insulinomas using radiolabeled exendin-4 has already been proven successful 
in a limited number of patients with insulinomas (17). Radio-guided tumor 
detection is limited to an acoustic signal derived from a probe with a certain 
detection angle, leading to limited spatial resolution (18). Combining fluorescence 
imaging with radio-guiding could exploit the benefits of both these techniques 
and enable detection of deep-seated lesions followed by precise lesion delineation. 
Combined radio-guiding and fluorescence-guiding could be achieved by 
development of a multimodal tracer by labeling exendin-4-IRDye800CW with a 
radionuclide. There is currently much attention for the development of such 
dual-labeled tracers (19). For example, the monoclonal antibody girentuximab 
labeled with 111In and IRDye800CW for radiodetection followed by fluores-
cence-guided resection of renal cell carcinoma is already being assessed clinically 
(NCT02497599). Development of a dual-labeled exendin-based tracer could be of 
interest if, upon clinical assessment, fluorescence-guided surgery of insulinomas 
and focal CHI using exendin-4-IRDye800CW proves to be hindered by the 
penetration depth of the fluorescent signal. However, radio-guiding has the 
disadvantage of causing a radiation burden for the surgeons. Therefore, if the 
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fluorescent signal of exendin-4-IRDye800CW is readily detected in the lesions, 
combination with radio-guiding will not be preferable.
Optimization of imaging systems
Important for the clinical translation of this fluorescence-guided surgery technique 
is the optimization of the imaging systems used by the surgeons to detect the 
fluorescent signal. Most clinical fluorescence imaging systems which are currently 
available have been developed for the detection of high concentrations of 
indocyanine green in the blood. With a targeted approach like exendin-4-IRDye-
800CW, the concentration of the fluorescent dye that can be reached within the 
tumor is much lower. So, while the current clinical fluorescent imaging systems 
are suitable for the detection of photons with wavelengths in the NIR range, their 
sensitivity needs improvement. Since there is currently much attention for targeted 
NIR fluorescence-guided surgery, steps are also being taken to improve the 
imaging systems by ameliorating software systems, emission filters, background 
correction and charge-coupled device cameras (20). 
Photodynamic therapy 
rtPDT with exendin-4-IRDye700DX has the potential to provide a minimally 
invasive treatment alternative for AHH and CHI. Even with sensitive and precise 
pre-operative localization of insulinomas and focal CHI and the possibility for 
fluorescence-guided surgery, the surgical treatment is still invasive. Ablating the 
lesion by specific irradiation with NIR light using diffuser fibers placed into the 
target tissue could provide a less invasive treatment method. Since rtPDT with 
exendin-4-IRDye700DX could specifically destroy GLP-1R positive cells, it could 
have a lower risk of side effects related to damage to adjacent tissues than surgical 
removal of the lesion. This could lead to a faster recovery and better quality of life 
for the patients after treatment. 
 In the future, rtPDT could also greatly improve the treatment of patients with 
nesidioblastosis and diffuse CHI, because it could be a minimally invasive way to 
cure these patients. Today, the only cure for nesidioblastosis and diffuse CHI is 
extensive pancreatic resection, which is associated with high morbidity levels. 
In patients unresponsive to medication this is currently the only treatment option. 
Treatment with rtPDT could destroy the diseased beta cells without causing 
damage to exocrine pancreatic tissue, eliminating the risk of pancreatic exocrine 
insufficiency which is associated with near-total pancreatectomy. Even for patients 
that do respond to medication, the current treatment is far from optimal, since the 
available medication often causes severe side effects. rtPDT could therefore also 
be a valuable alternative treatment option for these patients.
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Clinical translation
Before rtPDT with exendin-4-IRDye700DX can be translated into the clinic, it is 
important to assess the safety of the treatment. In the past, problems with PDT 
approaches have occurred because of the development of side effects, such as 
photo-allergic reactions damaging healthy tissues (21, 22). Because of the targeted 
approach, the uptake of exendin-4-IRDye700DX in target tissues is high with low 
background values. The kidneys and the duodenum are the only abdominal 
organs, besides the pancreatic beta cells, in which high tracer uptake is found. We 
therefore expect that specific irradiation of the target site using a fiber bundle, 
while avoiding irradiation of the kidneys and duodenum, will avoid damage of 
healthy tissue leading to side effects. In addition to this, the PS IRDye-700DX is 
only activated by NIR light and not by visible light. Even if some accumulation of 
the tracer in superficial organs like the skin would occur, this will therefore not 
result in photo-allergy.
 In addition to evaluation of the safety of the approach, the first step towards 
clinical translation is the validation of efficient targeting of the tracer to the target 
tissue in humans as well as the potential treatment efficacy by ex vivo analysis of 
human specimens.
 Besides this, clinical translation will depend on an effective way of delivering 
the light to the target tissue. While the first PDT approaches focused on superficial 
lesions, which are easily accessible with light, advances in the field now enable the 
use of PDT in deeply seated lesions using interstitial PDT. This entails delivery of 
NIR light either via percutaneous needles or endoscopically using diffuser fibers 
which are places into the target tissue. This approach has already demonstrated 
successful results in clinical studies in for example prostate cancer (23), head and 
neck cancer (24) and importantly pancreatic tumors (25). For successful clinical 
translation, optimization of the treatment regarding the dose of the tracer as well 
as the number of light sources, their specific placement and power output (26-28) 
are crucial.
Individualized treatment
Delivery of light using interstitial PDT can be tailored to the desired effect, like 
illumination of a small area with a high light intensity for insulinomas and focal 
CHI and illumination of a larger area with a lower light intensity for the treatment 
of nesidioblastosis and diffuse CHI. In patients with nesidioblastosis and diffuse 
CHI, the optimal rtPDT treatment would destroy a sufficient number of beta cells 
to prevent overproduction of insulin, while preserving enough beta cells to 
maintain glucose homeostasis. A possible way to achieve this is by quantification of 
[68Ga]Ga-NODAGA-exendin-4 PET scans performed for pre-operative diagnostics. 
A benefit of PET imaging is the possibility for reliable quantification (29). The 
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possibility of using radiolabeled exendin to quantify beta cell mass has already 
been demonstrated in rats, where pancreatic uptake of 111In-labeled exendin 
correlated linearly with beta cell mass (30). Furthermore, in humans, quantification 
of SPECT images showed a significantly lower uptake of 111In-labeled exendin in 
the pancreas of patients with type 1 diabetes as compared to healthy individuals 
(31). By correlating tracer uptake of 68Ga-labeled exendin in the pancreas with the 
amount of NIR irradiation needed to cure patients without developing pancreatic 
endocrine insufficiency, the treatment could be tailored to the individual patient.
The future in diagnostics and treatment of  
hyperinsulinemic hypoglycemia
In this thesis we show the potential benefit of exendin-based tracers for diagnosis 
as well as treatment of hyperinsulinemic hypoglycemia.
 [68Ga]Ga-exendin-4 PET/CT outperforms all current standard non-invasive 
imaging modalities used for the detection of insulinomas as well as focal lesions in 
CHI (chapter 2 & 3). By using the chelator NODAGA we can label exendin-4 with 
68Ga with a high specific activity enabling imaging with low pharmacological 
peptide doses. This has resulted in minimal side effects in adult patients as well as 
children. Furthermore, because of the low radiation dose to the patients, the tracer 
is safe for use in patients of all ages (chapter 4). We therefore believe [68Ga]
Ga-NODAGA-exendin-4 has the potential to become the primary diagnostic 
imaging modality for adult endogenous AHH as well as CHI. 
 After patients are diagnosed with a specific subform of AHH or CHI and 
potential lesions are localized using radiolabeled exendin-4, treatment of the 
patients can be optimized using the NIR fluorescent tracers exendin-4-IRDye-
800CW and exendin-4-IRDye700DX. Intra-operative fluorescence imaging using 
exendin- IRDye800CW can aid surgical removal of insulinomas and focal lesions 
in CHI by providing sensitive real-time visual information for lesion localization 
and delineation (chapter 5). In cases where removal of the tumor is hindered by 
the vicinity of vital structures or in patients with nesidioblastosis or diffuse CHI, 
surgery or medicinal treatment could be replaced by or complemented with rtPDT. 
By performing rtPDT with exendin-4-IRDye700DX, GLP-1R positive cells can be 
specifically destroyed without causing damage to other cells (chapter 6).
 By optimizing the diagnostic process as well as the treatment of patients with 
any form of hyperinsulinemic hypoglycemia, the use of exendin-based tracers 
potentially has a major impact on the quality of life of these patients in the future.
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In the rare disorder hyperinsulinemic hypoglycemia, uncontrolled overproduction 
of insulin by the pancreatic beta cells results in dangerously low blood glucose 
levels. Adult hyperinsulinemic hypoglycemia (AHH) is most commonly caused by 
insulinomas. Congenital hyperinsulinism (CHI), occurring in a focal or diffuse 
subform, is the most common cause of hyperinsulinemic hypoglycemia in children, 
often neonates.
 Because of the severe symptoms, AHH and CHI have a large impact on patient 
lives. Therefore, quick and accurate diagnosis is essential. For AHH, this entails 
sensitive and accurate detection and localization of insulinomas. For CHI, the 
distinction between the focal and the diffuse subform is key, as well as accurate 
localization of the focus in case of focal CHI. Diagnosis of AHH and CHI is 
currently challenged by the limited sensitivity of available imaging techniques. 
Treatment of AHH and CHI is also challenging. Medication leads to significant 
side effects and surgery, which is the only curative option, carries risks of 
complications.
 Exendin is a peptide which specifically binds the glucagon-like peptide 1 receptor 
(GLP-1R) on pancreatic beta cells. This thesis describes the use of exendin-based 
tracers for diagnostic imaging, intra-operative fluorescence imaging and receptor- 
targeted photodynamic therapy (rtPDT) of hyperinsulinemic hypoglycemia, as tools 
to overcome the challenges in diagnostics and treatment. 
Non-invasive imaging of hyperinsulinemic hypoglycaemia.
The current standard non-invasive imaging techniques used for detection of 
insulinomas; CT, MRI and somatostatin receptor PET, have limited sensitivity. In 
chapter two we describe a prospective, multicenter study in which we compare the 
effectiveness of [68Ga]Ga-NODAGA-exendin-4 PET/CT with all these standard 
imaging techniques for detection of insulinomas in 42 patients with AHH. [68Ga]
Ga-NODAGA-exendin-4 PET/CT performed better than all other imaging 
techniques with a higher accuracy and sensitivity. Furthermore, image quality of 
[68Ga]Ga-NODAGA-exendin-4 PET was better than somatostatin receptor PET. 
In chapter three we examine the effectiveness of [68Ga]Ga-NODAGA-exendin-4 
PET for detection of focal CHI. In 19 CHI patients, we compared [68Ga]Ga-NODA-
GA-exendin-4 PET with the standard imaging method [18F]F-DOPA PET. We show 
that the image quality of [68Ga]Ga-NODAGA-exendin-4 PET is superior, which 
leads to a better diagnostic accuracy and certainty which aids planning of the 
surgical treatment.
 The use of [68Ga]Ga-NODAGA-exendin-4 PET for diagnosis of AHH and CHI 
results in a radiation dose to the patients. In chapter four we show a dosimetry 
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study, based on human [68Ga]Ga-NODAGA-exendin-4 PET images, in which we 
find that the effective radiation doses are very low for adults as well as children, 
enabling safe use of this technique.
These chapters show the potential of [68Ga]Ga-NODAGA-exendin-4 PET to become 
the primary diagnostic imaging modality for AHH as well as CHI in the future.
Targeted optical imaging and photodynamic therapy of  
insulin-producing lesions
Even after successful pre-operative detection of insulinomas and focal CHI, 
surgery can be complicated by challenging intra-operative detection of the lesions. 
In chapter five, we describe near-infrared fluorescence imaging of GLP-1R positive 
cells using exendin-4-IRDye800CW. We show that this tracer successfully targets 
GLP-1R positive cells and enables in vivo fluorescence imaging of GLP-1R expressing 
tumors in mice. Furthermore, we show laparoscopic detection of the fluorescent 
signal of exendin-4-IRDye800CW in the pancreas of mini pigs. By allowing 
real-time intraoperative lesion detection, this technique could benefit surgical 
removal of insulinomas and focal lesions in CHI.
 Surgery of insulinomas and CHI carries major risks of morbidity. In chapter 
six we examine selective killing of GLP-1R positive cells using rtPDT with exendin- 
4-IRDye700DX as an alternative treatment strategy. We show that rtPDT causes 
effective and selective phototoxicity in GLP-1R positive cells in vitro and that rtPDT 
is able to induce cellular damage in GLP-1R expressing tumors in vivo in mice, 
thereby prolonging their survival. This shows the future potential of rtPDT with 






Bij de zeldzame ziekte hyperinsulinemische hypoglykemie, leidt ongecontroleerde 
overproductie van insuline door de beta cellen in het pancreas tot gevaarlijk lage 
bloedsuikerniveaus. Hyperinsulinemische hypoglykemie in volwassenen (AHH) 
wordt in de meeste gevallen veroorzaakt door een insulinoom. Congenitaal hype-
rinsulinisme (CHI), voorkomend in een focale of diffuse vorm, is de meest 
voorkomende oorzaak van hyperinsulinemische hypoglykemie bij kinderen, vaak 
pasgeboren kinderen.
 Vanwege de ernstige symptomen hebben AHH en CHI een grote invloed op 
het leven van patiënten. Snelle en accurate diagnose is daarom essentieel. In het 
geval van AHH betekent dit gevoelige en accurate detectie en lokalisatie van 
insulinomen. In het geval van CHI is het maken van onderscheid tussen de focale 
en diffuse vorm belangrijk. Bij de focale vorm is ook de precieze lokalisatie van de 
focus essentieel. De diagnose van AHH en CHI worden momenteel bemoeilijkt 
door de beperkte sensitiviteit van de beschikbare beeldvormingstechnieken. Ook 
de behandeling van AHH en CHI is een uitdaging. Medicatie leidt tot ernstige 
bijwerkingen en operaties, de enige behandeling die tot genezing kan leiden, 
brengen een risico op complicaties met zich mee.
 Exendin is een peptide dat specifiek bindt aan de glucagon-like peptide 1 
receptor (GLP-1R) op de beta cellen in het pancreas. Dit proefschrift beschrijft 
het gebruik van op exendin gebaseerde signaalmoleculen voor diagnostische 
beeldvorming, intra-operatieve fluorescentie beeldvorming en receptor-gerichte 
fotodynamische therapie (rtPDT) voor hyperinsulinemische hypoglykemie, als een 
middel om de uitdagingen bij de diagnostiek en therapie te overwinnen.
Niet-invasieve beeldvorming van hyperinsulinemische 
hypoglykemie
De huidige standaard niet-invasieve beeldvormingstechnieken gebruikt voor de 
detectie van insulinomen; CT, MRI en somatostatine-receptor PET, hebben 
beperkte sensitiviteit. In hoofdstuk 2 beschrijven we een prospectieve, multicen-
terstudie waarin we de effectiviteit van [68Ga]Ga-NODAGA-exendin-4 PET/CT 
voor de detectie van insulinomen vergelijken met al deze standaard beeldvor-
mingstechnieken in 42 patiënten met AHH. [68Ga]Ga-NODAGA-exendin-4 PET/
CT presteerde beter dan alle andere beeldvormingstechnieken met een hogere 
accuraatheid en gevoeligheid. Verder was de beeldkwaliteit van [68Ga]Ga-NO-
DAGA-exendin-4 PET beter dan van somatostatine-receptor PET. In hoofdstuk 3 
onderzoeken we de effectiviteit van [68Ga]Ga-NODAGA-exendin-4 PET/CT voor 
de detectie van de focale vorm van CHI. We vergeleken [68Ga]Ga-NODAGA-exen-
din-4 PET/CT met de standaard beeldvormingstechniek [18F]F-DOPA PET in 19 
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CHI patiënten. We laten een betere beeldkwaliteit van [68Ga]Ga-NODAGA-exen-
din-4 PET zien, leidend tot een betere diagnostische accuraatheid en zekerheid, 
wat helpt bij de planning van de chirurgische behandeling. 
 Het gebruik van [68Ga]Ga-NODAGA-exendin-4 PET voor de diagnose van AHH 
en CHI brengt een stralingsdosis voor de patiënt met zich mee. In hoofdstuk 4 
laten we een dosimetrie studie zien, gebaseerd op humane [68Ga]Ga-NO-
DAGA-exendin-4 PET/CT beelden. Hierin vinden we dat de effectieve stralingsdosis 
voor zowel volwassenen als kinderen heel laag is, waardoor deze techniek veilig 
gebruikt kan worden.
 Deze hoofdstukken laten de potentie zien van [68Ga]Ga-NODAGA-exendin-4 
PET om in de toekomst de primaire beeldvormingstechniek te worden voor zowel 
AHH als CHI. 
Gerichte optische beeldvorming en fotodynamische therapie van 
insuline-producerende lesies.
Zelfs na succesvolle pre-operatieve detectie van insulinomen en de focale vorm 
van CHI kan de chirurgische behandeling bemoeilijkt worden door moeizame in-
tra-operatieve detectie van de lesies. In hoofdstuk 5 beschrijven we nabij-infraro-
de fluorescentie beeldvorming van GLP-1R positieve cellen met behulp van exen-
din-4-IRDye800CW. We laten zien dat dit signaalmolecuul succesvol gericht is 
naar GLP-1R positieve cellen en dat dit in vivo fluorescentie beeldvorming van 
tumoren die de GLP-1R tot expressie brengen mogelijk maakt in muizen. Verder 
laten we laparoscopische detectie van het fluorescente signaal van exendin-4-IR-
Dye800CW in het pancreas van mini varkens zien. Door real-time intra-operatieve 
detectie van lesies mogelijk te maken, kan deze techniek de chirurgische 
verwijdering van insulinomen en focale lesies bij CHI ten goede komen.
 Chirurgische behandeling van insulinomen en CHI brengt grote morbiditeits-
risico’s met zich mee. In hoofdstuk 6 onderzoeken we het selectief doden van 
GLP-1R positieve cellen met behulp van rtPDT met exendin-4-IRDye700DX als 
alternatieve behandelingsstrategie. We laten zien dat rtPDT effectieve en selectieve 
lichtschade veroorzaakt bij GLP-1R positieve cellen in vitro. Verder laten we zien 
dat rtPDT in vivo in muizen celschade kan aanrichten in tumoren die de GLP-1R tot 
expressie brengen, waardoor de levensduur van de muizen verlengd wordt. Dit 
laat de toekomstige potentie zien van rtPDT met exendin-4-IRDye700DX als 

















All raw and processed data obtained during my PhD and described in this thesis 
have been stored on the hard drive of the department of Medical Imaging at the 
Radboud university medical center. This hard drive is password protected and 
automatic back-ups are made several times a day. Most of the data is captured in 
notebooks and a digital copy of these notebooks is stored on the hard drive as well. 
Raw data from equipment (e.g. SPECT/CT, gamma counter) are backed-up on 
university servers belonging to the department. Large data, for example SPECT/
CT images and immunohistochemical images are stored on external hard-drives 
and are located at the department of Medical Imaging.
 All mouse studies were performed according to the Institute of Laboratory 
Animal Research Guidelines. Animal experiments were approved by the Animal 
Ethical Committee of the Radboud University, Nijmegen, The Netherlands.
Clinical data
For the clinical studies described in this thesis, the European Guidance for 
Healthcare Professionals on Confidentiality and Privacy in Healthcare was 
respected, all documents and data were handled with strict confidentiality. In the 
documentation and data analysis phase, the patient-related data were recorded 
pseudonymously and were identifiable only by randomization number, initials 
and birth date. Data collected, being sensitive personal data (directive 95/46/EC), 
were kept treated and transferred in a confidential manner according to regulations. 
 All clinical data of patients participating in the studies described in this thesis 
are collected online in InferMed’s electronic data capture system MACRO, which is 
installed on a European server under supervision of Radboudumc ICT department. 
The following protection measures are in place:
• Daily full back ups are made.
• Recovery mechanisms are in place for fast system recovery.
• These rooms are placed in a secured space with video surveillance, which is only 
accessible for authorized personnel.
• These rooms are climate controlled, fire protected and deployed with emergency 
power.
• Access to the servers is secured by restricted accounts that are password protected.
• Servers are placed in separated and secured LAN zones.
• Servers will have correct OS patch levels, services and protection software.
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MACRO is designed to support the requirements of internationally recognized 
ICH Good Clinical Practice and FDA 21 CRF Part11. SOPs (Standard Operating 
Procedures) are in place for the data management procedures that will be followed.
Biological material are stored as linked anonymised material.
Accessible
All protocols and data are accessible by contacting the corresponding author or 
one of the researchers involved in these studies.
Interoperable
All protocols and data are documented in English.
Reusable
All data will be saved for at least 15 years after publication of the respective study. 
All used methods and data analyzed during these studies are available upon 
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Hoi allemaal. Daar is hij dan eindelijk, mijn boekje! Beter laat dan nooit zullen we 
maar zeggen. Maar zonder de hulp van heel veel mensen had ik het zeker niet laat, 
maar nooit voor elkaar gekregen. Ik wil dus iedereen die op welke manier dan ook 
heeft bijgedragen ontzettend bedanken!
Vanaf mijn eerste dag op de nucleaire geneeskunde tot de dag van vandaag is het 
een fantastische werkomgeving. ‘Het warme bad van de nucleaire 😊’ Ik denk dat 
deze combinatie van wetenschappelijke ondersteuning en onmetelijke gezelligheid 
maar zelden voorkomt. Allemaal bedankt voor deze topjaren waarvan er hopelijk 
nog veel zullen volgen.
Als eerste wil ik mijn promotieteam bedanken.
Lieve Martin, mijn leraar en partner in crime. Het is geweldig om voor je te werken. 
Bedankt voor alle vrijheid en het vertrouwen dat je me de aflopen jaren gegeven 
hebt. En natuurlijk voor alles wat ik van je geleerd heb. Ook al ben je soms druk 
en chaotisch, je maakt altijd tijd om even te sparren en staat altijd klaar met 
waardevolle input. Ook bedankt voor alle gezelligheid: kopjes koffie, (soms iets 
teveel) biertjes en de vele gezellige tripjes. We zijn een goed team en je helpt me 
altijd weer vooruit in mijn wetenschappelijke carrière. Bedankt voor alles!
Lieve Maarten, wat heb ik veel gehad aan al jouw kennis! Met mijn vragen kon ik 
altijd bij je terecht en je nam altijd rustig de tijd om te helpen. Ook nadat je weg bent 
gegaan bleef je altijd bereikbaar en heb je me geholpen met alle papers. Bedankt 
voor alles en hopelijk kunnen we nog vaak samen een mooi NVDO-feestje vieren!
Lieve Sanne, na een paar cocktails in Wenen konden we het gelijk goed met elkaar 
vinden en is er nog veel gezelligheid gevolgd! Je bent pas later aangesloten bij mijn 
promotieteam, maar ik heb ontzettend veel gehad aan je input, vooral het PDT 
paper was zonder jou niet zo mooi geworden!
Lieve Mijke, samen begonnen we op de nucleaire en het was meteen gezellig. Wat 
was het leuk om samen onze weg te zoeken in wat toen het ondoordringbare woud 
van de klinische studies leek. Toen je ervoor koos om naar Leuven te vertrekken 
heb ik wel even een traantje weg moeten pinken. Gelukkig woon je nu in Maastricht 
zodat het gemakkelijk is elkaar af en toe nog te zien. En hopelijk kunnen we ook 
nog veel samenwerken in de toekomst!
Annemarie, zonder jou als projectmanager had het BetaCure project nooit een 
succes kunnen worden! Samen hebben we alle frustraties kunnen delen, maar ook 
de successen en natuurlijk de vele gezellige tripjes. In je nieuwe functie werken we 
helaas niet meer samen, maar hopelijk kunnen we in plaats daarvan nog veel leuke 
dingen doen samen, zoals skiën! Ik ben super blij dat je mijn paranimf wil zijn!
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Lieve analisten, allemaal super bedankt voor alle hulp en geweldige organisatie 
van het lab! Desirée, na de dramatische eerste in vivo PDT experimenten hebben we 
er toch nog een succes van kunnen maken. Bedankt voor de lange fluorescente 
biodistributie dagen, ook aan Gerwin! Cathelijne, je werkt maar 3 dagen per week, 
maar het lijken er wel 7! Bedankt voor al je harde werk!
Alle PhDers, te veel om op te noemen, maar dat heb je als je 7 jaar over je boekje 
doet 😉. Allemaal super bedankt voor de gezelligheid! Van de koffiekamer, Aesculaaf, 
een karaokebar in Glasgow, de Choco in Barcelona, de Kuhstall in Düsseldorf, 
Iba-feestjes, Hollandse avonden en ga zo maar door. Wat een feest, zo’n promotietijd 
met jullie! 
Tom, bedankt voor de fijne samenwerking en super dat je een baan hebt gevonden 
waarin we elkaar in de toekomst wellicht nog tegenkomen. Ik ga je woordgrappen 
zeker missen!
Laura, samen zijn we een Rijnstate-Radboud team en dat werkt fantastisch! Ik ben 
blij dat ik je je allereerste ski-lesje heb mogen geven, je was een natuurtalent 😊. 
Ik hoop dat we nog lang zo fijn blijven samenwerken.
Daphne D, tijdens de monster reuma-experimenten waarbij we in de weekenden 
nog samen op PRIME stonden hebben we toch altijd veel gelachen. Bedankt voor 
de mooie afronding van deze projecten!
Daphne L, jouw technische kennis is een grote bijdrage voor veel projecten. 
Bedankt voor de samenwerking met dosimetrie! Gelukkig blijf je ook op de afdeling 
en kan ik dus veel van je blijven leren! 
Selen, your hard work was the basis for the exendin-IRDye800CW paper. Thank you 
for introducing me into the world of fluorescence! 
Patricia, bedankt voor alle hulp bij de PDT experimenten, en natuurlijk voor het 
leuke gezelschap tijdens onze tripjes naar Lille.
Iedereen in hotlab, bedankt voor het opzetten van de exendin labeling en alle 
volgende labelingen. Na slapeloze nachten over een onverklaarbaar HPLC-piekje is 
het toch nog allemaal goed gekomen! Peter L, bedankt voor alle coördinatie en al 
je antwoorden op mijn domme radiochemie vragen. Maichel, Gerben, Danny en 
Natasha, wat is het toch een k*t peptide he! Maar het heeft toch tot mooie resultaten 
geleid, dus bedankt voor het doorzettingsvermogen!




Michel, het opzetten van klinische studies was voor mij zonder enige ervaring een 
soort doolhof. Had ik mijn weg eindelijk gevonden, kwam ik toch weer een 
doodlopende straat tegen. Jij was echt de gids! Met al mijn vragen kon ik en kan ik 
nog steeds bij jou terecht. 
Erik Visser, bedankt voor je hulp bij het dosimetrie hoofdstuk. Ik heb enorm veel 
van je geleerd!
Alle laboranten, en in het bijzonder Jur en Peter. Dank jullie wel voor jullie hulp bij 
alle patiëntenscans. Zonder jullie onmetelijke flexibiliteit zou het nooit mogelijk 
zijn om zoveel klinische studies te doen op de afdeling. En als ik even in paniek 
raakte vanwege veel te lage bloedsuikers, bleven jullie altijd rustig en gaven me 
vertrouwen. Ik kan nooit genoeg lekkers in jullie snoeppot doen om jullie 
voldoende te bedanken!
Mijn lieve kamergenoten, Lieke, Sanne en René. Wat een ellende was en is het toch 
allemaal 😉. Gelukkig zitten we allemaal in hetzelfde schuitje. Met jullie kan ik 
geweldig sparren en gezellig kletsen. En na de grootste frustraties of teleurstellingen 
kan ik met jullie altijd heel snel weer lachen! 
Iedereen op PRIME en natuurlijk in het bijzonder Bianca. Bedankt voor al jullie 
hulp bij de dierexperimenten! 
All the partners in the BetaCure project, Fritz Andreae, Martin Béhé, Pratik Shah, 
Damian Wild, Pirjo Nuutila, Oliver Blankenstein, Olof Eriksson, Vikas Prasad, 
Adrienne Brouwers, Go van Dam, Christof Rottenburger, Winfried Brenner, 
François Pattou and many others. thank you for the great collaboration! I learned 
so much from all of you, especially that working together leads to the best results. 
I will take this with me throughout the rest of my career and hopefully we will 
keep the collaborations going. 
John Hermans, bedankt voor de hulp met het beoordelen van de CT’s en MRI’s en 
de prettige samenwerking!
Bedankt aan alle centra zowel nationaal als internationaal die bijgedragen hebben 
aan de inclusie van patiënten in de studies. 
Een heel speciaal bedankje aan alle patiënten en ouders van patiënten die deel 
hebben genomen aan de studies. Ik waardeer dit ontzettend en hopelijk heeft dit 




Al mijn lieve vrienden heel erg bedankt dat jullie er altijd voor mij zijn! 
Lieve Solange, mijn oudste en liefste vriendin, we hebben al zoveel samen mee - 
gemaakt, bedankt voor alles. Zodra het weer kan laten we de mannen op de kinderen 
passen en gaan wij lekker aan de wijn!
Lieve Frauke, na de Jekerstraat, of eigenlijk al na die eerste avond in de café de Wekker, 
is de liefde niet meer overgegaan. Bedankt voor alle gezelligheid, de avonturen en 
ontelbare mooie nachten. Ik ben super blij dat je mijn paranimf wil zijn! 
Lieve Femke, mijn lova! Je bent zo’n sterk en bijzonder persoon. Bedankt dat ik 
altijd met je kan praten, maar natuurlijk ook feesten. Ik kan niet wachten om te zien 
waar het leven je gaat brengen en wat je nog allemaal gaat doen en het samen met 
je te beleven. Ik ben trots op je!
Lieve Eva, al zien we elkaar nu even niet zo veel, je bent en blijft niet alleen een 
vriendin, maar een soort zusje. Hopelijk kunnen Pinky en Brain weer snel samen 
de kroegen onveilig maken.
Lieve Sarah, je was mijn liefste huisgenootje op het Ledig Erf en ik ben nog steeds 
zo blij met je vriendschap! Hester en Renate, van Leiden tot in Nijmegen zijn jullie 
me blijven steunen en is de gezellige vriendschap gebleven. Jullie zijn toppers! 
Judith, Nienke en Annemarie. Mijn ski-vakantie maatjes. Bedankt voor de leuke 
tripjes en andere gezellige dagen!
All my friends from the master; Tessa, Joao, Marcelo, Caspar, Timo, Ian, Steven and 
Jan, thank you for the great time we had together in Utrecht! We don’t see each 
other as much anymore, but I appreciate you all so much and hopefully we can all 
get together again really soon, the last time in Portugal was great!
Lieve Ammie en Frank, zonder jullie was ik nooit zo ver gekomen. Jullie hebben 
me altijd gestimuleerd en vrij gelaten om mijn eigen weg te gaan, ook al heb ik 
jullie ook vast wel wat kopzorgen opgeleverd. Bedankt voor alle steun en liefde!
Lieve Rik, van Maastricht naar Utrecht blijven we elkaar volgen. Het is zo fijn dat 
je dicht in de buurt ben en ik altijd bij je terecht kan! 
Lieve schoonfamilie, Ko, Heleen, Martine, Edith, Dennis, Stijn, Anne, Robin, Tom 
en Evi. Ik heb me vanaf het begin thuis gevoeld bij jullie. Bedankt voor alle lieve 
berichtjes en kaartjes als de promotietijd me even zwaar viel. Jullie zijn geweldig!
Lieve Arjan, het begon met een dak boven mijn hoofd, maar heeft uiteindelijk geleid tot 
een geweldige vriendschap en liefde, wie had dat gedacht! Hoe rot de dag ook 
geweest is, als ik thuiskom bij jou kan ik meteen weer lachen! Bedankt voor het 
helpen relativeren, je humor, je liefde, maar vooral natuurlijk al het lekker eten 😉.
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